<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0//FR" "http://www.w3.org/TR/REC-html40/strict.dtd">
<!-- template_7 -->
<HTML>
  <HEAD>
    <META http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
    <META name="organization" content="ANSM : Agence Nationale de Sécurité du Médicament et des Produit de santé">
    <META name="description" content="Résumé des Caractéristiques du Produit">
    <META name="keywords" content="IRBESARTAN/HYDROCHLOROTHIAZIDE SET 150 mg/12,5 mg, comprimé pelliculé, Médicament, Spécialité pharmaceutique, RCP, Résumé des Caractéristiques du Produit, Dénomination, Forme pharmaceutique, Indications, Contre-indications, Effets secondaires">
    <TITLE>Résumé des Caractéristiques du Produit</TITLE>
    <link rel="stylesheet" href="../style/spstyl01.css" type="text/css">
  </HEAD>
  <BODY>
<p class="AmmAnnexeTitre"><a name="RcpTitre">RÉSUMÉ DES CARACTÉRISTIQUES DU PRODUIT</a></p>
<p class="DateNotif">ANSM - Mis à jour le : 09/05/2014</p>
<p class="AmmAnnexeTitre1"><a name="RcpDenomination">1. DENOMINATION DU MEDICAMENT</a></p>
<p class=AmmDenomination>IRBESARTAN/HYDROCHLOROTHIAZIDE SET 150 mg/12,5 mg, comprimé pelliculé</p>
<p class="AmmAnnexeTitre1"><a name="RcpCompoQualitQuanti">2. COMPOSITION QUALITATIVE ET QUANTITATIVE</a></p>
<p class=AmmComposition>Irbésartan......................................................................................................................................... 150 mg</p>
<p class=AmmComposition>Hydrochlorothiazide......................................................................................................................... 12,5 mg</p>
<p class=AmmCorpsTexte align=center style='text-align:center'>Pour un comprimé pelliculé.</p>
<p class=AmmCorpsTexte><u>Excipient<span style='letter-spacing:-.4pt'> </span>à<span style='letter-spacing:-.05pt'> </span>effet<span style='letter-spacing:-.25pt'> </span>notoire</u> :</p>
<p class=AmmCorpsTexte>Chaque<span style='letter-spacing:-.3pt'> </span>co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.1pt'>p</span>ri<span style='letter-spacing:-.1pt'>m</span>é<span style='letter-spacing:-.4pt'> </span>contient<span style='letter-spacing:-.3pt'> </span>38,<span style='letter-spacing:-.05pt'>50</span><span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span>g<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>lactose<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.1pt'>m</span>ono<span style='letter-spacing:-.05pt'>h</span><span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:.05pt'>d</span><span style='letter-spacing:-.05pt'>r</span>até.</p>
<p class=AmmCorpsTexte>Pour la liste complète des excipients, voir rubrique 6.1.</p>
<p class="AmmAnnexeTitre1"><a name="RcpFormePharm">3. FORME PHARMACEUTIQUE</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278915">C<span style='letter-spacing: .1pt'>o</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>r<span style='letter-spacing:.05pt'>i</span><span style='letter-spacing:-.1pt'>m</span>é pelliculé.</a></p>
<p class=AmmCorpsTexte>Comprimé pelliculé, de forme oblongue, biconvexe de couleur pêche, gravé « IHC 150 » sur une face.</p>
<p class="AmmAnnexeTitre1"><a name="RcpDonneesCliniques">4. DONNEES CLINIQUES</a></p>
<p class="AmmAnnexeTitre2"><a name="RcpIndicTherap">4.1. Indications thérapeutiques</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278917">Traitement<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>h<span style='letter-spacing:.1pt'>y</span>pertension<span style='letter-spacing:-.55pt'> </span>artérielle<span style='letter-spacing: .05pt'> </span>essentielle.</a></p>
<p class=AmmCorpsTexte>Cette associa<span style='letter-spacing:.05pt'>t</span>ion<span style='letter-spacing:-.5pt'> </span>à dose<span style='letter-spacing:-.2pt'> </span>fixe<span style='letter-spacing:-.15pt'> </span>est<span style='letter-spacing:-.1pt'> </span>indiquée<span style='letter-spacing:-.4pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>pat<span style='letter-spacing:.05pt'>i</span>ents<span style='letter-spacing:-.35pt'> </span>adultes<span style='letter-spacing:-.3pt'> </span>dont<span style='letter-spacing:-.2pt'> </span>la pression<span style='letter-spacing:-.35pt'> </span>artérielle<span style='letter-spacing: .05pt'> </span>est insuffis<span style='letter-spacing:.05pt'>a</span>mm<span style='letter-spacing:.05pt'>e</span>nt<span style='letter-spacing:-.7pt'> </span>contrôlée<span style='letter-spacing:-.4pt'> </span>par<span style='letter-spacing:-.15pt'> </span>l'irb<span style='letter-spacing:.05pt'>é</span>sartan<span style='letter-spacing:-.4pt'> </span>seul<span style='letter-spacing:-.2pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.1pt'>'</span><span style='letter-spacing:-.05pt'>h</span><span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.05pt'>d</span>rochlorothia<span style='letter-spacing:-.05pt'>z</span>ide<span style='letter-spacing:-.9pt'> </span>seul<span style='letter-spacing:-.2pt'> </span>(voir<span style='letter-spacing:-.25pt'> </span>rubrique<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.05pt'>5</span>.1).</p>
<p class="AmmAnnexeTitre2"><a name="RcpPosoAdmin">4.2. Posologie et mode d'administration</a></p>
<p class=AmmAnnexeTitre3><a name="_Toc142278918">Posologie</a></p>
<p class=AmmCorpsTexte>IRBESARTAN/HYDROCHLOROTHIAZIDE SET peut être pris en une prise par jour, pendant ou en dehors des repas.</p>
<p class=AmmCorpsTexte>Une adaptation des doses de chacun des composants pris individuellement (irbésartan et hydrochlorothiazide) peut être recommandée.</p>
<p class=AmmCorpsTexte>La substitution de la monothérapie par l'association fixe sera envisagée si elle est cliniquement appropriée :</p>
<p class=AmmListePuces><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>IRBESARTAN/HYDROCHLOROTHIAZIDE SET 150 mg/12,5 mg peut être administré chez les patients dont la pression artérielle est insuffisamment contrôlée avec l'hydrochlorothiazide seul ou 150 mg d’irbésartan seul ;</p>
<p class=AmmListePuces><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>IRBESARTAN/HYDROCHLOROTHIAZIDE SET 300 mg/12,5 mg peut être administré chez les patients insuffisamment contrôlés par 300 mg d’irbésartan ou par IRBESARTAN/HYDROCHLOROTHIAZIDE SET 150 mg/12,5 mg.</p>
<p class=AmmListePuces><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>IRBESARTAN/HYDROCHLOROTHIAZIDE SET 300 mg/25 mg peut être administré chez les patients insuffisamment contrôlés par IRBESARTAN/HYDROCHLOROTHIAZIDE SET 300 mg/12,5 mg.</p>
<p class=AmmCorpsTexte style='margin-top:6.0pt'>Des doses supérieures à 300 mg d’irbésartan/25 mg d’hydrochlorothiazide par jour ne sont pas recommandées.</p>
<p class=AmmCorpsTexte>Si nécessaire, IRBESARTAN/HYDROCHLOROTHIAZIDE SET peut être administré avec un autre médicament antihypertenseur (voir rubrique 4.5).</p>
<p class=AmmAnnexeTitre3>Populations particulières</p>
<p class=AmmCorpsTexte><u>Insuffisance rénale</u> : en raison de la présence d’hydrochlorothiazide, IRBESARTAN/HYDROCHLOROTHIAZIDE SET n’est pas recommandé chez les patients atteints d'insuffisance rénale sévère (clairance de la créatinine &lt; 30 ml/min). Les diurétiques de l'anse sont préférables aux thiazidiques dans cette population. Un ajustement posologique n’est pas nécessaire chez les patients insuffisants rénaux dont la clairance de la créatinine est &#8805; 30 ml/min (voir rubriques 4.3 et 4.4).</p>
<p class=AmmCorpsTexte><u>Insuffisance hépatique</u> : IRBESARTAN/HYDROCHLOROTHIAZIDE SET n’est pas indiqué chez les patients ayant une insuffisance hépatique sévère. Les thiazidiques doivent être utilisés avec précaution chez les patients ayant une altération de la fonction hépatique. Un ajustement de la posologie n’est pas nécessaire chez les patients présentant une insuffisance hépatique légère à modérée (voir rubrique 4.3).</p>
<p class=AmmCorpsTexte><u>Sujets âgés</u> : aucune adaptation posologique d’IRBESARTAN/HYDROCHLOROTHIAZIDE SET n'est nécessaire chez le sujet âgé. </p>
<p class=AmmCorpsTexte><u>Population pédiatrique</u> : l’utilisation d’IRBESARTAN/HYDROCHLOROTHIAZIDE SET n’est pas recommandée chez les enfants et les adolescents car l'efficacité et la tolérance n'ont pas été établies. Aucune donnée n'est disponible.</p>
<p class=AmmAnnexeTitre3>Mode d'administration</p>
<p class=AmmCorpsTexte>Voie orale.</p>
<p class="AmmAnnexeTitre2"><a name="RcpContreIndic">4.3. Contre-indications</a></p>
<p class=AmmListePuces1><a name="_Toc142278919"><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>H<span style='letter-spacing:.1pt'>y</span>persensibilité<span style='letter-spacing:-.7pt'> </span>aux<span style='letter-spacing:-.15pt'> </span>principes<span style='letter-spacing:-.4pt'> </span>actifs,<span style='letter-spacing:-.25pt'> </span>à <span style='letter-spacing:.05pt'>l</span>'un<span style='letter-spacing: -.15pt'> </span>des<span style='letter-spacing:-.2pt'> </span>excip<span style='letter-spacing:-.05pt'>i</span>ents<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.1pt'>m</span>entionnés<span style='letter-spacing:-.45pt'> </span>à la rubrique<span style='letter-spacing:-.35pt'> </span>6.1<span style='letter-spacing:-.2pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>à<span style='letter-spacing:-.05pt'> </span>une autre<span style='letter-spacing: -.2pt'> </span>substance<span style='letter-spacing:-.4pt'> </span>dérivée<span style='letter-spacing:-.3pt'> </span>des<span style='letter-spacing:-.1pt'> </span>sulf<span style='letter-spacing:.05pt'>a</span><span style='letter-spacing:-.1pt'>m</span>ides<span style='letter-spacing:-.5pt'> </span>(l<span style='letter-spacing:.05pt'>’</span><span style='letter-spacing:-.05pt'>h</span><span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:.05pt'>d</span>roc<span style='letter-spacing:.1pt'>h</span>lorothiazide<span style='letter-spacing:-1.0pt'> </span>est<span style='letter-spacing:-.1pt'> </span>une<span style='letter-spacing:-.15pt'> </span>substance<span style='letter-spacing: -.45pt'> </span>dérivée<span style='letter-spacing:-.3pt'> </span>des sulf<span style='letter-spacing:.05pt'>a</span><span style='letter-spacing:-.1pt'>m</span>ides).</a></p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>Deuxi<span style='letter-spacing:.05pt'>è</span><span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:-.35pt'> </span>et troisi<span style='letter-spacing:.05pt'>è</span><span style='letter-spacing: -.1pt'>m</span>e<span style='letter-spacing:-.35pt'> </span>tr<span style='letter-spacing:.05pt'>i</span>mest<span style='letter-spacing:.05pt'>r</span>e<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la grosses<span style='letter-spacing:.05pt'>s</span>e<span style='letter-spacing: -.35pt'> </span>(voir<span style='letter-spacing:-.2pt'> </span>rubriques<span style='letter-spacing:-.4pt'> </span>4.4<span style='letter-spacing:-.15pt'> </span>et 4.6).</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>Insuffisance<span style='letter-spacing:-.55pt'> </span><span style='letter-spacing:.05pt'>r</span>énale<span style='letter-spacing:-.2pt'> </span>sévè<span style='letter-spacing:.05pt'>r</span>e<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:.05pt'>(</span>clairance<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing: .05pt'>l</span>a créatinine<span style='letter-spacing:-.45pt'> </span>&lt; 30<span style='letter-spacing:-.1pt'> m</span>l<span style='letter-spacing:.05pt'>/</span><span style='letter-spacing:-.1pt'>m</span>in).</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>H<span style='letter-spacing:.1pt'>y</span>pokalié<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.05pt'>i</span>e<span style='letter-spacing:-.55pt'> </span>réfrac<span style='letter-spacing:.1pt'>t</span>aire;<span style='letter-spacing:-.25pt'> </span>h<span style='letter-spacing:.1pt'>y</span>percalc<span style='letter-spacing:.05pt'>é</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>i</span>e.</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>Insuffisance<span style='letter-spacing:-.45pt'> </span>hépatique<span style='letter-spacing:-.45pt'> </span>sévère,<span style='letter-spacing:-.3pt'> </span>cirrhose<span style='letter-spacing:-.2pt'> </span>biliaire<span style='letter-spacing:-.3pt'> </span>et cholestase.</p>
<p class="AmmAnnexeTitre2"><a name="RcpMisesEnGarde">4.4. Mises en garde spéciales et précautions d'emploi</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278920"><u>H<span style='letter-spacing: .1pt'>y</span><span style='letter-spacing:-.05pt'>p</span><span style='letter-spacing:.05pt'>o</span>tension<span style='letter-spacing:-.65pt'> </span>-<span style='letter-spacing:-.05pt'> </span>patients<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.05pt'>h</span><span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.05pt'>p</span>ovolé<span style='letter-spacing:-.05pt'>m</span>iques</u> :<span style='letter-spacing: -.65pt'> </span>IRBESARTAN/HYDROCHLOROTHIAZIDE SET<span style='letter-spacing: -.5pt'> </span>a rar<span style='letter-spacing:.05pt'>e</span>ment<span style='letter-spacing:-.4pt'> </span>été<span style='letter-spacing:.1pt'> </span>associé<span style='letter-spacing:-.2pt'> </span>à une<span style='letter-spacing:-.15pt'> </span>h<span style='letter-spacing:.1pt'>y</span>potension s<span style='letter-spacing: .1pt'>y</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>tomatique<span style='letter-spacing:-.65pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.05pt'>h</span><span style='letter-spacing: .1pt'>y</span>pertendus<span style='letter-spacing:-.55pt'> </span>sans<span style='letter-spacing:-.2pt'> </span>autre<span style='letter-spacing:-.2pt'> </span>facteur<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>risque<span style='letter-spacing:-.25pt'> </span>d’<span style='letter-spacing:-.05pt'>h</span><span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.05pt'>p</span><span style='letter-spacing:.05pt'>o</span><span style='letter-spacing:-.05pt'>t</span>ension.<span style='letter-spacing:-.6pt'> </span>Une h<span style='letter-spacing:.1pt'>y</span>potension<span style='letter-spacing:-.55pt'> </span><span style='letter-spacing:-.05pt'>s</span><span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>to<span style='letter-spacing:-.1pt'>m</span>atiq<span style='letter-spacing:.1pt'>u</span>e<span style='letter-spacing:-.6pt'> </span>peut<span style='letter-spacing:-.2pt'> </span>survenir<span style='letter-spacing:-.35pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>pa<span style='letter-spacing:.05pt'>t</span>ients<span style='letter-spacing:-.3pt'> </span>présent<span style='letter-spacing:.05pt'>a</span>nt<span style='letter-spacing:-.45pt'> </span>une<span style='letter-spacing:-.15pt'> </span>d<span style='letter-spacing:-.05pt'>é</span>plétion<span style='letter-spacing:-.4pt'> </span>sodée<span style='letter-spacing:-.25pt'> </span>et/ou<span style='letter-spacing:-.2pt'> </span>une <span style='letter-spacing:-.05pt'>h</span><span style='letter-spacing:.1pt'>y</span>p<span style='letter-spacing:-.05pt'>o</span>volé<span style='letter-spacing:-.05pt'>m</span>ie<span style='letter-spacing:-.4pt'> </span>secondaire<span style='letter-spacing:-.45pt'> </span>à<span style='letter-spacing:.1pt'> </span>un<span style='letter-spacing:-.1pt'> </span>traitement<span style='letter-spacing: -.4pt'> </span>diurétiqu<span style='letter-spacing:-.1pt'>e</span>,<span style='letter-spacing:-.45pt'> </span><span style='letter-spacing:-.05pt'>un</span>e<span style='letter-spacing:-.1pt'> </span>ali<span style='letter-spacing:-.05pt'>m</span>entati<span style='letter-spacing:.1pt'>o</span>n<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.05pt'>h</span>yposodée,<span style='letter-spacing: -.55pt'> </span>une<span style='letter-spacing:-.15pt'> </span>diarrhée<span style='letter-spacing:-.3pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>des vo<span style='letter-spacing:-.1pt'>m</span>issements.<span style='letter-spacing: -.65pt'> </span>Ces<span style='letter-spacing:-.15pt'> </span>an<span style='letter-spacing:.1pt'>o</span><span style='letter-spacing:-.1pt'>m</span>a<span style='letter-spacing:.05pt'>l</span>ies<span style='letter-spacing:-.35pt'> </span>doivent<span style='letter-spacing:-.35pt'> </span>être<span style='letter-spacing:-.15pt'> </span>corrigées<span style='letter-spacing:-.4pt'> </span>avant<span style='letter-spacing:-.25pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>initiation<span style='letter-spacing: -.35pt'> </span>du<span style='letter-spacing:-.1pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.05pt'>e</span>nt<span style='letter-spacing:-.2pt'> </span>par<span style='letter-spacing:-.15pt'> </span>IRBESARTAN/HYDROCHLOROTHIAZIDE SET.</a></p>
<p class=AmmCorpsTexte><u>Sténose<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.15pt'> </span>l'<span style='letter-spacing:.05pt'>a</span>rtère<span style='letter-spacing:-.25pt'> </span>rénale<span style='letter-spacing:-.3pt'> </span>-<span style='letter-spacing:.05pt'> </span>H<span style='letter-spacing: .1pt'>y</span>p<span style='letter-spacing:-.05pt'>e</span>rtension<span style='letter-spacing:-.6pt'> </span>artérielle ré<span style='letter-spacing: .1pt'>n</span>ovasculaire</u> :<span style='letter-spacing:-.65pt'> </span>il existe<span style='letter-spacing:-.25pt'> </span>un<span style='letter-spacing: -.1pt'> </span>risque<span style='letter-spacing:-.25pt'> </span>accru d'h<span style='letter-spacing:.1pt'>y</span>potension<span style='letter-spacing:-.6pt'> </span>sévère<span style='letter-spacing:-.3pt'> </span>et <span style='letter-spacing:.1pt'>d</span><span style='letter-spacing:-.05pt'>'</span>insuffisance<span style='letter-spacing:-.6pt'> </span>ré<span style='letter-spacing:.1pt'>n</span>ale<span style='letter-spacing:-.15pt'> </span>lorsque<span style='letter-spacing:-.3pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing:-.35pt'> </span>présentant<span style='letter-spacing: -.45pt'> </span>une<span style='letter-spacing:-.15pt'> </span>sténose<span style='letter-spacing:-.3pt'> </span>bilatér<span style='letter-spacing:.05pt'>a</span>le<span style='letter-spacing:-.35pt'> </span>de l'ar<span style='letter-spacing:.05pt'>t</span>ère<span style='letter-spacing:-.25pt'> </span>réna<span style='letter-spacing:.05pt'>l</span>e<span style='letter-spacing:-.15pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>une<span style='letter-spacing:-.15pt'> </span>sténose<span style='letter-spacing:-.3pt'> </span>artér<span style='letter-spacing:.1pt'>i</span>elle<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:.05pt'>r</span>énale<span style='letter-spacing:-.3pt'> </span>sur<span style='letter-spacing:-.15pt'> </span>rein<span style='letter-spacing:-.15pt'> </span>fonction<span style='letter-spacing:.05pt'>n</span>ellement<span style='letter-spacing:-.75pt'> </span>unique,<span style='letter-spacing:-.4pt'> </span>sont<span style='letter-spacing:-.2pt'> </span>traités<span style='letter-spacing:-.25pt'> </span>par inhibiteurs<span style='letter-spacing: -.45pt'> </span>de<span style='letter-spacing:-.15pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>enz<span style='letter-spacing:.1pt'>y</span>me<span style='letter-spacing:-.35pt'> </span>de conversion<span style='letter-spacing: -.5pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>antagonist<span style='letter-spacing:-.05pt'>e</span>s<span style='letter-spacing:-.5pt'> </span>des<span style='letter-spacing:-.15pt'> </span>récepteurs<span style='letter-spacing: -.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>angiotensine-II.<span style='letter-spacing: -.65pt'> </span>Bien<span style='letter-spacing:-.2pt'> </span>que l<span style='letter-spacing:-.05pt'>'</span>on<span style='letter-spacing:-.1pt'> </span>n<span style='letter-spacing:.05pt'>’</span>ait<span style='letter-spacing:-.1pt'> </span>pas<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>données<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>ce t<span style='letter-spacing:.1pt'>y</span>pe<span style='letter-spacing:-.2pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>l<span style='letter-spacing: -.05pt'>'</span>utilisation<span style='letter-spacing:-.5pt'> </span>d’IRBESARTAN/HYDROCHLOROTHIAZIDE SET,<span style='letter-spacing:-.5pt'> </span>on<span style='letter-spacing: -.15pt'> </span>devrait<span style='letter-spacing:-.3pt'> </span>s<span style='letter-spacing:.05pt'>’</span>attendre<span style='letter-spacing:-.4pt'> </span>à un<span style='letter-spacing:-.1pt'> </span>effet s<span style='letter-spacing:.05pt'>i</span><span style='letter-spacing:-.1pt'>m</span>ilaire.</p>
<p class=AmmCorpsTexte><u>Insuffisance<span style='letter-spacing:-.55pt'> </span><span style='letter-spacing:.05pt'>r</span>énale<span style='letter-spacing:-.25pt'> </span>et<span style='letter-spacing:-.05pt'> </span>tran<span style='letter-spacing:.05pt'>sp</span>lantation<span style='letter-spacing:-.65pt'> </span>rénale</u> :<span style='letter-spacing: -.35pt'> </span>quand<span style='letter-spacing:-.25pt'> </span>IRBESARTAN/HYDROCHLOROTHIAZIDE SET<span style='letter-spacing:-.5pt'> </span>est<span style='letter-spacing: -.1pt'> </span>utilisé<span style='letter-spacing:-.25pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.35pt'> </span>présentant une<span style='letter-spacing: -.15pt'> </span>altération<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la fonction<span style='letter-spacing: -.35pt'> </span>r<span style='letter-spacing:-.1pt'>é</span>nale,<span style='letter-spacing:-.3pt'> </span>un<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>c</span>ontrôle<span style='letter-spacing:-.3pt'> </span>périodique<span style='letter-spacing:-.45pt'> </span>des<span style='letter-spacing:-.15pt'> </span>taux<span style='letter-spacing:-.2pt'> </span>sériques<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>potassi<span style='letter-spacing:.1pt'>u</span><span style='letter-spacing:-.1pt'>m</span>,<span style='letter-spacing:-.45pt'> </span>de créatinine<span style='letter-spacing: -.4pt'> </span>et<span style='letter-spacing:.1pt'> </span>d’acide<span style='letter-spacing:-.3pt'> </span>uri<span style='letter-spacing:-.05pt'>qu</span>e<span style='letter-spacing:-.25pt'> </span>est<span style='letter-spacing:-.1pt'> </span>rec<span style='letter-spacing:.1pt'>o</span>mmandé.<span style='letter-spacing:-.7pt'> </span>Aucune<span style='letter-spacing:-.35pt'> </span>expérience<span style='letter-spacing: -.45pt'> </span>n'est<span style='letter-spacing:-.2pt'> </span>disponible<span style='letter-spacing:-.5pt'> </span>concernant l<span style='letter-spacing: -.05pt'>'</span>utilisation<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>IRBESARTAN/HYDROCHLOROTHIAZIDE SET<span style='letter-spacing:-.5pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.35pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing: -.25pt'> </span>eu<span style='letter-spacing:-.1pt'> </span>une<span style='letter-spacing:-.15pt'> </span>transplantation<span style='letter-spacing: -.6pt'> </span>rénale<span style='letter-spacing:-.25pt'> </span>récente.<span style='letter-spacing:-.35pt'> </span>IRBESARTAN/HYDROCHLOROTHIAZIDE SET<span style='letter-spacing:-.5pt'> </span>ne doit<span style='letter-spacing:-.15pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>être<span style='letter-spacing:-.15pt'> </span>utilisé<span style='letter-spacing:-.25pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.35pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing: -.25pt'> </span>une<span style='letter-spacing:-.15pt'> </span>insuff<span style='letter-spacing:-.05pt'>i</span>sance<span style='letter-spacing:-.55pt'> </span>réna<span style='letter-spacing:.05pt'>l</span>e<span style='letter-spacing: -.2pt'> </span>sévère<span style='letter-spacing:-.3pt'> </span>(clairance<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la créat<span style='letter-spacing:.1pt'>i</span>nine <span style='font-family: "Courier New"'>&lt;<span style='letter-spacing:-3.9pt'> </span></span>30<span style='letter-spacing:-.1pt'> m</span>l/<span style='letter-spacing:-.1pt'>m</span>in)<span style='letter-spacing:-.2pt'> </span>(voir<span style='letter-spacing:-.2pt'> </span>rubr<span style='letter-spacing:-.05pt'>i</span>que<span style='letter-spacing:-.4pt'> </span>4.3).<span style='letter-spacing:-.2pt'> </span>Une<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.05pt'>hy</span><span style='letter-spacing:.05pt'>p</span>erazoté<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.05pt'>i</span>e<span style='letter-spacing:-.55pt'> </span>liée<span style='letter-spacing:.05pt'> </span>à la prise<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing: -.1pt'> </span>diurétiqu<span style='letter-spacing:-.05pt'>e</span>s<span style='letter-spacing:-.5pt'> </span>thiazidiques<span style='letter-spacing: -.5pt'> </span>peut survenir<span style='letter-spacing:-.35pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing:-.35pt'> </span>atteints<span style='letter-spacing:-.3pt'> </span>d<span style='letter-spacing:.05pt'>’</span>une<span style='letter-spacing: -.25pt'> </span>altération<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la fonction<span style='letter-spacing: -.3pt'> </span>r<span style='letter-spacing:-.05pt'>é</span>nale.<span style='letter-spacing:-.25pt'> </span>Une<span style='letter-spacing:-.2pt'> </span>adaptation<span style='letter-spacing:-.4pt'> </span><span style='letter-spacing:-.05pt'>p</span><span style='letter-spacing:.05pt'>o</span>so<span style='letter-spacing:-.05pt'>l</span>ogique n<span style='letter-spacing:.05pt'>’</span>est<span style='letter-spacing: -.2pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>nécessai<span style='letter-spacing:.05pt'>r</span>e<span style='letter-spacing:-.4pt'> </span>chez<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>l</span>es<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.35pt'> </span>dont<span style='letter-spacing:-.2pt'> </span>la clairance<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la créati<span style='letter-spacing:.1pt'>n</span>ine<span style='letter-spacing: -.45pt'> </span>est<span style='letter-spacing:-.15pt'> </span>&#8805; 30<span style='letter-spacing:-.05pt'> </span>ml/<span style='letter-spacing:-.05pt'>m</span>in.<span style='letter-spacing:-.3pt'> </span>Cependant, chez<span style='letter-spacing: -.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>pati<span style='letter-spacing:.05pt'>e</span>nts<span style='letter-spacing:-.35pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing:-.3pt'> </span>une<span style='letter-spacing:-.2pt'> </span>insuffisance<span style='letter-spacing: -.55pt'> </span><span style='letter-spacing:.05pt'>r</span>énale<span style='letter-spacing:-.2pt'> </span>l<span style='letter-spacing:.05pt'>é</span>gère<span style='letter-spacing:-.2pt'> </span>à<span style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.1pt'>m</span>odé<span style='letter-spacing:.05pt'>r</span>ée<span style='letter-spacing:-.3pt'> </span>(cl<span style='letter-spacing:.05pt'>a</span>irance<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la <span style='letter-spacing:.05pt'>c</span>réatinine &#8805; 30<span style='letter-spacing:-.1pt'> m</span>l<span style='letter-spacing:.05pt'>/</span>min<span style='letter-spacing:-.25pt'> </span>mais<span style='letter-spacing:-.2pt'> </span><span style='font-family:"Courier New"'>&lt;<span style='letter-spacing:-3.9pt'> </span></span>60<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span>l<span style='letter-spacing:.05pt'>/</span>min),<span style='letter-spacing:-.3pt'> </span>cette a<span style='letter-spacing:.05pt'>s</span>sociation<span style='letter-spacing: -.5pt'> </span>à dose<span style='letter-spacing:-.2pt'> </span>fixe<span style='letter-spacing:-.15pt'> </span>doit<span style='letter-spacing:-.15pt'> </span>être<span style='letter-spacing:-.15pt'> </span>a<span style='letter-spacing:.1pt'>d</span><span style='letter-spacing:-.1pt'>m</span>inistr<span style='letter-spacing:.05pt'>é</span>e<span style='letter-spacing:-.45pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>pré<span style='letter-spacing:.05pt'>c</span>aution.</p>
<p class=AmmCorpsTexte><u>Insuffisance<span style='letter-spacing:-.45pt'> </span>hépatique</u> :<span style='letter-spacing:-.4pt'> </span>il<span style='letter-spacing:-.05pt'> </span>convient<span style='letter-spacing:-.4pt'> </span><span style='letter-spacing:-.05pt'>d</span>’ut<span style='letter-spacing:-.05pt'>i</span>liser<span style='letter-spacing:-.4pt'> </span>les<span style='letter-spacing:-.1pt'> </span>thiaz<span style='letter-spacing:.05pt'>i</span>diques<span style='letter-spacing:-.3pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>prudence<span style='letter-spacing:-.4pt'> </span>chez<span style='letter-spacing:-.1pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.35pt'> </span>présentant une<span style='letter-spacing:-.15pt'> </span>insuffisance<span style='letter-spacing:-.5pt'> </span>hépatique<span style='letter-spacing:-.4pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>une<span style='letter-spacing: -.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>a<span style='letter-spacing:.05pt'>l</span>ad<span style='letter-spacing:-.05pt'>i</span>e<span style='letter-spacing:-.15pt'> </span>évolutive<span style='letter-spacing: -.4pt'> </span>du<span style='letter-spacing:-.1pt'> </span>foie<span style='letter-spacing:-.15pt'> </span>car<span style='letter-spacing:-.15pt'> </span>des<span style='letter-spacing:-.15pt'> </span>al<span style='letter-spacing:.05pt'>t</span>érations,<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>ê</span>me<span style='letter-spacing:-.25pt'> </span>discrètes,<span style='letter-spacing:-.4pt'> </span>de <span style='letter-spacing:.05pt'>l</span><span style='letter-spacing:-.05pt'>'</span>équilibre<span style='letter-spacing: -.4pt'> </span>hydro-électrol<span style='letter-spacing:.1pt'>y</span>t<span style='letter-spacing:-.05pt'>i</span>que<span style='letter-spacing:-.85pt'> </span>peuvent<span style='letter-spacing:-.4pt'> </span>déclencher<span style='letter-spacing: -.45pt'> </span>un<span style='letter-spacing:-.1pt'> </span>coma<span style='letter-spacing:-.25pt'> </span>hépat<span style='letter-spacing:.1pt'>i</span>que.<span style='letter-spacing:-.45pt'> </span>Il<span style='letter-spacing:-.05pt'> </span>n’exis<span style='letter-spacing:-.05pt'>t</span>e<span style='letter-spacing:-.3pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.15pt'> </span>données clin<span style='letter-spacing:-.05pt'>i</span>ques<span style='letter-spacing: -.2pt'> </span>dispon<span style='letter-spacing:-.05pt'>i</span>bles<span style='letter-spacing:-.5pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>IRBESARTAN/HYDROCHLOROTHIAZIDE SET<span style='letter-spacing:-.5pt'> </span>c<span style='letter-spacing: .05pt'>h</span>ez<span style='letter-spacing:-.1pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.35pt'> </span>insuffisants<span style='letter-spacing:-.5pt'> </span>hépatiques.</p>
<p class=AmmCorpsTexte><u>Sténose<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.15pt'> </span>la<span style='letter-spacing:-.05pt'> </span>valve<span style='letter-spacing:-.25pt'> </span>aortique<span style='letter-spacing:-.4pt'> </span>et<span style='letter-spacing:.05pt'> </span><span style='letter-spacing: -.1pt'>m</span>itra<span style='letter-spacing:.1pt'>l</span>e,<span style='letter-spacing:-.2pt'> </span>cardio<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.1pt'>y</span>opathie<span style='letter-spacing:-.75pt'> </span>obstructive<span style='letter-spacing:-.5pt'> </span>h<span style='letter-spacing:.1pt'>y</span>pertrophique</u> :<span style='letter-spacing: -.7pt'> </span>comme<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:.05pt'>av</span>ec<span style='letter-spacing:-.05pt'> </span>les autres<span style='letter-spacing:-.25pt'> </span>vasodilatateurs,<span style='letter-spacing:-.7pt'> </span>une<span style='letter-spacing:-.15pt'> </span>prudence<span style='letter-spacing:-.4pt'> </span>particulière<span style='letter-spacing: -.5pt'> </span>est<span style='letter-spacing:-.1pt'> </span>i<span style='letter-spacing:.1pt'>n</span>diquée<span style='letter-spacing:-.4pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.35pt'> </span>s<span style='letter-spacing:.1pt'>o</span>uffrant<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>sténose aortique<span style='letter-spacing:-.3pt'> </span>ou<span style='letter-spacing: -.1pt'> m</span>itrale<span style='letter-spacing:-.05pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>cardio<span style='letter-spacing:-.05pt'>m</span>yopat<span style='letter-spacing:-.05pt'>h</span>ie<span style='letter-spacing:-.65pt'> </span>obstructive<span style='letter-spacing: -.5pt'> </span><span style='letter-spacing:-.05pt'>h</span><span style='letter-spacing:.1pt'>y</span>pertro<span style='letter-spacing:-.05pt'>p</span><span style='letter-spacing:.05pt'>h</span>i<span style='letter-spacing:-.05pt'>q</span>ue.</p>
<p class=AmmCorpsTexte><u>H<span style='letter-spacing:.1pt'>y</span>peraldost<span style='letter-spacing:-.05pt'>é</span>ronisme<span style='letter-spacing:-.95pt'> </span>primaire</u> :<span style='letter-spacing:-.4pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.35pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>hyperaldosté<span style='letter-spacing:.05pt'>r</span>onisme<span style='letter-spacing:-.85pt'> </span>pri<span style='letter-spacing:-.1pt'>m</span>aire<span style='letter-spacing:-.25pt'> </span>ne<span style='letter-spacing:-.05pt'> </span>répondent généralement<span style='letter-spacing:-.55pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>aux<span style='letter-spacing:-.15pt'> </span>médicaments<span style='letter-spacing:-.55pt'> </span>antihypertenseurs<span style='letter-spacing: -.75pt'> </span>agissant<span style='letter-spacing:-.35pt'> </span>par<span style='letter-spacing:-.15pt'> </span>l'inte<span style='letter-spacing:.05pt'>r</span><span style='letter-spacing:-.1pt'>m</span>édiaire<span style='letter-spacing:-.55pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing: -.05pt'>'</span>inhibition<span style='letter-spacing:-.45pt'> </span>du s<span style='letter-spacing:.1pt'>y</span>stème<span style='letter-spacing:-.35pt'> </span>rénine-angiotensine.<span style='letter-spacing:-.85pt'> </span>En<span style='letter-spacing:-.1pt'> </span>conséquence,<span style='letter-spacing:-.6pt'> </span>l<span style='letter-spacing:-.1pt'>'</span>utilisation<span style='letter-spacing:-.4pt'> </span>d’IRBESARTAN/HYDROCHLOROTHIAZIDE SET<span style='letter-spacing:-.5pt'> </span>n’est<span style='letter-spacing:-.2pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>rec<span style='letter-spacing:.1pt'>o</span>mmandée.</p>
<p class=AmmCorpsTexte><u>Effets<span style='letter-spacing:-.2pt'> </span>métaboliques<span style='letter-spacing:-.55pt'> </span>et<span style='letter-spacing:-.05pt'> </span>endocriniens</u> :<span style='letter-spacing:-.6pt'> </span>les<span style='letter-spacing: -.1pt'> </span><span style='letter-spacing:.05pt'>th</span>iazidiques<span style='letter-spacing:-.5pt'> </span>sont<span style='letter-spacing:-.2pt'> </span>susceptibles<span style='letter-spacing:-.55pt'> </span>d'entraîner<span style='letter-spacing: -.45pt'> </span>une<span style='letter-spacing:-.15pt'> </span>intolérance<span style='letter-spacing:-.45pt'> </span>au glucose.<span style='letter-spacing: -.35pt'> </span>Chez<span style='letter-spacing:-.25pt'> </span>les<span style='letter-spacing:-.1pt'> </span>diabétiques,<span style='letter-spacing: -.5pt'> </span>une<span style='letter-spacing:-.15pt'> </span>adaptation<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.15pt'> </span>la <span style='letter-spacing:-.05pt'>p</span><span style='letter-spacing:.05pt'>o</span>sologie<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>insuline<span style='letter-spacing:-.35pt'> </span>ou<span style='letter-spacing:-.15pt'> </span>des<span style='letter-spacing: -.15pt'> </span>hyp<span style='letter-spacing:-.05pt'>o</span>g<span style='letter-spacing:-.05pt'>l</span><span style='letter-spacing:.1pt'>y</span>cémiants oraux<span style='letter-spacing:-.25pt'> </span>peut<span style='letter-spacing: -.2pt'> </span>se<span style='letter-spacing:-.15pt'> </span>révéler<span style='letter-spacing:-.3pt'> </span>néc<span style='letter-spacing:.05pt'>es</span>saire.<span style='letter-spacing:-.5pt'> </span>Un<span style='letter-spacing:-.15pt'> </span>diabète<span style='letter-spacing:-.3pt'> </span>sucré<span style='letter-spacing:-.25pt'> </span>l<span style='letter-spacing:-.05pt'>a</span>tent<span style='letter-spacing:-.1pt'> </span>peut<span style='letter-spacing:-.2pt'> </span>se<span style='letter-spacing:-.1pt'> </span>révéler<span style='letter-spacing:-.25pt'> </span>à l<span style='letter-spacing:-.05pt'>'</span>occasion<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.05pt'>d</span><span style='letter-spacing:.05pt'>’</span><span style='letter-spacing:-.05pt'>u</span>n<span style='letter-spacing:-.15pt'> </span>traitement par<span style='letter-spacing: -.15pt'> </span>thiazidique.</p>
<p class=AmmCorpsTexte>Des<span style='letter-spacing:-.15pt'> </span>au<span style='letter-spacing:.1pt'>g</span>mentations<span style='letter-spacing:-.65pt'> </span>des<span style='letter-spacing:-.15pt'> </span>taux<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>cholestérol<span style='letter-spacing:-.5pt'> </span>et de<span style='letter-spacing:-.15pt'> </span>triglycérides<span style='letter-spacing:-.55pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été observées<span style='letter-spacing:-.45pt'> </span><span style='letter-spacing: .05pt'>s</span>ous<span style='letter-spacing:-.2pt'> </span>trait<span style='letter-spacing:.05pt'>e</span><span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:.1pt'>n</span>t<span style='letter-spacing:-.15pt'> </span>par diurétiques<span style='letter-spacing:-.5pt'> </span>t<span style='letter-spacing: -.05pt'>h</span>iazidiques.<span style='letter-spacing:-.55pt'> </span>Cependant,<span style='letter-spacing:-.5pt'> </span>à la dose<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>12<span style='letter-spacing: -.05pt'>,</span>5<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.1pt'>m</span>g<span style='letter-spacing:-.1pt'> </span>contenue<span style='letter-spacing:-.3pt'> </span>dans<span style='letter-spacing:-.25pt'> </span>IRBESARTAN/HYDROCHLOROTHIAZIDE SET,<span style='letter-spacing:-.5pt'> </span>des<span style='letter-spacing: -.15pt'> </span>effets min<span style='letter-spacing:.1pt'>i</span><span style='letter-spacing:-.1pt'>m</span>es<span style='letter-spacing:-.4pt'> </span>voire<span style='letter-spacing:-.2pt'> </span>aucun<span style='letter-spacing:-.25pt'> </span>effet<span style='letter-spacing:-.2pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été signalés.</p>
<p class=AmmCorpsTexte>Une<span style='letter-spacing:-.2pt'> </span>hyperur<span style='letter-spacing:-.05pt'>i</span>cé<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.05pt'>i</span>e<span style='letter-spacing:-.55pt'> </span>peut<span style='letter-spacing:-.2pt'> </span>survenir<span style='letter-spacing:-.35pt'> </span>ou<span style='letter-spacing:-.15pt'> </span>une<span style='letter-spacing: -.2pt'> </span>crise<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.05pt'> </span>goutte<span style='letter-spacing:-.25pt'> </span>peut<span style='letter-spacing:-.2pt'> </span>être<span style='letter-spacing:-.15pt'> </span>déclenchée<span style='letter-spacing: -.45pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>certains<span style='letter-spacing:-.35pt'> </span>patients recevant<span style='letter-spacing: -.35pt'> </span>des<span style='letter-spacing:-.1pt'> </span>diurétiques<span style='letter-spacing:-.5pt'> </span>thiazidiques.</p>
<p class=AmmCorpsTexte><u>Equilibre<span style='letter-spacing:-.45pt'> </span>hydroélectrol<span style='letter-spacing:.1pt'>y</span>tique</u> :<span style='letter-spacing: -.95pt'> </span>pour<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.05pt'>t</span>out<span style='letter-spacing:-.2pt'> </span>patient<span style='letter-spacing:-.25pt'> </span>sous<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.05pt'>t</span>raitement<span style='letter-spacing: -.4pt'> </span>diurétique,<span style='letter-spacing:-.45pt'> </span>une<span style='letter-spacing:-.15pt'> </span>surveillance<span style='letter-spacing: -.5pt'> </span>régulière des<span style='letter-spacing:-.15pt'> </span>électrol<span style='letter-spacing:.1pt'>y</span>tes<span style='letter-spacing:-.5pt'> </span>sériques<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:.05pt'>se</span>ra<span style='letter-spacing:-.15pt'> </span>effectu<span style='letter-spacing:.05pt'>é</span>e<span style='letter-spacing:-.35pt'> </span>à<span style='letter-spacing:.05pt'> </span>intervalles<span style='letter-spacing:-.45pt'> </span><span style='letter-spacing:.05pt'>a</span>ppropriés.</p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.15pt'> </span>thiazidiques,<span style='letter-spacing:-.5pt'> </span>dont<span style='letter-spacing:-.2pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>hydrochloro<span style='letter-spacing: -.05pt'>t</span>hiazide,<span style='letter-spacing:-.85pt'> </span>peuv<span style='letter-spacing:-.1pt'>e</span>nt<span style='letter-spacing:-.4pt'> </span>provoquer<span style='letter-spacing:-.45pt'> </span>un<span style='letter-spacing:-.1pt'> </span>déséquilibre<span style='letter-spacing:-.55pt'> </span>h<span style='letter-spacing:.1pt'>y</span>droélectro<span style='letter-spacing:-.05pt'>l</span><span style='letter-spacing:.1pt'>y</span>t<span style='letter-spacing:-.05pt'>i</span>que (h<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:.05pt'>p</span>okalié<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.05pt'>i</span>e,<span style='letter-spacing:-.65pt'> </span>h<span style='letter-spacing:.1pt'>y</span>ponatrémie<span style='letter-spacing:-.6pt'> </span>et a<span style='letter-spacing:.05pt'>l</span>calose<span style='letter-spacing:-.25pt'> </span>hypoch<span style='letter-spacing:-.05pt'>l</span>o<span style='letter-spacing:-.05pt'>r</span>émique).<span style='letter-spacing:-.85pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>signes<span style='letter-spacing:-.25pt'> </span>d<span style='letter-spacing:.05pt'>’</span>alerte<span style='letter-spacing:-.05pt'> </span>d’un<span style='letter-spacing:-.25pt'> </span>déséquilibre h<span style='letter-spacing:.1pt'>y</span>droélectro<span style='letter-spacing: -.05pt'>l</span><span style='letter-spacing:.1pt'>y</span>t<span style='letter-spacing:-.05pt'>i</span>que<span style='letter-spacing:-.8pt'> </span>sont<span style='letter-spacing:-.25pt'> </span>sécheresse<span style='letter-spacing: -.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la bouche,<span style='letter-spacing:-.35pt'> </span>soif,<span style='letter-spacing:-.2pt'> </span>faiblesse,<span style='letter-spacing:-.4pt'> </span>lé<span style='letter-spacing:.05pt'>th</span>argie,<span style='letter-spacing:-.3pt'> </span>so<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.1pt'>n</span>olence,<span style='letter-spacing:-.55pt'> </span>agitation, douleurs<span style='letter-spacing:-.4pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>u</span>sculaires<span style='letter-spacing:-.5pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>cra<span style='letter-spacing:-.1pt'>m</span>pes,<span style='letter-spacing:-.4pt'> </span>fatig<span style='letter-spacing:.1pt'>u</span>e<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>u</span>sculaire,<span style='letter-spacing:-.4pt'> </span><span style='letter-spacing:-.05pt'>h</span><span style='letter-spacing:.1pt'>y</span>potensi<span style='letter-spacing:-.05pt'>o</span><span style='letter-spacing:.05pt'>n</span>,<span style='letter-spacing:-.6pt'> </span>oligurie,<span style='letter-spacing:-.35pt'> </span>tach<span style='letter-spacing:.1pt'>y</span>cardie<span style='letter-spacing:-.5pt'> </span>et tr<span style='letter-spacing:-.05pt'>o</span>ubles gastro-intestinaux<span style='letter-spacing:-.8pt'> </span>tels que<span style='letter-spacing:-.2pt'> </span>nausées<span style='letter-spacing:-.35pt'> </span>et vomis<span style='letter-spacing:.05pt'>se</span>ments.</p>
<p class=AmmCorpsTexte>L'h<span style='letter-spacing:.1pt'>y</span>pokali<span style='letter-spacing:.05pt'>é</span>mie<span style='letter-spacing:-.7pt'> </span>induite<span style='letter-spacing:-.3pt'> </span>par<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>thiazidiques<span style='letter-spacing: -.5pt'> </span>peut<span style='letter-spacing:-.2pt'> </span>ê<span style='letter-spacing:-.05pt'>t</span>re<span style='letter-spacing:-.1pt'> </span>réduite<span style='letter-spacing:-.3pt'> </span>par<span style='letter-spacing:-.15pt'> </span>l'a<span style='letter-spacing:.05pt'>s</span>sociation<span style='letter-spacing:-.55pt'> </span>de<span style='letter-spacing:-.1pt'> </span>ces<span style='letter-spacing: -.15pt'> </span>diurétiques<span style='letter-spacing:-.5pt'> </span>à l<span style='letter-spacing:-.05pt'>'</span>irbésartan.<span style='letter-spacing: -.45pt'> </span>Le<span style='letter-spacing:-.1pt'> </span>risque<span style='letter-spacing:-.25pt'> </span>d’<span style='letter-spacing:-.05pt'>h</span>ypokalié<span style='letter-spacing:-.05pt'>m</span>ie<span style='letter-spacing:-.5pt'> </span>est<span style='letter-spacing:-.1pt'> </span>plus<span style='letter-spacing:-.2pt'> </span>i<span style='letter-spacing:-.1pt'>m</span>portant<span style='letter-spacing:-.45pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.35pt'> </span>porteu<span style='letter-spacing:-.05pt'>r</span>s<span style='letter-spacing:-.35pt'> </span>d’<span style='letter-spacing:-.05pt'>u</span><span style='letter-spacing:.05pt'>n</span>e<span style='letter-spacing:-.2pt'> </span>cirrh<span style='letter-spacing:-.05pt'>o</span>se hépatique,<span style='letter-spacing: -.45pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patien<span style='letter-spacing:.1pt'>t</span>s<span style='letter-spacing:-.35pt'> </span>présentant<span style='letter-spacing: -.45pt'> </span>une<span style='letter-spacing:-.15pt'> </span>diurèse<span style='letter-spacing:-.3pt'> </span><span style='letter-spacing:.05pt'>i</span>mportante,<span style='letter-spacing:-.45pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.25pt'> </span>qui<span style='letter-spacing:-.15pt'> </span>reçoivent<span style='letter-spacing:-.45pt'> </span>des prises orales<span style='letter-spacing: -.25pt'> </span><span style='letter-spacing:.05pt'>in</span>adéquates<span style='letter-spacing:-.5pt'> </span>d’électrol<span style='letter-spacing: .1pt'>y</span>tes<span style='letter-spacing:-.6pt'> </span>et chez<span style='letter-spacing:-.15pt'> </span>les<span style='letter-spacing:-.1pt'> </span>pat<span style='letter-spacing:.05pt'>i</span>ents<span style='letter-spacing:-.35pt'> </span>traités<span style='letter-spacing:-.25pt'> </span>s<span style='letter-spacing:.05pt'>i</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>u</span>lta<span style='letter-spacing:.1pt'>n</span><span style='letter-spacing:.05pt'>é</span><span style='letter-spacing:-.1pt'>m</span>ent<span style='letter-spacing:-.5pt'> </span>par<span style='letter-spacing:-.15pt'> </span>des corticostéroïdes<span style='letter-spacing:-.7pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>par<span style='letter-spacing:-.15pt'> </span>l'<span style='letter-spacing:.05pt'>A</span>CTH.<span style='letter-spacing:-.4pt'> </span>Inver<span style='letter-spacing:-.05pt'>s</span><span style='letter-spacing:.05pt'>e</span>ment,<span style='letter-spacing:-.5pt'> </span>une<span style='letter-spacing:-.15pt'> </span>hyperkali<span style='letter-spacing: .05pt'>é</span><span style='letter-spacing:-.1pt'>m</span>ie<span style='letter-spacing:-.55pt'> </span><span style='letter-spacing:.1pt'>p</span>eut<span style='letter-spacing:-.15pt'> </span>s<span style='letter-spacing:.05pt'>u</span>rvenir<span style='letter-spacing:-.35pt'> </span>du<span style='letter-spacing:-.1pt'> </span>fait de<span style='letter-spacing:-.1pt'> </span>l'irbésartan, c<span style='letter-spacing:.1pt'>o</span><span style='letter-spacing:-.1pt'>m</span>posant<span style='letter-spacing:-.5pt'> </span>d’IRBESARTAN/HYDROCHLOROTHIAZIDE SET,<span style='letter-spacing:-.55pt'> </span>en<span style='letter-spacing:-.1pt'> </span>particulier<span style='letter-spacing:-.4pt'> </span>en<span style='letter-spacing:-.1pt'> </span>présence<span style='letter-spacing:-.4pt'> </span><span style='letter-spacing:.1pt'>d</span><span style='letter-spacing:.05pt'>’</span>insuffisance<span style='letter-spacing: -.6pt'> </span>rénale<span style='letter-spacing:-.25pt'> </span>et/ou<span style='letter-spacing:-.2pt'> </span>d<span style='letter-spacing:.05pt'>’</span>insuffisance cardiaque<span style='letter-spacing:-.45pt'> </span>et de<span style='letter-spacing:-.1pt'> </span>diabète<span style='letter-spacing:-.3pt'> </span>sucré.<span style='letter-spacing:-.25pt'> </span>Un<span style='letter-spacing:-.15pt'> </span>contrôle<span style='letter-spacing:-.35pt'> </span>approprié<span style='letter-spacing:-.45pt'> </span>du<span style='letter-spacing:-.1pt'> </span>potassi<span style='letter-spacing:.1pt'>u</span>m<span style='letter-spacing:-.5pt'> </span>sérique<span style='letter-spacing:-.3pt'> </span>chez<span style='letter-spacing:-.1pt'> </span>ces<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing:-.35pt'> </span>à<span style='letter-spacing:.1pt'> </span>risque est rec<span style='letter-spacing:.1pt'>o</span>mma<span style='letter-spacing:.1pt'>n</span><span style='letter-spacing:.05pt'>d</span>é.<span style='letter-spacing:-.6pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>diurétiques<span style='letter-spacing: -.5pt'> </span>d<span style='letter-spacing:-.05pt'>'</span>épar<span style='letter-spacing:.1pt'>g</span><span style='letter-spacing:.05pt'>n</span>e<span style='letter-spacing:-.35pt'> </span>potassique,<span style='letter-spacing: -.5pt'> </span>les<span style='letter-spacing:-.1pt'> </span>suppléments<span style='letter-spacing:-.55pt'> </span>en<span style='letter-spacing:-.1pt'> </span>potassium<span style='letter-spacing:-.5pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>les<span style='letter-spacing:-.1pt'> </span>s<span style='letter-spacing:.1pt'>u</span>bstituts salés<span style='letter-spacing:-.1pt'> </span>contenant<span style='letter-spacing:-.45pt'> </span>du<span style='letter-spacing:-.15pt'> </span>potassium<span style='letter-spacing:-.5pt'> </span>doivent<span style='letter-spacing:-.35pt'> </span>êt<span style='letter-spacing:.05pt'>r</span>e<span style='letter-spacing: -.1pt'> </span>a<span style='letter-spacing:.1pt'>d</span><span style='letter-spacing:-.1pt'>m</span>inistrés<span style='letter-spacing:-.4pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>prudence<span style='letter-spacing:-.4pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>IRBESARTAN/HYDROCHLOROTHIAZIDE SET<span style='letter-spacing:-.5pt'> </span>(voir rubrique<span style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>4</span>.5).</p>
<p class=AmmCorpsTexte>Il<span style='letter-spacing:-.05pt'> </span>n<span style='letter-spacing:.05pt'>’</span>est<span style='letter-spacing:-.2pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>d<span style='letter-spacing:-.05pt'>é</span><span style='letter-spacing:-.1pt'>m</span>ontré<span style='letter-spacing:-.4pt'> </span>que<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.05pt'>l</span><span style='letter-spacing:-.05pt'>'</span><span style='letter-spacing:.05pt'>i</span>rbésartan<span style='letter-spacing:-.4pt'> </span>puisse<span style='letter-spacing:-.25pt'> </span>réduire<span style='letter-spacing:-.4pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>prévenir<span style='letter-spacing:-.35pt'> </span>une<span style='letter-spacing:-.2pt'> </span>h<span style='letter-spacing: .1pt'>y</span>ponatré<span style='letter-spacing:-.05pt'>m</span>ie<span style='letter-spacing:-.5pt'> </span>induite<span style='letter-spacing:-.35pt'> </span>par<span style='letter-spacing:-.15pt'> </span>les diurétiques.<span style='letter-spacing:-.55pt'> </span>Une<span style='letter-spacing:-.2pt'> </span>déplétion<span style='letter-spacing:-.4pt'> </span>chlorée<span style='letter-spacing:-.3pt'> </span>est<span style='letter-spacing:-.1pt'> </span>en<span style='letter-spacing: -.1pt'> </span>général<span style='letter-spacing:-.3pt'> </span>p<span style='letter-spacing:-.05pt'>e</span>u<span style='letter-spacing:-.15pt'> </span>i<span style='letter-spacing:-.1pt'>m</span>portante<span style='letter-spacing:-.4pt'> </span>et dans<span style='letter-spacing:-.2pt'> </span>la plupart<span style='letter-spacing:-.3pt'> </span>des<span style='letter-spacing:-.15pt'> </span>cas,<span style='letter-spacing:-.05pt'> </span>ne<span style='letter-spacing:-.1pt'> </span>requiert aucun<span style='letter-spacing:-.25pt'> </span>traitement.</p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.15pt'> </span>thiazidiques<span style='letter-spacing:-.5pt'> </span>peuvent<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.05pt'>r</span>éduire<span style='letter-spacing:-.25pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>excrétion<span style='letter-spacing:-.35pt'> </span>ur<span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.05pt'>n</span>aire<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>calci<span style='letter-spacing:.1pt'>u</span>m<span style='letter-spacing:-.4pt'> </span>et<span style='letter-spacing:.1pt'> </span>prov<span style='letter-spacing:-.05pt'>o</span>quer<span style='letter-spacing:-.45pt'> </span>u<span style='letter-spacing:-.05pt'>n</span>e<span style='letter-spacing:-.1pt'> </span>élévation<span style='letter-spacing:-.35pt'> </span>légère<span style='letter-spacing:-.25pt'> </span>et transitoire<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la calcé<span style='letter-spacing:-.05pt'>m</span>ie<span style='letter-spacing:-.2pt'> </span>en<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>absence<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>désor<span style='letter-spacing:-.1pt'>d</span>re<span style='letter-spacing:-.4pt'> </span>connu<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.05pt'>d</span>u<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span>étabolis<span style='letter-spacing:-.05pt'>m</span>e<span style='letter-spacing:-.45pt'> </span>calcique.<span style='letter-spacing:-.35pt'> </span>Une<span style='letter-spacing:-.2pt'> </span>hypercalcémie i<span style='letter-spacing:-.1pt'>m</span>portante<span style='letter-spacing: -.45pt'> </span>peut<span style='letter-spacing:-.2pt'> </span>être<span style='letter-spacing:-.15pt'> </span>le s<span style='letter-spacing:.1pt'>y</span>mptô<span style='letter-spacing:-.05pt'>m</span>e<span style='letter-spacing:-.4pt'> </span>d’une<span style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>h</span><span style='letter-spacing:.1pt'>y</span>perparathyroïdie<span style='letter-spacing: -.85pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>a</span>squée.<span style='letter-spacing:-.35pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>thiaz<span style='letter-spacing:.1pt'>i</span>diques<span style='letter-spacing:-.3pt'> </span>doivent<span style='letter-spacing:-.35pt'> </span>être interro<span style='letter-spacing: -.05pt'>m</span>pus<span style='letter-spacing:-.55pt'> </span>avant<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.05pt'>d</span><span style='letter-spacing:.05pt'>’</span>exp<span style='letter-spacing:-.05pt'>l</span>orer<span style='letter-spacing:-.45pt'> </span>la<span style='letter-spacing:.05pt'> </span>fonction<span style='letter-spacing:-.4pt'> </span>parath<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.05pt'>r</span>oïdi<span style='letter-spacing:-.05pt'>e</span>nne.</p>
<p class=AmmCorpsTexte>Une<span style='letter-spacing:-.2pt'> </span>au<span style='letter-spacing:.1pt'>g</span><span style='letter-spacing:-.1pt'>m</span>entation<span style='letter-spacing:-.55pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>élimination<span style='letter-spacing: -.45pt'> </span>uri<span style='letter-spacing:-.05pt'>n</span>aire<span style='letter-spacing:-.35pt'> </span>du<span style='letter-spacing:-.1pt'> </span>mag<span style='letter-spacing:-.05pt'>n</span>ési<span style='letter-spacing:.1pt'>u</span>m<span style='letter-spacing:-.55pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing:-.25pt'> </span>été d<span style='letter-spacing:.05pt'>é</span><span style='letter-spacing:-.1pt'>m</span>ontrée<span style='letter-spacing:-.35pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>thia<span style='letter-spacing:.05pt'>z</span>idiques,<span style='letter-spacing:-.55pt'> </span>il peut<span style='letter-spacing:-.2pt'> </span>en<span style='letter-spacing:-.1pt'> </span>résulter<span style='letter-spacing:-.35pt'> </span>une<span style='letter-spacing:-.15pt'> </span>h<span style='letter-spacing:.1pt'>y</span>pomagnés<span style='letter-spacing:.05pt'>é</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>i</span>e.</p>
<p class=AmmCorpsTexte><u>Lithiu<span style='letter-spacing:-.05pt'>m</span></u><span style='letter-spacing:-.05pt'> </span>:<span style='letter-spacing:-.35pt'> </span>l'association<span style='letter-spacing:-.5pt'> </span>du<span style='letter-spacing:-.15pt'> </span>li<span style='letter-spacing:-.05pt'>t</span>hium<span style='letter-spacing:-.3pt'> </span>et<span style='letter-spacing:.05pt'> </span>d’IRBESARTAN/HYDROCHLOROTHIAZIDE SET<span style='letter-spacing:-.45pt'> </span>est<span style='letter-spacing:-.1pt'> </span>déconseillée<span style='letter-spacing:-.5pt'> </span>(voir<span style='letter-spacing:-.2pt'> </span>rub<span style='letter-spacing:-.05pt'>r</span>ique<span style='letter-spacing:-.4pt'> </span>4.5).</p>
<p class=AmmCorpsTexte><u>Test<span style='letter-spacing:-.2pt'> </span>antidopage</u> :<span style='letter-spacing:-.5pt'> </span>ce<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:-.1pt'>m</span>édicament<span style='letter-spacing:-.45pt'> </span>contient<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing: -.05pt'>'</span>h<span style='letter-spacing:.1pt'>y</span>d<span style='letter-spacing:-.05pt'>r</span>och<span style='letter-spacing:-.05pt'>l</span>oro<span style='letter-spacing:-.05pt'>t</span>hiazide,<span style='letter-spacing:-.85pt'> </span><span style='letter-spacing:-.05pt'>p</span>rincipe<span style='letter-spacing:-.3pt'> </span>actif<span style='letter-spacing:.05pt'> </span>pouvant<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.05pt'>i</span>ndui<span style='letter-spacing:-.05pt'>r</span>e<span style='letter-spacing:-.25pt'> </span>une réaction<span style='letter-spacing:-.35pt'> </span>positive<span style='letter-spacing:-.35pt'> </span>des<span style='letter-spacing:-.15pt'> </span>tests<span style='letter-spacing:-.2pt'> </span>pratiqués<span style='letter-spacing:-.4pt'> </span>lors<span style='letter-spacing:-.15pt'> </span>des<span style='letter-spacing:-.15pt'> </span>contrôles<span style='letter-spacing: -.4pt'> </span>antidopage.</p>
<p class=AmmCorpsTexte><u>Général</u> :<span style='letter-spacing:-.4pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.35pt'> </span>dont<span style='letter-spacing:-.2pt'> </span>la tonicité<span style='letter-spacing:-.3pt'> </span>vasculaire<span style='letter-spacing:-.45pt'> </span>et<span style='letter-spacing:.1pt'> </span>la fonction<span style='letter-spacing:-.35pt'> </span>r<span style='letter-spacing: -.05pt'>é</span>nale<span style='letter-spacing:-.3pt'> </span>dépendent<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>façon prédo<span style='letter-spacing:-.1pt'>m</span>inante<span style='letter-spacing: -.55pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>activité<span style='letter-spacing:.1pt'> </span>du<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing: -.05pt'>s</span><span style='letter-spacing:.1pt'>y</span>stème<span style='letter-spacing:-.3pt'> </span>rénine-ang<span style='letter-spacing: -.1pt'>i</span>otensine-aldosté<span style='letter-spacing:.05pt'>r</span>one<span style='letter-spacing:-1.4pt'> </span>(par<span style='letter-spacing:-.2pt'> </span>exe<span style='letter-spacing:-.05pt'>m</span>p<span style='letter-spacing:.05pt'>l</span>e<span style='letter-spacing:-.3pt'> </span>les<span style='letter-spacing:-.1pt'> </span>pati<span style='letter-spacing:.05pt'>e</span>nts présentant<span style='letter-spacing: -.45pt'> </span>une<span style='letter-spacing:-.15pt'> </span>insuffisance<span style='letter-spacing:-.55pt'> </span>cardiaque<span style='letter-spacing: -.45pt'> </span>congestive<span style='letter-spacing:-.45pt'> </span>sévère<span style='letter-spacing:-.3pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>une<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>a<span style='letter-spacing:.05pt'>l</span>adie<span style='letter-spacing:-.2pt'> </span>rénale<span style='letter-spacing:-.25pt'> </span>s<span style='letter-spacing:.1pt'>o</span>us-jacente,<span style='letter-spacing:-.55pt'> </span>y c<span style='letter-spacing:.1pt'>o</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>ris une<span style='letter-spacing:-.15pt'> </span>sténose<span style='letter-spacing: -.3pt'> </span>des<span style='letter-spacing:-.15pt'> </span>artères<span style='letter-spacing:-.3pt'> </span>ré<span style='letter-spacing:.1pt'>n</span>ales),<span style='letter-spacing:-.35pt'> </span>le traitement<span style='letter-spacing: -.5pt'> </span>par<span style='letter-spacing:-.15pt'> </span>inhibiteurs<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>e<span style='letter-spacing:.1pt'>n</span>z<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>conversion<span style='letter-spacing:-.5pt'> </span>ou antagonistes<span style='letter-spacing: -.55pt'> </span>des<span style='letter-spacing:-.15pt'> </span>récepteu<span style='letter-spacing:.05pt'>r</span>s<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>angiotensine-II<span style='letter-spacing:-.65pt'> </span>agiss<span style='letter-spacing:-.05pt'>a</span>nt<span style='letter-spacing:-.35pt'> </span>sur<span style='letter-spacing:-.15pt'> </span>ce s<span style='letter-spacing:.1pt'>y</span>stè<span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:-.3pt'> </span>a<span style='letter-spacing:.1pt'> </span>été associé<span style='letter-spacing:-.3pt'> </span>à une<span style='letter-spacing: -.15pt'> </span>hypotension aiguë,<span style='letter-spacing:-.2pt'> </span>une<span style='letter-spacing:-.15pt'> </span>azoté<span style='letter-spacing:-.05pt'>m</span>ie,<span style='letter-spacing:-.4pt'> </span>une<span style='letter-spacing:-.15pt'> </span>oligurie<span style='letter-spacing:-.3pt'> </span>ou,<span style='letter-spacing:-.2pt'> </span>rare<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:-.05pt'>e</span>nt,<span style='letter-spacing:-.35pt'> </span>à une<span style='letter-spacing:-.15pt'> </span>insuffisance<span style='letter-spacing:-.55pt'> </span><span style='letter-spacing:.05pt'>r</span>énale<span style='letter-spacing:-.2pt'> </span>aiguë.<span style='letter-spacing:-.25pt'> </span>C<span style='letter-spacing:.1pt'>o</span>mme<span style='letter-spacing:-.35pt'> </span>avec n<span style='letter-spacing:.05pt'>’</span>i<span style='letter-spacing:-.1pt'>m</span>porte<span style='letter-spacing:-.45pt'> </span>quel<span style='letter-spacing:-.2pt'> </span>agent<span style='letter-spacing:-.25pt'> </span>antihypertenseur,<span style='letter-spacing:-.7pt'> </span>une<span style='letter-spacing:-.15pt'> </span>baisse<span style='letter-spacing:-.25pt'> </span>b<span style='letter-spacing:-.1pt'>r</span>utale<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la pression<span style='letter-spacing:-.35pt'> </span>artérie<span style='letter-spacing:.1pt'>l</span>le<span style='letter-spacing:-.3pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patients porteurs<span style='letter-spacing:-.35pt'> </span>d<span style='letter-spacing: .05pt'>’</span>une<span style='letter-spacing:-.25pt'> </span>cardiopathie<span style='letter-spacing:-.5pt'> </span>isché<span style='letter-spacing:-.05pt'>m</span>ique<span style='letter-spacing:-.4pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>d<span style='letter-spacing:.05pt'>’</span>u<span style='letter-spacing:.05pt'>n</span>e<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span>a<span style='letter-spacing:.05pt'>l</span>adie<span style='letter-spacing:-.2pt'> </span>cardiovasculaire<span style='letter-spacing:-.65pt'> </span>ischémique<span style='letter-spacing: -.5pt'> </span>pourrait entraîner<span style='letter-spacing:-.35pt'> </span>un<span style='letter-spacing:-.1pt'> </span>infarctus<span style='letter-spacing:-.4pt'> </span>du<span style='letter-spacing:-.1pt'> </span>myocarde<span style='letter-spacing:-.45pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>un<span style='letter-spacing:-.1pt'> </span>accident<span style='letter-spacing:-.3pt'> </span>vasculaire<span style='letter-spacing:-.4pt'> </span><span style='letter-spacing:.05pt'>c</span>éré<span style='letter-spacing:.1pt'>b</span>ral.</p>
<p class=AmmCorpsTexte>Des<span style='letter-spacing:-.15pt'> </span>réactions<span style='letter-spacing:-.4pt'> </span>d’h<span style='letter-spacing:.1pt'>y</span>persensibilité<span style='letter-spacing:-.75pt'> </span>à l<span style='letter-spacing:-.05pt'>'</span>h<span style='letter-spacing:.1pt'>y</span>d<span style='letter-spacing:-.05pt'>r</span>ochlorothiaz<span style='letter-spacing:-.05pt'>i</span>de<span style='letter-spacing:-.9pt'> </span>peuvent<span style='letter-spacing:-.35pt'> </span>survenir<span style='letter-spacing:-.35pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing:-.35pt'> </span>a<span style='letter-spacing:.1pt'>v</span>ec<span style='letter-spacing: -.1pt'> </span>ou sans<span style='letter-spacing:-.2pt'> </span>anté<span style='letter-spacing:.05pt'>c</span>éd<span style='letter-spacing:.05pt'>e</span>nts<span style='letter-spacing:-.45pt'> </span>allergiques<span style='letter-spacing: -.5pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>d<span style='letter-spacing:.05pt'>’</span>asth<span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:-.3pt'> </span>bronchique.<span style='letter-spacing: -.55pt'> </span>Cependant,<span style='letter-spacing:-.5pt'> </span>ces<span style='letter-spacing:-.15pt'> </span>ré<span style='letter-spacing:.05pt'>a</span>ctions<span style='letter-spacing:-.35pt'> </span>allergiques<span style='letter-spacing: -.5pt'> </span>sont<span style='letter-spacing:-.2pt'> </span>plus vrais<span style='letter-spacing:.05pt'>e</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>b</span>lab<span style='letter-spacing:.05pt'>l</span>es<span style='letter-spacing:-.65pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>l<span style='letter-spacing:.05pt'>e</span>s<span style='letter-spacing:-.05pt'> </span>p<span style='letter-spacing:.05pt'>a</span>tients<span style='letter-spacing:-.35pt'> </span>présentant<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>tels antécédents.</p>
<p class=AmmCorpsTexte>Des<span style='letter-spacing:-.15pt'> </span>cas<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.1pt'>d</span><span style='letter-spacing:-.05pt'>'</span>exacerbation<span style='letter-spacing: -.6pt'> </span>ou<span style='letter-spacing:-.15pt'> </span>d<span style='letter-spacing:-.05pt'>'</span>activation<span style='letter-spacing: -.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>lupus<span style='letter-spacing:-.25pt'> </span>é<span style='letter-spacing:-.1pt'>r</span><span style='letter-spacing:.1pt'>y</span>t<span style='letter-spacing:-.05pt'>h</span><span style='letter-spacing:.05pt'>é</span><span style='letter-spacing:-.1pt'>m</span>ateux<span style='letter-spacing:-.4pt'> </span>dissé<span style='letter-spacing:-.1pt'>m</span>iné<span style='letter-spacing:-.4pt'> </span>ont<span style='letter-spacing:-.1pt'> </span>été<span style='letter-spacing:.05pt'> </span>rapportés<span style='letter-spacing:-.35pt'> </span>lo<span style='letter-spacing:-.05pt'>r</span>s<span style='letter-spacing: -.15pt'> </span>de l<span style='letter-spacing:-.05pt'>'</span>utilisation<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>diurétiques<span style='letter-spacing:-.5pt'> </span>thiazidiques.</p>
<p class=AmmCorpsTexte>Des<span style='letter-spacing:-.15pt'> </span>cas<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>réactions<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>photosensibilité<span style='letter-spacing:-.65pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été rapportés<span style='letter-spacing:-.4pt'> </span>avec<span style='letter-spacing: -.2pt'> </span>les<span style='letter-spacing:-.05pt'> </span>diurétiques<span style='letter-spacing:-.5pt'> </span>thiazidiques<span style='letter-spacing: -.55pt'> </span>(voir rubrique<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.05pt'>4</span>.8).<span style='letter-spacing:-.25pt'> </span>Si<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>telles réactions<span style='letter-spacing:-.4pt'> </span>surviennent<span style='letter-spacing:-.5pt'> </span>du<span style='letter-spacing:-.05pt'>r</span>ant<span style='letter-spacing:-.3pt'> </span>le trait<span style='letter-spacing:.05pt'>e</span>ment,<span style='letter-spacing:-.25pt'> </span>il est<span style='letter-spacing:-.1pt'> </span>rec<span style='letter-spacing:.1pt'>o</span>mmandé<span style='letter-spacing:-.55pt'> </span>d<span style='letter-spacing:.05pt'>’</span>arrêter<span style='letter-spacing:-.4pt'> </span>celui-ci.<span style='letter-spacing:-.1pt'> </span>Si<span style='letter-spacing:-.1pt'> </span>la reprise<span style='letter-spacing:-.3pt'> </span>du<span style='letter-spacing:-.1pt'> </span>trait<span style='letter-spacing:.05pt'>e</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>e</span>nt<span style='letter-spacing:-.15pt'> </span>par<span style='letter-spacing:-.15pt'> </span>diurétique<span style='letter-spacing: -.45pt'> </span>est<span style='letter-spacing:-.15pt'> </span>jugée<span style='letter-spacing:-.25pt'> </span>néces<span style='letter-spacing:.05pt'>s</span>aire,<span style='letter-spacing:-.5pt'> </span>il<span style='letter-spacing:.1pt'> </span>est<span style='letter-spacing:-.1pt'> </span>rec<span style='letter-spacing:.1pt'>o</span>mmandé<span style='letter-spacing:-.65pt'> </span>de<span style='letter-spacing:-.1pt'> </span>prot<span style='letter-spacing:-.05pt'>é</span><span style='letter-spacing:.05pt'>g</span>er<span style='letter-spacing:-.35pt'> </span>les zones<span style='letter-spacing: -.25pt'> </span>exposées<span style='letter-spacing:-.4pt'> </span>au<span style='letter-spacing:-.1pt'> </span>soleil<span style='letter-spacing:-.25pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>aux<span style='letter-spacing: -.15pt'> </span>UVA<span style='letter-spacing:-.25pt'> </span>artificiels.</p>
<p class=AmmCorpsTexte><u>Gross<span style='letter-spacing:.05pt'>e</span>sse</u> :<span style='letter-spacing:-.4pt'> </span>les<span style='letter-spacing: -.1pt'> </span>inhibiteurs<span style='letter-spacing:-.5pt'> </span>des<span style='letter-spacing:-.15pt'> </span>récepteu<span style='letter-spacing:.05pt'>r</span>s<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:.05pt'>’</span>ang<span style='letter-spacing:-.05pt'>i</span>ote<span style='letter-spacing:.05pt'>n</span>sine<span style='letter-spacing:-.6pt'> </span>II<span style='letter-spacing:-.05pt'> </span>(ARAII)<span style='letter-spacing:-.4pt'> </span>dont<span style='letter-spacing:-.2pt'> </span>IRBESARTAN/HYDROCHLOROTHIAZIDE SET<span style='letter-spacing:-.5pt'> </span>ne<span style='letter-spacing: -.1pt'> </span>doivent<span style='letter-spacing:-.35pt'> </span>pas être<span style='letter-spacing:-.15pt'> </span>débutés<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:.05pt'>a</span>u cours<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la<span style='letter-spacing:-.05pt'> </span>grossesse.<span style='letter-spacing: -.4pt'> </span>A<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>o</span>ins<span style='letter-spacing:-.25pt'> </span>que<span style='letter-spacing:-.05pt'> </span>le<span style='letter-spacing:.1pt'> </span>trait<span style='letter-spacing:.05pt'>e</span>ment<span style='letter-spacing:-.2pt'> </span>par<span style='letter-spacing:-.15pt'> </span>ARAII<span style='letter-spacing:-.3pt'> </span>ne<span style='letter-spacing:-.1pt'> </span>s<span style='letter-spacing:.1pt'>o</span>it<span style='letter-spacing:-.1pt'> </span>considéré<span style='letter-spacing:-.4pt'> </span>comme essentiel,<span style='letter-spacing:-.4pt'> </span>il e<span style='letter-spacing:.05pt'>s</span>t<span style='letter-spacing:-.1pt'> </span>rec<span style='letter-spacing:.1pt'>o</span>mmandé<span style='letter-spacing:-.55pt'> </span>de<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span>odifier<span style='letter-spacing:-.4pt'> </span>le trait<span style='letter-spacing:.05pt'>e</span>ment<span style='letter-spacing:-.2pt'> </span>antih<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:.05pt'>p</span>ertenseur<span style='letter-spacing:-.75pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:.1pt'>p</span>atientes<span style='letter-spacing:-.35pt'> </span>qui envisagent<span style='letter-spacing: -.4pt'> </span>une<span style='letter-spacing:-.15pt'> </span>grossesse<span style='letter-spacing:-.4pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>un<span style='letter-spacing:-.1pt'> m</span>édica<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.5pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing:-.25pt'> </span>un<span style='letter-spacing:-.1pt'> </span>prof<span style='letter-spacing:-.05pt'>i</span>l<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>s</span>écurité<span style='letter-spacing:-.3pt'> </span>établi<span style='letter-spacing:.1pt'> </span>pendant<span style='letter-spacing:-.35pt'> </span>la g<span style='letter-spacing:-.05pt'>r</span>ossesse. En<span style='letter-spacing:-.1pt'> </span>cas<span style='letter-spacing: -.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>diagnostic<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>g<span style='letter-spacing:-.05pt'>r</span>ossesse,<span style='letter-spacing:-.45pt'> </span>le traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.4pt'> </span>p<span style='letter-spacing:-.1pt'>a</span>r<span style='letter-spacing:-.15pt'> </span>un<span style='letter-spacing:-.1pt'> </span>ARAII<span style='letter-spacing:-.3pt'> </span>doit<span style='letter-spacing:-.15pt'> </span>être<span style='letter-spacing:-.15pt'> </span>arrê<span style='letter-spacing:.05pt'>t</span>é<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>i</span>mmédiatement<span style='letter-spacing:-.55pt'> </span>et si néces<span style='letter-spacing: .05pt'>s</span>aire<span style='letter-spacing:-.45pt'> </span>un<span style='letter-spacing:-.1pt'> </span>trait<span style='letter-spacing:.05pt'>e</span><span style='letter-spacing:-.1pt'>m</span>ent<span style='letter-spacing:-.15pt'> </span>al<span style='letter-spacing:.05pt'>t</span>ernatif<span style='letter-spacing:-.25pt'> </span>sera<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing: .1pt'>d</span>ébuté<span style='letter-spacing:-.25pt'> </span>(voir<span style='letter-spacing:-.2pt'> </span>rubriques<span style='letter-spacing:-.4pt'> </span>4.3<span style='letter-spacing:-.15pt'> </span>et 4.6).</p>
<p class=AmmCorpsTexte><u>Lactose</u> : ce médicament contient du lactose. Son utilisation est déconseillée chez les patients présentant une intolérance au galactose, un déficit en lactase de Lapp ou un syndrome de malabsorption du glucose ou du galactose (maladies héréditaires rares).</p>
<p class=AmmCorpsTexte><u>Myopie<span style='letter-spacing:-.35pt'> </span>Aig<span style='letter-spacing:-.05pt'>u</span>ë<span style='letter-spacing:-.25pt'> </span>et<span style='letter-spacing:-.05pt'> </span>Glauc<span style='letter-spacing:.1pt'>o</span>me<span style='letter-spacing:-.5pt'> </span>Aigu<span style='letter-spacing:-.25pt'> </span>Secondaire<span style='letter-spacing:-.5pt'> </span>à<span style='letter-spacing:-.05pt'> </span>Angle<span style='letter-spacing:-.3pt'> </span>Fer<span style='letter-spacing:-.1pt'>m</span>é</u> :<span style='letter-spacing:-.25pt'> </span>l<span style='letter-spacing:.05pt'>e</span>s médic<span style='letter-spacing:.05pt'>a</span>ments<span style='letter-spacing: -.6pt'> </span>à<span style='letter-spacing:.05pt'> </span>base<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>sulf<span style='letter-spacing:.05pt'>a</span><span style='letter-spacing:-.1pt'>m</span>ides ou<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing: -.1pt'> </span>dérivés<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>sulfa<span style='letter-spacing:-.1pt'>m</span>ide,<span style='letter-spacing:-.35pt'> </span>peuvent<span style='letter-spacing:-.3pt'> </span>p<span style='letter-spacing:-.05pt'>r</span>ovoquer<span style='letter-spacing:-.45pt'> </span>une<span style='letter-spacing:-.15pt'> </span>réaction<span style='letter-spacing:-.3pt'> </span>idio<span style='letter-spacing:-.05pt'>s</span><span style='letter-spacing:.05pt'>y</span>ncratique<span style='letter-spacing:-.65pt'> </span>donnant<span style='letter-spacing:-.35pt'> </span>lieu<span style='letter-spacing:-.15pt'> </span>à une<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.1pt'>y</span>opie transitoire<span style='letter-spacing:-.45pt'> </span>et à un<span style='letter-spacing:-.1pt'> </span>glaucome<span style='letter-spacing:-.45pt'> </span>aigu<span style='letter-spacing:-.2pt'> </span>à angle<span style='letter-spacing:-.25pt'> </span>fe<span style='letter-spacing:.05pt'>r</span><span style='letter-spacing:-.1pt'>m</span>é.<span style='letter-spacing:-.3pt'> </span><span style='letter-spacing:.05pt'>L</span><span style='letter-spacing:-.1pt'>'</span>h<span style='letter-spacing:.1pt'>y</span>drochlorothia<span style='letter-spacing: -.05pt'>z</span>ide<span style='letter-spacing:-.95pt'> </span>étant<span style='letter-spacing:-.2pt'> </span>une<span style='letter-spacing:-.2pt'> </span>sulf<span style='letter-spacing:.05pt'>a</span><span style='letter-spacing:-.1pt'>m</span>ide,<span style='letter-spacing:-.45pt'> </span>s<span style='letter-spacing:.05pt'>e</span>uls<span style='letter-spacing:-.2pt'> des cas </span>isolés<span style='letter-spacing: -.25pt'> </span>de glaucome<span style='letter-spacing:-.45pt'> </span>aigu<span style='letter-spacing:-.2pt'> </span>à angle<span style='letter-spacing:-.25pt'> </span>fermé<span style='letter-spacing:-.25pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été rapportés<span style='letter-spacing: -.4pt'> </span>jusqu<span style='letter-spacing:-.05pt'>'</span>alors<span style='letter-spacing:-.45pt'> </span>avec<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>l</span><span style='letter-spacing:-.05pt'>'</span>hydrochlo<span style='letter-spacing:-.05pt'>r</span>oth<span style='letter-spacing:-.05pt'>i</span>azide.<span style='letter-spacing:-.95pt'> </span>Les s<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>tômes<span style='letter-spacing:-.5pt'> </span>incluent<span style='letter-spacing:-.3pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>apparition<span style='letter-spacing:-.4pt'> </span>so<span style='letter-spacing:-.05pt'>u</span><span style='letter-spacing:.05pt'>d</span>ai<span style='letter-spacing:-.05pt'>n</span>e<span style='letter-spacing:-.35pt'> </span>d<span style='letter-spacing:-.05pt'>'</span>une<span style='letter-spacing:-.25pt'> </span>rédu<span style='letter-spacing:-.05pt'>c</span>tion<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>acuité<span style='letter-spacing:-.2pt'> </span>visuelle<span style='letter-spacing:-.3pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>d<span style='letter-spacing:-.05pt'>'</span>une<span style='letter-spacing:-.25pt'> </span>do<span style='letter-spacing:-.05pt'>u</span>leur<span style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>o</span>culaire et surviennent<span style='letter-spacing:-.5pt'> </span>en<span style='letter-spacing:-.1pt'> </span>règle<span style='letter-spacing:-.2pt'> </span>générale<span style='letter-spacing:-.4pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.05pt'> </span>heures<span style='letter-spacing:-.3pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>les<span style='letter-spacing: -.1pt'> </span>s<span style='letter-spacing:.05pt'>e</span>maines<span style='letter-spacing:-.4pt'> </span>s<span style='letter-spacing:.05pt'>u</span>ivant<span style='letter-spacing:-.25pt'> </span>le début<span style='letter-spacing:-.3pt'> </span>du<span style='letter-spacing:-.1pt'> </span>traitement.<span style='letter-spacing:-.4pt'> </span>Un glaucome<span style='letter-spacing: -.45pt'> </span>aigu<span style='letter-spacing:-.2pt'> </span>à angle<span style='letter-spacing:-.25pt'> </span>fermé<span style='letter-spacing:-.25pt'> </span>non<span style='letter-spacing:-.15pt'> </span>traité peut<span style='letter-spacing:-.2pt'> </span>in<span style='letter-spacing:-.05pt'>d</span><span style='letter-spacing:.05pt'>u</span>ire<span style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>u</span><span style='letter-spacing:.05pt'>n</span>e<span style='letter-spacing:-.1pt'> </span>perte<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la vision<span style='letter-spacing:-.25pt'> </span>per<span style='letter-spacing:-.1pt'>m</span>anente.<span style='letter-spacing:-.55pt'> </span>La<span style='letter-spacing:-.1pt'> </span>première mesure<span style='letter-spacing:-.2pt'> </span>à adopter<span style='letter-spacing:-.35pt'> </span>est<span style='letter-spacing:-.1pt'> </span>l'arrêt<span style='letter-spacing:-.25pt'> </span>du<span style='letter-spacing:-.1pt'> </span>t<span style='letter-spacing:-.15pt'>r</span>aitement<span style='letter-spacing:-.4pt'> </span>le plus<span style='letter-spacing:-.2pt'> </span>rapi<span style='letter-spacing:-.05pt'>d</span><span style='letter-spacing:.05pt'>e</span><span style='letter-spacing:-.1pt'>m</span>ent<span style='letter-spacing:-.4pt'> </span>possible.<span style='letter-spacing:-.4pt'> </span>Un<span style='letter-spacing:-.15pt'> </span>recours<span style='letter-spacing:-.3pt'> </span>rapide<span style='letter-spacing:-.25pt'> </span>à un trait<span style='letter-spacing:.05pt'>e</span>ment<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>é</span>dic<span style='letter-spacing:.05pt'>a</span><span style='letter-spacing:-.1pt'>m</span>enteux<span style='letter-spacing:-.6pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>à la chirurgie<span style='letter-spacing:-.4pt'> </span>peut<span style='letter-spacing:-.2pt'> </span>s<span style='letter-spacing:-.15pt'>'</span>av<span style='letter-spacing:.05pt'>é</span>rer<span style='letter-spacing:-.35pt'> </span>néce<span style='letter-spacing:.05pt'>s</span>saire<span style='letter-spacing:-.4pt'> </span>si<span style='letter-spacing:-.05pt'> </span>la pression<span style='letter-spacing: -.35pt'> </span>intraoculaire<span style='letter-spacing:-.5pt'> </span>reste incontrôlée.<span style='letter-spacing:-.55pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>fac<span style='letter-spacing:.05pt'>t</span>eurs<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>risque<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>survenue<span style='letter-spacing:-.35pt'> </span>d<span style='letter-spacing:-.05pt'>'</span>un<span style='letter-spacing:-.25pt'> </span>glaucome<span style='letter-spacing:-.45pt'> </span>aigu<span style='letter-spacing:-.2pt'> </span>à angle<span style='letter-spacing:-.25pt'> </span>fermé<span style='letter-spacing:-.25pt'> </span>peuvent<span style='letter-spacing:-.35pt'> </span>inclure<span style='letter-spacing:-.3pt'> </span>les antécédents<span style='letter-spacing: -.45pt'> </span><span style='letter-spacing:.1pt'>d</span><span style='letter-spacing:-.05pt'>'</span>al<span style='letter-spacing:.05pt'>l</span>ergies<span style='letter-spacing:-.3pt'> </span>aux<span style='letter-spacing:-.15pt'> </span>sulfa<span style='letter-spacing:-.1pt'>m</span>ides<span style='letter-spacing:-.5pt'> </span>ou<span style='letter-spacing:-.15pt'> </span>à la pénicilline<span style='letter-spacing: -.4pt'> </span>(voir<span style='letter-spacing:-.2pt'> </span>rubrique<span style='letter-spacing:-.35pt'> </span>4.8).</p>
<p class="AmmAnnexeTitre2"><a name="RcpInteractions">4.5. Interactions avec d'autres médicaments et autres formes d'interactions</a></p>
<p class=AmmCorpsTexte><u>Autres antihypertenseurs</u> : l'effet antihypertenseur d’IRBESARTAN/HYDROCHLOROTHIAZIDE SET peut être augmenté lors de l'utilisation simultanée d’autres antihypertenseurs. L'irbésartan et l'hydrochlorothiazide (à des doses allant jusqu’à 300 mg d’irbésartan et 25 mg d’hydrochlorothiazide) ont été administrés sans problème de tolérance avec d'autres antihypertenseurs dont les antagonistes calciques et les bêtabloquants. Un traitement préalable par des diurétiques à dose élevée peut provoquer une hypovolémie et un risque d’hypotension lorsqu'un traitement par l'irbésartan avec ou sans diurétiques thiazidiques est instauré, sauf si la déplétion volémique est préalablement corrigée (voir rubrique 4.4).</p>
<p class=AmmCorpsTexte><u>Lithium</u><b> </b>: des augmentations réversibles des concentrations sériques et de la toxicité du lithium ont été rapportées avec les inhibiteurs de l'enzyme de conversion. A ce jour, des effets similaires ont été très rarement rapportés avec l'irbésartan. De plus, la clairance rénale du lithium étant réduite par les thiazidiques, le risque de toxicité du lithium est majoré avec IRBESARTAN/HYDROCHLOROTHIAZIDE SET. Par conséquent, l'association de lithium et d’IRBESARTAN/HYDROCHLOROTHIAZIDE SET est déconseillée (voir rubrique 4.4). Si cette association se révèle nécessaire, une surveillance stricte de la lithémie est recommandée.</p>
<p class=AmmCorpsTexte><u>Médicaments modifiant la kaliémie<b> </b></u>: la déplétion potassique due à l'hydrochlorothiazide est atténuée par l'effet épargneur de potassium de l'irbésartan. Cependant, on peut s’attendre à ce que cet effet de l'hydrochlorothiazide sur la kaliémie soit potentialisé par d’autres médicaments qui induisent une perte potassique ou une hypokaliémie (tels que les diurétiques hypokaliémiants, les laxatifs,<b> </b>l'amphotéricine B, le carbenoxolone, la pénicilline G sodique). A l'inverse, en se fondant sur l'expérience acquise avec les autres médicaments intervenant sur le système rénine-angiotensine, l'administration concomitante d’IRBESARTAN/HYDROCHLOROTHIAZIDE SET avec des diurétiques d’épargne potassique, une supplémentation en potassium, des sels de régime contenant du potassium ou d’autres médicaments qui peuvent augmenter les taux de potassium plasmatique (par exemple héparine sodique) peut donner lieu à une élévation de la kaliémie.Il est recommandé une surveillance adéquate du potassium sérique chez les patients à risque (voir rubrique 4.4).</p>
<p class=AmmCorpsTexte><u>Médicaments dont l'effet est influencé par des perturbations de la kaliémie</u> : un dosage régulier de la kaliémie est recommandé lorsqu’IRBESARTAN/HYDROCHLOROTHIAZIDE SET est administré avec des médicaments dont l'effet est influencé par des perturbations des concentrations sériques de potassium (par exemple digitaliques, antiarythmiques).</p>
<p class=AmmAnnexeTitre2Bis><span style='color:windowtext;font-weight:normal'>Anti-inflammatoires non stéroïdiens</span><span style='color:windowtext;font-weight:normal; text-decoration:none'> : lorsque les antagonistes de l'angiotensine II sont administrés simultanément avec des anti-inflammatoires non stéroïdiens (c'est-à dire les inhibiteurs sélectifs de la cyclo-oxygénase de type 2 (COX-2), l'acide acétylsalicylique (&gt; 3 g/jour) et les anti-inflammatoires non stéroïdiens non sélectifs), une atténuation de l'effet anti-hypertenseur peut se produire.</span></p>
<p class=AmmAnnexeTitre2Bis><span style='color:windowtext;font-weight:normal; text-decoration:none'>Comme avec les inhibiteurs de l'enzyme de conversion de l'angiotensine, l'utilisation concomitante des antagonistes de l'angiotensine II et des anti-inflammatoires non stéroïdiens non sélectifs peut accroître le risque de détérioration de la fonction rénale, avec une possibilité d'insuffisance rénale aiguë, et une augmentation du potassium sérique en particulier chez les patients présentant une fonction rénale préalablement altérée. L'association devra être administrée avec prudence, en particulier chez les personnes âgées. Les patients devront être correctement hydratés et une surveillance de la fonction rénale devra être envisagée après l'initiation de l'association thérapeutique, puis périodiquement.</span></p>
<p class=AmmAnnexeTitre2Bis style='page-break-after:auto'><span style='color:windowtext;font-weight:normal'>Autres informations sur les interactions de l'irbésartan</span><span style='color:windowtext;font-weight:normal; text-decoration:none'> : dans les études cliniques, la pharmacocinétique de l'irbésartan n'a pas été modifiée par l'administration simultanée d'hydrochlorothiazide. L'irbésartan est principalement métabolisé par le CYP2C9 et dans une moindre mesure par glucuronidation. Il n’a pas été observé d’interactions pharmacocinétique et pharmacodynamique significatives quand l'irbésartan a été administré simultanément avec la warfarine, un médicament métabolisé par le CYP2C9. Les effets des inducteurs du CYP2C9, tels que la rifampicine, sur la pharmacocinétique de l'irbésartan n'ont pas été évalués. La pharmacocinétique de la digoxine n'a pas été altérée par l'administration simultanée d'irbésartan.</span></p>
<p class=AmmAnnexeTitre2Bis style='page-break-after:auto'><span style='color:windowtext;font-weight:normal'>Autres informations sur les interactions de l'hydrochlorothiazide</span><span style='color:windowtext; font-weight:normal;text-decoration:none'> : les médicaments suivants peuvent avoir une interaction lorsqu’ils sont administrés simultanément avec les diurétiques thiazidiques :</span></p>
<p class=AmmAnnexeTitre2Bis style='page-break-after:auto'><i><span style='color:windowtext;font-weight:normal;text-decoration:none'>Alcool </span></i><span style='color:windowtext;font-weight:normal;text-decoration:none'>: une potentialisation de l'hypotension orthostatique peut survenir ;</span></p>
<p class=AmmAnnexeTitre2Bis style='page-break-after:auto'><i><span style='color:windowtext;font-weight:normal;text-decoration:none'>Antidiabétiques (médicaments oraux et insulines)</span></i><span style='color:windowtext; font-weight:normal;text-decoration:none'> : une adaptation posologique de l'antidiabétique peut être nécessaire (voir rubrique 4.4) ;</span></p>
<p class=AmmCorpsTexte><i>Résines : colestyramine et colestipol<b> </b></i>: l'absorption de l'hydrochlorothiazide est altérée en présence de résines échangeuses d’anions. IRBESARTAN/HYDROCHLOROTHIAZIDE SET doit être pris au moins une heure avant ou quatre heures après ces médicaments<b> </b>;</p>
<p class=AmmAnnexeTitre2Bis style='page-break-after:auto'><i><span style='color:windowtext;font-weight:normal;text-decoration:none'>Corticostéroïdes, ACTH</span></i><span style='color:windowtext;font-weight:normal;text-decoration: none'> : une déplétion électrolytique, et en particulier, une hypokaliémie, peut être aggravée;</span></p>
<p class=AmmAnnexeTitre2Bis style='page-break-after:auto'><i><span style='color:windowtext;font-weight:normal;text-decoration:none'>Digitaliques</span></i><span style='color:windowtext;font-weight:normal;text-decoration:none'> : l'hypokaliémie ou l'hypomagnésémie induite par les thiazidiques favorise l'apparition de troubles du rythme cardiaque induits par les digitaliques (voir rubrique 4.4) ;</span></p>
<p class=AmmAnnexeTitre2Bis style='page-break-after:auto'><i><span style='color:windowtext;font-weight:normal;text-decoration:none'>Anti-inflammatoires non stéroïdiens</span></i><span style='color:windowtext;font-weight:normal; text-decoration:none'> : l'administration d’un anti-inflammatoire non stéroïdien peut réduire les effets diurétiques, natriurétiques et antihypertenseurs des diurétiques thiazidiques chez certains patients ;</span></p>
<p class=AmmAnnexeTitre2Bis style='page-break-after:auto'><i><span style='color:windowtext;font-weight:normal;text-decoration:none'>Amines vasopressives (par exemple noradrénaline) </span></i><span style='color:windowtext; font-weight:normal;text-decoration:none'>: l'effet des amines vasopressives peut être atténué, mais pas suffisamment pour en exclure l'usage ;</span></p>
<p class=AmmAnnexeTitre2Bis style='page-break-after:auto'><i><span style='color:windowtext;font-weight:normal;text-decoration:none'>Myorelaxants non-dépolarisants (par exemple tubocurarine)</span></i><span style='color:windowtext; font-weight:normal;text-decoration:none'> : l'effet des myorelaxants non dépolarisants peut être potentialisé par l'hydrochlorothiazide ;</span></p>
<p class=AmmAnnexeTitre2Bis style='page-break-after:auto'><i><span style='color:windowtext;font-weight:normal;text-decoration:none'>Médicaments hypo-uricémiants</span></i><span style='color:windowtext;font-weight:normal; text-decoration:none'> : une adaptation de la posologie des médicaments hypo-uricémiants peut s’avérer nécessaire puisque l'hydrochlorothiazide peut élever le taux d’acide urique sérique. Une augmentation du dosage de probénécide ou de sulfinpyrazone peut être nécessaire. L'administration simultanée de diurétiques thiazidiques peut augmenter l'incidence des réactions d’hypersensibilité à l'allopurinol ;</span></p>
<p class=AmmAnnexeTitre2Bis style='page-break-after:auto'><i><span style='color:windowtext;font-weight:normal;text-decoration:none'>Sels de calcium </span></i><span style='color:windowtext;font-weight:normal;text-decoration: none'>: en réduisant l'élimination du calcium, les diurétiques thiazidiques peuvent augmenter la calcémie. Dans le cas où une supplémentation calcique ou des médicaments épargneurs de calcium (par exemple traitement par la vitamine D) doivent être prescrits, il est nécessaire de surveiller le taux de calcium sérique et d’adapter la posologie du calcium en fonction des résultats ;</span></p>
<p class=AmmAnnexeTitre2Bis style='page-break-after:auto'><i><span style='color:windowtext;font-weight:normal;text-decoration:none'>Carbamazépine</span></i><span style='color:windowtext;font-weight:normal;text-decoration:none'> : l'administration concomitante de carbamazépine et d'hydrochlorothiazide a été associée à un risque d'hyponatrémie symptomatique. Il est nécessaire de surveiller les électrolytes en cas d'administration simultanée. Si possible, une autre classe de diurétiques doit être utilisée.</span></p>
<p class=AmmAnnexeTitre2Bis><i><span style='color:windowtext;font-weight:normal; text-decoration:none'>Autres interactions</span></i><span style='color:windowtext; font-weight:normal;text-decoration:none'> : l'effet hyperglycémiant des bêtabloquants et du diazoxide peut être augmenté par les thiazidiques. Les agents anticholinergiques (tels que l'atropine, le bépéridène) peuvent augmenter la biodisponibilité des diurétiques thiazidiques par diminution de la motilité gastro-intestinale et de la vitesse de vidange gastrique. Les thiazidiques peuvent augmenter le risque d’effets indésirables de l'amantadine. Les thiazidiques peuvent réduire l'excrétion rénale des médicaments cytotoxiques (tels que cyclophosphamide, methotrexate) et potentialisent leurs effets myélosuppressifs.</span></p>
<p class="AmmAnnexeTitre2"><a name="RcpGrossAllait">4.6. Grossesse et allaitement</a></p>
<p class=AmmAnnexeTitre3>Gross<span style='letter-spacing:.05pt'>e</span>sse :</p>
<p class=AmmAnnexeTitre4>Antagonistes<span style='letter-spacing:-.55pt'> </span>des<span style='letter-spacing:-.15pt'> </span>récepteurs<span style='letter-spacing: -.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l'angiot<span style='letter-spacing:-.05pt'>e</span><span style='letter-spacing:.05pt'>n</span>sine-II<span style='letter-spacing:-.7pt'> </span>(ARAII)<span style='text-decoration:none'> :</span></p>
<p class=AmmCorpsTexte>L<span style='letter-spacing:.05pt'>’</span>utilisation<span style='letter-spacing:-.6pt'> </span>des<span style='letter-spacing:-.15pt'> </span>ARAII<span style='letter-spacing:-.25pt'> </span>est<span style='letter-spacing:-.1pt'> </span>décons<span style='letter-spacing:-.05pt'>e</span>illée<span style='letter-spacing:-.3pt'> </span>pendant<span style='letter-spacing:-.35pt'> </span>le 1<span style='letter-spacing:-.05pt'>e</span>r<span style='letter-spacing:-.15pt'> </span>trimestre<span style='letter-spacing: -.35pt'> </span>de<span style='letter-spacing:-.15pt'> </span>la grossesse<span style='letter-spacing:-.4pt'> </span><span style='letter-spacing:.05pt'>(</span>voir<span style='letter-spacing:-.2pt'> </span>rubrique<span style='letter-spacing:-.4pt'> </span>4.4). L<span style='letter-spacing:.05pt'>’</span>utilisation<span style='letter-spacing:-.6pt'> </span>des<span style='letter-spacing:-.15pt'> </span>ARAII<span style='letter-spacing:-.25pt'> </span>e<span style='letter-spacing:.05pt'>s</span>t<span style='letter-spacing:-.1pt'> </span>contre-indiquée<span style='letter-spacing: -.7pt'> </span>aux<span style='letter-spacing:-.15pt'> </span>2ème<span style='letter-spacing:-.2pt'> </span>et 3<span style='letter-spacing:.05pt'>è</span><span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:-.2pt'> </span>tr<span style='letter-spacing:.05pt'>i</span>mestres<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la g<span style='letter-spacing: .05pt'>r</span>osses<span style='letter-spacing:.05pt'>s</span>e<span style='letter-spacing:-.35pt'> </span>(voir rubriques<span style='letter-spacing: -.4pt'> </span>4<span style='letter-spacing:-.05pt'>.</span>3<span style='letter-spacing:-.2pt'> </span>et<span style='letter-spacing:.05pt'> </span>4.4).</p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.15pt'> </span>données<span style='letter-spacing:-.35pt'> </span>épidé<span style='letter-spacing:-.05pt'>m</span>iolog<span style='letter-spacing:-.05pt'>i</span>ques<span style='letter-spacing:-.8pt'> </span>dispon<span style='letter-spacing:-.05pt'>i</span>bles<span style='letter-spacing:-.5pt'> </span>concerna<span style='letter-spacing:.1pt'>n</span>t<span style='letter-spacing:-.45pt'> </span>le risque<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing: -.1pt'> </span>malfo<span style='letter-spacing:.05pt'>r</span>m<span style='letter-spacing:-.05pt'>a</span>tion<span style='letter-spacing:-.6pt'> </span>après<span style='letter-spacing:-.25pt'> </span>exposition<span style='letter-spacing: -.4pt'> </span>aux IEC<span style='letter-spacing:-.2pt'> </span>lors<span style='letter-spacing:-.15pt'> </span>du<span style='letter-spacing:-.1pt'> </span>1er<span style='letter-spacing:-.15pt'> </span>tr<span style='letter-spacing:.05pt'>i</span><span style='letter-spacing:-.1pt'>m</span>est<span style='letter-spacing:.05pt'>r</span>e<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la grossesse<span style='letter-spacing:-.4pt'> </span>ne<span style='letter-spacing: -.1pt'> </span>p<span style='letter-spacing:-.15pt'>e</span>rmette<span style='letter-spacing:.1pt'>n</span>t<span style='letter-spacing:-.45pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>conclure.<span style='letter-spacing:-.4pt'> </span>Cependant<span style='letter-spacing:-.45pt'> </span>une<span style='letter-spacing:-.15pt'> </span>petite augmentation<span style='letter-spacing:-.55pt'> </span>du<span style='letter-spacing:-.1pt'> </span>risque<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.15pt'> </span>malform<span style='letter-spacing:-.05pt'>a</span>tion<span style='letter-spacing:-.6pt'> </span>congénitale<span style='letter-spacing:-.45pt'> </span>ne<span style='letter-spacing:-.1pt'> </span>peut<span style='letter-spacing:-.2pt'> </span>être<span style='letter-spacing:-.15pt'> </span>exclue.<span style='letter-spacing:-.3pt'> </span>Il<span style='letter-spacing:-.05pt'> n</span><span style='letter-spacing:.05pt'>’</span>ex<span style='letter-spacing:-.05pt'>i</span>ste<span style='letter-spacing:-.25pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>d’étu<span style='letter-spacing:-.05pt'>d</span>es épidé<span style='letter-spacing:-.05pt'>m</span>iolog<span style='letter-spacing:-.05pt'>i</span>ques<span style='letter-spacing:-.8pt'> </span>dispon<span style='letter-spacing:-.05pt'>i</span>bles<span style='letter-spacing:-.5pt'> </span>concerna<span style='letter-spacing:.1pt'>n</span>t<span style='letter-spacing:-.45pt'> </span>l’utilisat<span style='letter-spacing:-.05pt'>i</span>on<span style='letter-spacing:-.15pt'> </span>des<span style='letter-spacing:-.15pt'> </span>ARAII<span style='letter-spacing:-.25pt'> </span>au<span style='letter-spacing:-.1pt'> </span>1er<span style='letter-spacing: -.15pt'> </span>trimestre<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la grossesse, cependant<span style='letter-spacing:-.45pt'> </span>un<span style='letter-spacing:-.15pt'> </span>risque<span style='letter-spacing:-.25pt'> </span>s<span style='letter-spacing:.05pt'>i</span><span style='letter-spacing:-.1pt'>m</span>ila<span style='letter-spacing:.1pt'>i</span>re<span style='letter-spacing:-.2pt'> </span>aux<span style='letter-spacing:-.15pt'> </span>IEC<span style='letter-spacing:-.2pt'> </span>pourrait<span style='letter-spacing:-.35pt'> </span>exi<span style='letter-spacing:-.05pt'>s</span>ter<span style='letter-spacing:-.3pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>cette classe.<span style='letter-spacing:-.3pt'> </span>A<span style='letter-spacing: -.05pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>ins<span style='letter-spacing:-.2pt'> </span>que<span style='letter-spacing:-.15pt'> </span>le traitement avec<span style='letter-spacing: -.2pt'> </span>un<span style='letter-spacing:-.1pt'> </span>AR<span style='letter-spacing:.05pt'>A</span>II<span style='letter-spacing:-.3pt'> </span>soit<span style='letter-spacing:-.15pt'> </span>considéré<span style='letter-spacing: -.4pt'> </span>c<span style='letter-spacing:.1pt'>o</span>mme<span style='letter-spacing:-.3pt'> </span><span style='letter-spacing:.05pt'>es</span>sentiel,<span style='letter-spacing:-.35pt'> </span>il est<span style='letter-spacing:-.1pt'> </span>rec<span style='letter-spacing:.1pt'>o</span>mmandé<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> m</span>odifier<span style='letter-spacing:-.4pt'> </span><span style='letter-spacing:.05pt'>l</span>e trait<span style='letter-spacing:.05pt'>e</span>ment antih<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:.05pt'>p</span>ertenseur<span style='letter-spacing:-.75pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:.1pt'>p</span>atientes<span style='letter-spacing:-.35pt'> </span>qui<span style='letter-spacing:-.15pt'> </span>envisagent<span style='letter-spacing:-.45pt'> </span>une<span style='letter-spacing:-.2pt'> </span>grossesse<span style='letter-spacing:-.4pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>un<span style='letter-spacing:-.1pt'> m</span>édicament<span style='letter-spacing: -.45pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing:-.25pt'> </span>un<span style='letter-spacing:-.1pt'> </span>profil de<span style='letter-spacing:-.1pt'> </span>sécurité<span style='letter-spacing: -.35pt'> </span>é<span style='letter-spacing:.05pt'>t</span>abli<span style='letter-spacing:-.15pt'> </span>pendant<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.05pt'>l</span>a grossesse.<span style='letter-spacing:-.45pt'> </span>En<span style='letter-spacing:-.1pt'> </span>cas<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>d<span style='letter-spacing:-.1pt'>i</span>agnostic<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>gro<span style='letter-spacing: -.05pt'>s</span>sesse,<span style='letter-spacing:-.45pt'> </span>le traitement<span style='letter-spacing:-.4pt'> </span>par<span style='letter-spacing:-.15pt'> </span>un<span style='letter-spacing:-.15pt'> </span>ARAII doit<span style='letter-spacing: -.15pt'> </span>être<span style='letter-spacing:-.15pt'> </span>arrêté<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:.05pt'>i</span>mmédiat<span style='letter-spacing:.05pt'>e</span>ment<span style='letter-spacing:-.65pt'> </span>et si<span style='letter-spacing:-.05pt'> </span>né<span style='letter-spacing: .05pt'>c</span>essai<span style='letter-spacing:.05pt'>r</span>e<span style='letter-spacing:-.4pt'> </span>un<span style='letter-spacing:-.1pt'> </span>trait<span style='letter-spacing:.05pt'>e</span><span style='letter-spacing:-.1pt'>m</span>ent<span style='letter-spacing:-.15pt'> </span>alter<span style='letter-spacing:.1pt'>n</span>atif<span style='letter-spacing:-.25pt'> </span>sera<span style='letter-spacing:-.2pt'> </span>débuté.</p>
<p class=AmmCorpsTexte>L<span style='letter-spacing:.05pt'>’</span>exposition<span style='letter-spacing:-.6pt'> </span>aux<span style='letter-spacing:-.15pt'> </span>ARAII<span style='letter-spacing:-.3pt'> </span>au<span style='letter-spacing:-.1pt'> </span>cours<span style='letter-spacing:-.25pt'> </span>des<span style='letter-spacing:-.15pt'> </span>2è<span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:-.15pt'> </span>et 3è<span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>t</span>r<span style='letter-spacing: .05pt'>i</span><span style='letter-spacing:-.1pt'>m</span>est<span style='letter-spacing:.05pt'>r</span>es<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:.05pt'>l</span>a grossesse<span style='letter-spacing:-.4pt'> </span>est<span style='letter-spacing: -.1pt'> </span>connue<span style='letter-spacing:-.3pt'> </span>pour entraîner<span style='letter-spacing:-.35pt'> </span>une<span style='letter-spacing:-.15pt'> </span>foetotoxicité<span style='letter-spacing:-.55pt'> </span>(di<span style='letter-spacing:-.1pt'>m</span>inution<span style='letter-spacing:-.45pt'> </span><span style='letter-spacing:-.05pt'>d</span>e<span style='letter-spacing:-.05pt'> </span>la fon<span style='letter-spacing:-.05pt'>c</span>tion<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.05pt'>r</span>énale,<span style='letter-spacing:-.2pt'> </span>oligo<span style='letter-spacing:-.05pt'>h</span>ydra<span style='letter-spacing:-.1pt'>m</span>nios,<span style='letter-spacing:-.75pt'> </span>retard<span style='letter-spacing:-.2pt'> </span>d’ossification des os<span style='letter-spacing:-.1pt'> </span>du<span style='letter-spacing:-.1pt'> </span>crâne)<span style='letter-spacing:-.25pt'> </span>et une<span style='letter-spacing:-.15pt'> </span>to<span style='letter-spacing:-.05pt'>x</span>icité<span style='letter-spacing:-.15pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>le <span style='letter-spacing:.1pt'>n</span>ouvea<span style='letter-spacing: -.05pt'>u</span>-né<span style='letter-spacing:-.5pt'> </span>(i<span style='letter-spacing:-.05pt'>n</span>suffisance<span style='letter-spacing: -.55pt'> </span>ré<span style='letter-spacing:.1pt'>n</span>ale,<span style='letter-spacing:-.25pt'> </span>hypotens<span style='letter-spacing:-.05pt'>i</span>on,<span style='letter-spacing:-.55pt'> </span><span style='letter-spacing:-.05pt'>h</span>yperkal<span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.05pt'>é</span><span style='letter-spacing:-.1pt'>m</span>ie). (Voir<span style='letter-spacing: -.15pt'> </span>rubr<span style='letter-spacing:-.05pt'>i</span>que<span style='letter-spacing:-.4pt'> </span>5.3).</p>
<p class=AmmCorpsTexte>En<span style='letter-spacing:-.1pt'> </span>cas<span style='letter-spacing:-.15pt'> </span>d<span style='letter-spacing:.05pt'>’</span>exposition<span style='letter-spacing:-.55pt'> </span>aux<span style='letter-spacing:-.15pt'> </span>ARAII<span style='letter-spacing:-.3pt'> </span>à partir<span style='letter-spacing:-.15pt'> </span>du<span style='letter-spacing:-.1pt'> </span>2è<span style='letter-spacing: -.1pt'>m</span>e<span style='letter-spacing:-.2pt'> </span>tr<span style='letter-spacing:.05pt'>im</span>estre<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la g<span style='letter-spacing:.05pt'>r</span>ossesse<span style='letter-spacing:-.4pt'> </span>il est<span style='letter-spacing:-.05pt'> </span>rec<span style='letter-spacing:.1pt'>o</span>mmandé<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>faire une<span style='letter-spacing:-.15pt'> </span>échographie<span style='letter-spacing:-.55pt'> </span>fœtale<span style='letter-spacing:-.25pt'> </span>afin<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>vérifier<span style='letter-spacing:-.3pt'> </span>la <span style='letter-spacing:-.05pt'>f</span>onction<span style='letter-spacing:-.35pt'> </span>ré<span style='letter-spacing:-.05pt'>n</span>ale<span style='letter-spacing:-.15pt'> </span>et les<span style='letter-spacing:-.1pt'> </span>os<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing: .1pt'>d</span>e<span style='letter-spacing:-.05pt'> </span>la voute<span style='letter-spacing:-.25pt'> </span>du<span style='letter-spacing:-.15pt'> </span>crâne.</p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.15pt'> </span>nouveau-nés<span style='letter-spacing:-.55pt'> </span>de <span style='letter-spacing:-.1pt'>m</span>ère<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.05pt'>t</span>raitée<span style='letter-spacing:-.05pt'> </span>par<span style='letter-spacing:-.15pt'> </span>un<span style='letter-spacing:-.1pt'> </span>inhibiteur<span style='letter-spacing: -.5pt'> </span>des<span style='letter-spacing:-.15pt'> </span>récepteurs<span style='letter-spacing:-.45pt'> </span>de l<span style='letter-spacing:.05pt'>’</span>ang<span style='letter-spacing:-.05pt'>i</span>otensine<span style='letter-spacing:-.6pt'> </span>II<span style='letter-spacing:-.05pt'> </span>doivent<span style='letter-spacing:-.35pt'> </span>ê<span style='letter-spacing:-.05pt'>t</span>re surveillés<span style='letter-spacing:-.4pt'> </span>sur<span style='letter-spacing: -.15pt'> </span>le plan<span style='letter-spacing:-.2pt'> </span>tensionnel<span style='letter-spacing:-.45pt'> </span>(voir<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.05pt'>r</span><span style='letter-spacing:.05pt'>u</span><span style='letter-spacing:-.05pt'>b</span>riques<span style='letter-spacing:-.4pt'> </span>4.3<span style='letter-spacing:-.15pt'> </span>et<span style='letter-spacing: -.05pt'> </span>4.4).</p>
<p class=AmmCorpsTexte><i><u>Hydrochlorothiazide</u> :</i></p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.15pt'> </span>données<span style='letter-spacing:-.35pt'> </span>concernant<span style='letter-spacing: -.45pt'> </span>l’utilisation<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.15pt'> </span>l<span style='letter-spacing:.05pt'>’</span>hydroch<span style='letter-spacing:-.05pt'>l</span>orothiazide<span style='letter-spacing: -.95pt'> </span>pendant<span style='letter-spacing:-.35pt'> </span>la grossesse,<span style='letter-spacing:-.45pt'> </span>et particulièrement pendant<span style='letter-spacing:-.3pt'> </span>le 1<sup><span style='font-size:7.0pt'>er<span style='letter-spacing:.9pt'> </span></span></sup>trimestre,<span style='letter-spacing:-.4pt'> </span>s<span style='letter-spacing:.1pt'>o</span>nt<span style='letter-spacing:-.2pt'> </span>li<span style='letter-spacing:-.05pt'>m</span>ité<span style='letter-spacing:.05pt'>e</span>s.<span style='letter-spacing:-.05pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>études<span style='letter-spacing:-.3pt'> </span>an<span style='letter-spacing:.05pt'>i</span>mal<span style='letter-spacing: .05pt'>e</span>s<span style='letter-spacing:-.25pt'> </span>sont<span style='letter-spacing:-.2pt'> </span>insuffisantes.</p>
<p class=AmmCorpsTexte>L<span style='letter-spacing:.05pt'>’</span>hydrochlorothiazide<span style='letter-spacing:-1.0pt'> </span>traverse<span style='letter-spacing:-.35pt'> </span>la barr<span style='letter-spacing:.05pt'>i</span>è<span style='letter-spacing:.05pt'>r</span>e<span style='letter-spacing:-.3pt'> </span>placentaire.<span style='letter-spacing:-.4pt'> </span>C<span style='letter-spacing:.1pt'>o</span><span style='letter-spacing:-.1pt'>mp</span>te<span style='letter-spacing:-.2pt'> </span>tenu<span style='letter-spacing:-.2pt'> </span>du<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>é</span>cani<span style='letter-spacing:.05pt'>s</span>me<span style='letter-spacing:-.35pt'> </span>d<span style='letter-spacing:.05pt'>’</span>action pharmacologique<span style='letter-spacing:-.7pt'> </span>de<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>l</span><span style='letter-spacing:.05pt'>’</span>hyd<span style='letter-spacing:-.05pt'>r</span>ochlorothiaz<span style='letter-spacing:-.05pt'>i</span>de,<span style='letter-spacing:-.95pt'> </span>son<span style='letter-spacing:-.15pt'> </span>utilis<span style='letter-spacing:-.05pt'>a</span>tion<span style='letter-spacing:-.45pt'> </span>au<span style='letter-spacing:-.1pt'> </span>cours<span style='letter-spacing:-.3pt'> </span>des<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.05pt'>2</span><sup><span style='font-size:7.0pt'>è<span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:.95pt'> </span></span></sup>et 3<sup><span style='font-size:7.0pt;letter-spacing:.05pt'>è</span></sup><sup><span style='font-size:7.0pt;letter-spacing:-.05pt'>m</span></sup><sup><span style='font-size:7.0pt'>e<span style='letter-spacing:.95pt'> </span></span></sup>tr<span style='letter-spacing:.05pt'>i</span><span style='letter-spacing:-.1pt'>m</span>estres<span style='letter-spacing:-.25pt'> </span>de grossesse<span style='letter-spacing: -.4pt'> </span>pe<span style='letter-spacing:.1pt'>u</span>t<span style='letter-spacing:-.15pt'> </span>di<span style='letter-spacing:-.1pt'>m</span>inuer<span style='letter-spacing:-.35pt'> </span>la<span style='letter-spacing:.1pt'> </span>perfusion<span style='letter-spacing:-.4pt'> </span>fœto-placentaire<span style='letter-spacing: -.6pt'> </span>et entraîner<span style='letter-spacing:-.4pt'> </span>des<span style='letter-spacing:-.15pt'> </span>effe<span style='letter-spacing:.05pt'>t</span>s<span style='letter-spacing:-.25pt'> </span>fœt<span style='letter-spacing:.05pt'>a</span>ux<span style='letter-spacing:-.3pt'> </span>et néonat<span style='letter-spacing:-.05pt'>a</span>ux<span style='letter-spacing:-.45pt'> </span>tels qu<span style='letter-spacing:-.1pt'>’</span>un<span style='letter-spacing:-.1pt'> </span>ictère,<span style='letter-spacing:-.2pt'> </span>un<span style='letter-spacing:-.1pt'> </span>déséquilibre<span style='letter-spacing:-.5pt'> </span>élec<span style='letter-spacing:-.1pt'>t</span>rol<span style='letter-spacing:.1pt'>y</span>tique<span style='letter-spacing:-.35pt'> </span>et une<span style='letter-spacing:-.15pt'> </span>thro<span style='letter-spacing: -.1pt'>m</span>bopénie.</p>
<p class=AmmCorpsTexte>L’hydroch<span style='letter-spacing:-.05pt'>l</span>o<span style='letter-spacing:-.05pt'>r</span>othiazide<span style='letter-spacing: -.95pt'> </span>ne<span style='letter-spacing:-.1pt'> </span>doit<span style='letter-spacing:-.15pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>être<span style='letter-spacing:-.1pt'> </span>utilisé<span style='letter-spacing:-.2pt'> </span>pour<span style='letter-spacing:-.25pt'> </span>t<span style='letter-spacing: -.05pt'>r</span>aiter<span style='letter-spacing:-.05pt'> </span>l’œdème<span style='letter-spacing:-.4pt'> </span>gestationnel,<span style='letter-spacing: -.6pt'> </span>l’hypertension gestationnelle<span style='letter-spacing:-.55pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>la préécla<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.1pt'>p</span>sie<span style='letter-spacing:-.5pt'> </span>en<span style='letter-spacing:-.1pt'> </span>raison<span style='letter-spacing:-.25pt'> </span>du<span style='letter-spacing:-.2pt'> </span>risque<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>di<span style='letter-spacing:-.1pt'>m</span>inution<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la volémie<span style='letter-spacing:-.3pt'> </span>et de l<span style='letter-spacing:.05pt'>’</span>hypoperfusion<span style='letter-spacing:-.7pt'> </span>placentaire,<span style='letter-spacing: -.45pt'> </span>sans<span style='letter-spacing:-.2pt'> </span>effet<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.1pt'>b</span>én<span style='letter-spacing:-.05pt'>é</span>fique<span style='letter-spacing:-.4pt'> </span>sur<span style='letter-spacing:-.15pt'> </span>l<span style='letter-spacing:.05pt'>’</span>évolution<span style='letter-spacing:-.5pt'> </span>de<span style='letter-spacing:-.15pt'> </span>la<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:-.1pt'>m</span>aladie.</p>
<p class=AmmCorpsTexte>L<span style='letter-spacing:.05pt'>’</span>hydroch<span style='letter-spacing:-.05pt'>l</span>o<span style='letter-spacing:-.05pt'>r</span>othiazide<span style='letter-spacing:-.95pt'> </span>ne<span style='letter-spacing:-.1pt'> </span>doit<span style='letter-spacing:-.15pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>être<span style='letter-spacing:-.15pt'> </span>utilisé<span style='letter-spacing:-.2pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>t<span style='letter-spacing: -.05pt'>r</span>aiter<span style='letter-spacing:-.05pt'> </span>l<span style='letter-spacing:.05pt'>’</span>hypertension<span style='letter-spacing: -.65pt'> </span>artérielle<span style='letter-spacing:.05pt'> </span>essentiel<span style='letter-spacing:.1pt'>l</span>e<span style='letter-spacing:-.4pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les f<span style='letter-spacing:.05pt'>e</span>mmes<span style='letter-spacing:-.25pt'> </span>ence<span style='letter-spacing:.1pt'>i</span>ntes<span style='letter-spacing:-.4pt'> </span>sauf<span style='letter-spacing:-.2pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>rar<span style='letter-spacing:.05pt'>e</span>s<span style='letter-spacing:-.2pt'> </span>c<span style='letter-spacing:.05pt'>a</span>s où<span style='letter-spacing:-.1pt'> </span>aucun<span style='letter-spacing:-.25pt'> </span>autre<span style='letter-spacing:-.2pt'> </span>trait<span style='letter-spacing:.05pt'>e</span>ment<span style='letter-spacing:-.2pt'> </span>n<span style='letter-spacing:.05pt'>’</span>est<span style='letter-spacing:-.2pt'> </span>possibl<span style='letter-spacing:-.05pt'>e</span>.</p>
<p class=AmmCorpsTexte>IRBESARTAN/HYDROCHLOROTHIAZIDE SET<span style='letter-spacing:-.5pt'> </span>contenant<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing: -.05pt'>'h</span><span style='letter-spacing:.1pt'>y</span>droch<span style='letter-spacing:-.05pt'>l</span>oro<span style='letter-spacing:-.05pt'>t</span>hiazide,<span style='letter-spacing:-.85pt'> </span>il <span style='letter-spacing:-.05pt'>n</span>’est<span style='letter-spacing:-.2pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>rec<span style='letter-spacing:.1pt'>o</span>mmandé<span style='letter-spacing:-.55pt'> </span>durant<span style='letter-spacing:-.3pt'> </span>le pr<span style='letter-spacing:.05pt'>e</span><span style='letter-spacing:-.1pt'>m</span>ier<span style='letter-spacing:-.35pt'> </span>tr<span style='letter-spacing:.05pt'>i</span>mest<span style='letter-spacing:.05pt'>r</span>e<span style='letter-spacing:-.25pt'> </span>de la grosses<span style='letter-spacing: .05pt'>s</span>e.<span style='letter-spacing:-.45pt'> </span>Un<span style='letter-spacing:-.15pt'> </span>chang<span style='letter-spacing:.05pt'>e</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>e</span>nt<span style='letter-spacing:-.5pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>un<span style='letter-spacing:-.1pt'> </span>trait<span style='letter-spacing:.05pt'>e</span><span style='letter-spacing:-.1pt'>m</span>ent<span style='letter-spacing:-.15pt'> </span>alt<span style='letter-spacing:-.1pt'>e</span>r<span style='letter-spacing:.1pt'>n</span>atif<span style='letter-spacing:-.1pt'> </span>adapté<span style='letter-spacing:-.3pt'> </span>devra<span style='letter-spacing:-.25pt'> </span>être<span style='letter-spacing:-.15pt'> </span>eff<span style='letter-spacing:.05pt'>e</span>c<span style='letter-spacing:.05pt'>t</span>ué<span style='letter-spacing:-.25pt'> </span>avant<span style='letter-spacing:-.25pt'> </span>d<span style='letter-spacing:.05pt'>’</span>envisager une<span style='letter-spacing:-.15pt'> </span>grossess<span style='letter-spacing:.05pt'>e</span>.</p>
<p class=AmmAnnexeTitre3>Allaitement :</p>
<p class=AmmAnnexeTitre4>Antagonistes<span style='letter-spacing:-.55pt'> </span>des<span style='letter-spacing:-.15pt'> </span>récepteurs<span style='letter-spacing: -.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l'angiot<span style='letter-spacing:-.05pt'>e</span><span style='letter-spacing:.05pt'>n</span>sine-II<span style='letter-spacing:-.7pt'> </span>(ARAII)<span style='text-decoration:none'> :</span></p>
<p class=AmmCorpsTexte>Aucune<span style='letter-spacing:-.35pt'> </span>info<span style='letter-spacing:-.05pt'>r</span>mation<span style='letter-spacing:-.45pt'> </span>n’étant<span style='letter-spacing:-.25pt'> </span>dispon<span style='letter-spacing:-.05pt'>i</span>ble<span style='letter-spacing:-.45pt'> </span>concern<span style='letter-spacing:-.05pt'>a</span>nt<span style='letter-spacing:-.5pt'> </span>l’u<span style='letter-spacing:-.05pt'>t</span>ilisation<span style='letter-spacing: -.45pt'> </span>d’IRBESARTAN/HYDROCHLOROTHIAZIDE SET<span style='letter-spacing: -.5pt'> </span>au<span style='letter-spacing:-.15pt'> </span>cours<span style='letter-spacing:-.25pt'> de l’allaitement,</span><span style='letter-spacing: .05pt'> </span>IRBESARTAN/HYDROCHLOROTHIAZIDE SET<span style='letter-spacing: -.5pt'> </span>n’est<span style='letter-spacing:-.2pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>rec<span style='letter-spacing:.1pt'>o</span>mmandé.<span style='letter-spacing:-.6pt'> </span>Il<span style='letter-spacing:-.05pt'> </span>est<span style='letter-spacing:-.05pt'> </span>conseillé<span style='letter-spacing: -.4pt'> </span>d’u<span style='letter-spacing:-.05pt'>t</span>iliser<span style='letter-spacing:-.4pt'> </span>des<span style='letter-spacing:-.15pt'> </span>trai<span style='letter-spacing:.1pt'>t</span><span style='letter-spacing:.05pt'>e</span><span style='letter-spacing:-.1pt'>m</span>ents<span style='letter-spacing:-.2pt'> </span>al<span style='letter-spacing:.05pt'>t</span>ernatifs a<span style='letter-spacing: .1pt'>y</span>ant<span style='letter-spacing:-.3pt'> </span>un<span style='letter-spacing:-.1pt'> </span>p<span style='letter-spacing:-.05pt'>r</span>o<span style='letter-spacing:-.05pt'>f</span>il<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>sécurité<span style='letter-spacing:-.35pt'> </span>mieux<span style='letter-spacing:-.25pt'> </span>établi<span style='letter-spacing:.05pt'> </span>au<span style='letter-spacing:-.1pt'> </span>cours<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.15pt'> </span>l’allaitement,<span style='letter-spacing:-.55pt'> </span>en<span style='letter-spacing:-.1pt'> </span>particulier<span style='letter-spacing:-.4pt'> </span>pour<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.05pt'>l</span><span style='letter-spacing:.05pt'>’</span>allaitement des nouveau-nés<span style='letter-spacing:-.6pt'> </span>et des<span style='letter-spacing:-.15pt'> </span>pré<span style='letter-spacing:-.1pt'>m</span>aturés.</p>
<p class=AmmCorpsTexte>On<span style='letter-spacing:-.15pt'> </span>ignore<span style='letter-spacing:-.3pt'> </span>si<span style='letter-spacing:-.05pt'> l'</span>irbésartan<span style='letter-spacing:-.45pt'> </span>et<span style='letter-spacing:.1pt'> </span>ses<span style='letter-spacing:-.1pt'> </span>métabolites<span style='letter-spacing: -.45pt'> </span>sont<span style='letter-spacing:-.2pt'> </span>excré<span style='letter-spacing:.1pt'>t</span>és<span style='letter-spacing:-.35pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le lait<span style='letter-spacing:.1pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>la femme.<span style='letter-spacing:-.35pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>données pharmacod<span style='letter-spacing:.1pt'>y</span>na<span style='letter-spacing:-.1pt'>m</span>iques<span style='letter-spacing:-.95pt'> </span>et t<span style='letter-spacing:.1pt'>o</span>xicolog<span style='letter-spacing:-.05pt'>i</span>ques<span style='letter-spacing:-.65pt'> </span>disponibles<span style='letter-spacing:-.5pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>le rat,<span style='letter-spacing:-.15pt'> </span>ont<span style='letter-spacing: -.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>ontré<span style='letter-spacing:-.3pt'> </span>que<span style='letter-spacing:-.15pt'> </span>l'irbesartan<span style='letter-spacing:-.5pt'> </span>et ses métabolites<span style='letter-spacing: -.45pt'> </span>sont<span style='letter-spacing:-.2pt'> </span>excrétés<span style='letter-spacing:-.35pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le lait (voir<span style='letter-spacing:-.2pt'> </span>rubri<span style='letter-spacing:-.05pt'>q</span>ue<span style='letter-spacing:-.35pt'> </span>5<span style='letter-spacing:-.05pt'>.</span>3).</p>
<p class=AmmCorpsTexte> </p>
<p class=AmmCorpsTexte><i><u>Hydrochlorothiazide</u> :</i></p>
<p class=AmmCorpsTexte>L’hydroch<span style='letter-spacing:-.05pt'>l</span>o<span style='letter-spacing:-.05pt'>r</span>othiazide<span style='letter-spacing: -.95pt'> </span>est<span style='letter-spacing:-.1pt'> </span>excrété<span style='letter-spacing:-.25pt'> </span>dans<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>l</span>e lait<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:-.1pt'>m</span>at<span style='letter-spacing:-.05pt'>e</span>rnel<span style='letter-spacing:-.25pt'> </span>en<span style='letter-spacing:-.1pt'> </span>petite quantité.<span style='letter-spacing:-.4pt'> </span>Les<span style='letter-spacing: -.15pt'> </span>diurétiques<span style='letter-spacing:-.5pt'> thiazidiques à </span>fortes<span style='letter-spacing:-.25pt'> </span>doses<span style='letter-spacing:-.25pt'> </span>provoquant<span style='letter-spacing:-.55pt'> </span>une<span style='letter-spacing:-.15pt'> </span>diurèse<span style='letter-spacing:-.3pt'> </span>intense<span style='letter-spacing:-.3pt'> </span>peuvent<span style='letter-spacing:-.2pt'> </span>inhiber<span style='letter-spacing:-.25pt'> </span>la<span style='letter-spacing:.05pt'> </span>production<span style='letter-spacing:-.55pt'> </span>de<span style='letter-spacing:-.15pt'> </span>lait. L’utilisation<span style='letter-spacing:-.5pt'> </span>d’IRBESARTAN/HYDROCHLOROTHIAZIDE SET<span style='letter-spacing:-.5pt'> </span>au<span style='letter-spacing: -.1pt'> </span>cours<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>l</span><span style='letter-spacing:.05pt'>’</span>allaite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.1pt'> </span>n’est<span style='letter-spacing:-.2pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>rec<span style='letter-spacing:.1pt'>o</span>mmandé.<span style='letter-spacing:-.6pt'> </span>Si<span style='letter-spacing:-.1pt'> </span>IRBESARTAN/HYDROCHLOROTHIAZIDE SET<span style='letter-spacing:-.5pt'> </span>est<span style='letter-spacing: -.1pt'> </span>utilisé<span style='letter-spacing:-.25pt'> </span>au<span style='letter-spacing:-.1pt'> </span>cours<span style='letter-spacing:-.25pt'> </span>de l<span style='letter-spacing:.05pt'>’</span>allaitement,<span style='letter-spacing: -.55pt'> </span>les<span style='letter-spacing:-.1pt'> </span>doses<span style='letter-spacing:-.25pt'> </span>utilisées<span style='letter-spacing: -.35pt'> </span>doivent<span style='letter-spacing:-.35pt'> </span>être<span style='letter-spacing:-.15pt'> </span>les<span style='letter-spacing:-.1pt'> </span>plus<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>f</span>aibles<span style='letter-spacing:-.25pt'> </span>possibles.</p>
<p class=AmmAnnexeTitre3>Fécondité<span style='text-decoration:none'> :</span></p>
<p class=AmmCorpsTexte>L<span style='letter-spacing:-.05pt'>'</span>irbésartan<span style='letter-spacing:-.5pt'> </span>n<span style='letter-spacing:-.05pt'>'</span>a<span style='letter-spacing:-.05pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>présen<span style='letter-spacing:.05pt'>t</span>é<span style='letter-spacing:-.3pt'> </span>d<span style='letter-spacing:-.05pt'>'</span>ef<span style='letter-spacing:.05pt'>f</span>ets<span style='letter-spacing:-.25pt'> </span>sur<span style='letter-spacing:-.05pt'> </span>la fécon<span style='letter-spacing:-.05pt'>d</span>ité<span style='letter-spacing: -.3pt'> </span>des<span style='letter-spacing:-.15pt'> </span>rats<span style='letter-spacing:-.15pt'> </span>trai<span style='letter-spacing:.1pt'>t</span>és<span style='letter-spacing:-.05pt'> </span>et leurs<span style='letter-spacing:-.2pt'> </span>descendances<span style='letter-spacing:-.6pt'> </span>jusqu<span style='letter-spacing:-.05pt'>'</span>aux doses<span style='letter-spacing: -.25pt'> </span>entraînant<span style='letter-spacing:-.45pt'> </span>les<span style='letter-spacing:-.1pt'> </span>pr<span style='letter-spacing:.05pt'>e</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>i</span>ers<span style='letter-spacing:-.3pt'> </span>signes<span style='letter-spacing:-.25pt'> </span>de toxicité<span style='letter-spacing:-.3pt'> </span>parentale<span style='letter-spacing:-.4pt'> </span>(voir<span style='letter-spacing:-.2pt'> </span>rubrique<span style='letter-spacing:-.35pt'> </span>5.3).</p>
<p class="AmmAnnexeTitre2"><a name="RcpConduite">4.7. Effets sur l'aptitude à conduire des véhicules et à utiliser des machines</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278929">Aucune étude n'a été réalisée sur les effets de l'irbésartan sur l'aptitude à conduire des véhicules et à utiliser des machines. En se basant sur ses propriétés pharmacodynamiques, il est peu probable que l'irbésartan affecte cette aptitude. Lors de la conduite de véhicules ou l'utilisation de machines, il devra être pris en compte que des vertiges ou de la fatigue peuvent survenir lors du traitement.</a></p>
<p class="AmmAnnexeTitre2"><a name="RcpEffetsIndesirables">4.8. Effets indésirables</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278930"><b><u>Association Irbésartan/hydrochlorothiazide</u></b></a></p>
<p class=AmmCorpsTexte>Parmi les 898 patients hypertendus qui ont reçu diverses posologies d'irbésartan/hydrochlorothiazide (fourchette : de 37,5 mg/6,25 mg à 300 mg/25 mg) dans des études contrôlées <i>versus</i> placebo, 29,5 % des patients ont eu des effets indésirables. Les effets indésirables les plus fréquemment rapportés ont été vertiges (5,6 %), fatigue (4,9 %), nausées/vomissements (1,8 %), et miction anormale (1,4 %). De plus, des augmentations de l'azote uréique du sang (BUN) (2,3 %), de créatine kinase (1,7 %) et de créatinine (1,1 %) ont aussi été fréquemment observées lors des essais cliniques.</p>
<p class=AmmCorpsTexte>Le Tableau 1 décrit les effets indésirables rapportés spontanément ainsi que ceux observés dans les études contrôlées <i>versus</i> placebo.</p>
<p class=AmmCorpsTexte>La fréquence des effets indésirables listés ci-dessous est définie selon la convention suivante: très fréquent (&#8805; 1/10); fréquent (&#8805; 1/100, &lt; 1/10); peu fréquent (&#8805; 1/1.000, &lt; 1/100); rare (&#8805; 1/10.000, &lt; 1/1.000); très rare (&lt; 1/10.000). Dans chaque groupe de fréquence, les effets indésirables sont présentés par ordre décroissant de gravité.</p>
<p class=AmmCorpsTexte><u>Tableau 1 : Effets indésirables observés au cours des essais cliniques versus placebo et modifications spontanées*</u></p>
<table class=AmmCorpsTexteTable border=1 cellspacing=0 cellpadding=0
style='margin-left:3.5pt;border-collapse:collapse;border:none'>
<thead>
<tr>
<td width=238 valign=top style='width:178.3pt;border:solid windowtext 1.0pt;
border-bottom:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i>Investigations</i></p>
</td>
<td width=102 valign=top style='width:76.4pt;border-top:solid windowtext 1.0pt;
border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Fréquents :</p>
</td>
<td width=340 valign=top style='width:254.75pt;border-top:solid windowtext 1.0pt;
border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>augmentation des taux sanguins de l'azote, uréique, créatinine et créatine kinase</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr>
<td width=238 valign=top style='width:178.3pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'> </p>
</td>
<td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Peu fréquents :</p>
</td>
<td width=340 valign=top style='width:254.75pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Baisses du potassium et du sodium plasmatiques</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr>
<td width=238 valign=top style='width:178.3pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i>Affections cardiaques</i></p>
</td>
<td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Peu fréquents :</p>
</td>
<td width=340 valign=top style='width:254.75pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>syncope, hypotension, tachycardie, œdème</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr>
<td width=238 valign=top style='width:178.3pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i>Affections du système nerveux</i></p>
</td>
<td width=102 valign=top style='width:76.4pt;border:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Fréquents :</p>
</td>
<td width=340 valign=top style='width:254.75pt;border:none;border-right:
solid windowtext 1.0pt;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>vertiges</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr>
<td width=238 valign=top style='width:178.3pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'> </p>
</td>
<td width=102 valign=top style='width:76.4pt;border:none;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Peu fréquents :</p>
</td>
<td width=340 valign=top style='width:254.75pt;border:none;border-right:
solid windowtext 1.0pt;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>vertiges orthostatiques</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr>
<td width=238 valign=top style='width:178.3pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'> </p>
</td>
<td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Fréquence Indéterminée :</p>
</td>
<td width=340 valign=top style='width:254.75pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>céphalées</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr>
<td width=238 valign=top style='width:178.3pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i>Affections de l'oreille et du labyrinthe</i></p>
</td>
<td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Fréquence Indéterminée :</p>
</td>
<td width=340 valign=top style='width:254.75pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>acouphènes</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr>
<td width=238 valign=top style='width:178.3pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i>Affections respiratoires, thoraciques et médiastinales</i></p>
</td>
<td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Fréquence Indéterminée :</p>
</td>
<td width=340 valign=top style='width:254.75pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>toux</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:12.0pt'>
<td width=238 valign=top style='width:178.3pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i>Affections gastrointestinales</i></p>
</td>
<td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Fréquents :</p>
</td>
<td width=340 valign=top style='width:254.75pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>nausées/vomissements</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=238 valign=top style='width:178.3pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'> </p>
</td>
<td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Peu fréquents :</p>
</td>
<td width=340 valign=top style='width:254.75pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>diarrhée</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=238 valign=top style='width:178.3pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'> </p>
</td>
<td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Fréquence Indéterminée :</p>
</td>
<td width=340 valign=top style='width:254.75pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>dyspepsie, dysgueusie</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=238 valign=top style='width:178.3pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i>Affections du rein et des voies urinaires</i></p>
</td>
<td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Fréquents :</p>
</td>
<td width=340 valign=top style='width:254.75pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>miction anormale</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=238 valign=top style='width:178.3pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'> </p>
</td>
<td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Fréquence indéterminée :</p>
</td>
<td width=340 valign=top style='width:254.75pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>altération de la fonction rénale incluant des cas isolés<br> d'insuffisance rénale chez des patients à risque (<a href="#Rcp_4_4_MisesEnGarde_2"><span class=MsoPageNumber><span style='font-family:Arial'>voir rubrique 4.4</span></span></a>)</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=238 valign=top style='width:178.3pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i>Affections musculo-squelettiques et systémiques</i></p>
</td>
<td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Fréquence Indéterminée :</p>
</td>
<td width=340 valign=top style='width:254.75pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>arthralgies, myalgies</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:11.5pt'>
<td width=238 valign=top style='width:178.3pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i> </i></p>
</td>
<td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Peu fréquents :</p>
</td>
<td width=340 valign=top style='width:254.75pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Œdème des extrémités</p>
</td>
<td style='height:11.5pt;border:none' width=0 height=15></td>
</tr>
<tr style='height:12.0pt'>
<td width=238 valign=top style='width:178.3pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i>Affections du métabolisme et de la nutrition</i></p>
</td>
<td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Fréquence Indéterminée :</p>
</td>
<td width=340 valign=top style='width:254.75pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>hyperkaliémie</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=238 valign=top style='width:178.3pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i>Affections vasculaires</i></p>
</td>
<td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Peu fréquents :</p>
</td>
<td width=340 valign=top style='width:254.75pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>bouffées vasomotrices</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=238 valign=top style='width:178.3pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i>Troubles généraux et accidents liés au site d'administration</i></p>
</td>
<td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Fréquents :</p>
</td>
<td width=340 valign=top style='width:254.75pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>fatigue</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=238 valign=top style='width:178.3pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i>Affections du système immunitaire</i></p>
</td>
<td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Fréquence Indéterminée :</p>
</td>
<td width=340 valign=top style='width:254.75pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Cas de réactions d'hypersensibilité, tels qu'angio-œdème (rash), urticaire</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=238 valign=top style='width:178.3pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i>Affections hépatobiliaires</i></p>
</td>
<td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Fréquence Indéterminée :</p>
</td>
<td width=340 valign=top style='width:254.75pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>ictères, anomalie de la fonction hépatique</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:11.5pt'>
<td width=238 valign=top style='width:178.3pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i> </i></p>
</td>
<td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Peu fréquents :</p>
</td>
<td width=340 valign=top style='width:254.75pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Ictères</p>
</td>
<td style='height:11.5pt;border:none' width=0 height=15></td>
</tr>
<tr style='height:11.5pt'>
<td width=238 valign=top style='width:178.3pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i>Affections des organes de la reproduction et du sein</i></p>
</td>
<td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Peu fréquents :</p>
</td>
<td width=340 valign=top style='width:254.75pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:11.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>dysfonctionnement sexuel, modifications de la libido</p>
</td>
<td style='height:11.5pt;border:none' width=0 height=15></td>
</tr>
</thead>
</table>
<p class=AmmAnnexeTitre3>Information complémentaire sur chaque composant</p>
<p class=AmmCorpsTexte>En plus des effets indésirables listés ci-dessus pour l'association des composants, d'autres événements indésirables rapportés par ailleurs avec l'un des composants peuvent être des événements indésirables d'IRBESARTAN/HYDROCHLOROTHIAZIDE SET.</p>
<p class=AmmCorpsTexte>Les tableaux 2 et 3 ci-dessous décrivent les évènements indésirables rapportés avec les composants individuels d'IRBESARTAN/HYDROCHLOROTHIAZIDE SET.</p>
<p class=AmmCorpsTexte><u>Tableau 2 : Effets indésirables rapportés avec l'utilisation de l'irbésartan seul</u></p>
<table class=AmmCorpsTexteTable border=1 cellspacing=0 cellpadding=0
style='margin-left:3.5pt;border-collapse:collapse;border:none'>
<thead>
<tr style='height:12.0pt'>
<td width=238 valign=top style='width:178.3pt;border:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i>Troubles généraux et anomalies au site d'administration</i></p>
</td>
<td width=102 valign=top style='width:76.4pt;border:solid windowtext 1.0pt;
border-left:none;padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Peu fréquents :</p>
</td>
<td width=340 valign=top style='width:254.75pt;border:solid windowtext 1.0pt;
border-left:none;padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>douleur thoracique</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
</thead>
</table>
<p class=AmmCorpsTexte style='margin-top:6.0pt'><u>Tableau 3 : Evènements indésirables rapportés avec l'utilisation de l'hydrochlorothiazide seul</u></p>
<table class=AmmCorpsTexteTable border=1 cellspacing=0 cellpadding=0
style='margin-left:3.5pt;border-collapse:collapse;border:none'>
<thead>
<tr>
<td width=204 style='width:152.85pt;border:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i>Investigations</i></p>
</td>
<td width=102 style='width:76.4pt;border:solid windowtext 1.0pt;border-left:
none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Fréquence indéterminée :</p>
</td>
<td width=374 valign=top style='width:280.2pt;border:solid windowtext 1.0pt;
border-left:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>déséquilibre électrolytique (y compris hypokaliémie et hyponatrémie, <a href="#Rcp_4_4_MisesEnGarde_2"><span class=MsoPageNumber><span style='font-family:Arial'>voir section 4.4</span></span></a>), hyperuricémie, glycosurie, hyperglycémie, augmentation du cholestérol et des triglycérides</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr>
<td width=204 valign=top style='width:152.85pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i>Affections cardiaques</i></p>
</td>
<td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Fréquence indéterminée :</p>
</td>
<td width=374 valign=top style='width:280.2pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>arythmies </p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr>
<td width=204 style='width:152.85pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i>Affections hématologiques et du système lymphatique</i></p>
</td>
<td width=102 style='width:76.4pt;border-top:none;border-left:none;
border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Fréquence indéterminée :</p>
</td>
<td width=374 valign=top style='width:280.2pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>anémie aplasique, insuffisance médullaire, neutropénie/agranulocytose, anémie hémolytique, leucopénie, thrombopénie</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr>
<td width=204 valign=top style='width:152.85pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i>Affections du système nerveux</i></p>
</td>
<td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Fréquence Indéterminée :</p>
</td>
<td width=374 valign=top style='width:280.2pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>vertiges, paresthésie, sensation de tête vide, agitation</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr>
<td width=204 valign=top style='width:152.85pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i>Affections oculaires</i></p>
</td>
<td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Fréquence Indéterminée :</p>
</td>
<td width=374 valign=top style='width:280.2pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>trouble transitoire de la vision, xanthopsie, myopie aigüe et glaucome aigu secondaire à angle fermé.</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr>
<td width=204 valign=top style='width:152.85pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i>Affections respiratoires, thoraciques et médiastinales</i></p>
</td>
<td width=102 style='width:76.4pt;border-top:none;border-left:none;
border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Fréquence Indéterminée :</p>
</td>
<td width=374 valign=top style='width:280.2pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>détresses respiratoires (y compris pneumopathie et œdème pulmonaire)</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr>
<td width=204 valign=top style='width:152.85pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i>Affections gastrointestinales</i></p>
</td>
<td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Fréquence Indéterminée :</p>
</td>
<td width=374 valign=top style='width:280.2pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>pancréatite, anorexie, diarrhée, constipation, irritation gastrique, sialadénite, perte d'appétit</p>
</td>
<td style='border:none' width=0><p class='AmmCorpsTexte'> </td>
</tr>
<tr style='height:12.0pt'>
<td width=204 valign=top style='width:152.85pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i>Affections du rein et des voies urinaires</i></p>
</td>
<td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Fréquence Indéterminée :</p>
</td>
<td width=374 valign=top style='width:280.2pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>néphrite interstitielle, altération de la fonction rénale</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=204 style='width:152.85pt;border-top:none;border-left:solid windowtext 1.0pt;
border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i>Affections de la peau et du tissu sous-cutané</i></p>
</td>
<td width=102 style='width:76.4pt;border-top:none;border-left:none;
border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Fréquence Indéterminée :</p>
</td>
<td width=374 valign=top style='width:280.2pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>réactions anaphylactiques, nécrolyse, épidermique toxique, angéites nécrosantes (vasculaires et cutanées), réactions de type lupus érythémateux disséminé, aggravation d'un lupus érythémateux cutané, réactions de photosensiblisation, rash, urticaire</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=204 valign=top style='width:152.85pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i>Affections musculo-squelettiques et systémiques</i></p>
</td>
<td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Fréquence Indéterminée :</p>
</td>
<td width=374 valign=top style='width:280.2pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>faiblesse, spasme musculaire</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=204 valign=top style='width:152.85pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i>Affections vasculaires</i></p>
</td>
<td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Fréquence Indéterminée :</p>
</td>
<td width=374 valign=top style='width:280.2pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>hypotension orthostatique</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=204 valign=top style='width:152.85pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i>Troubles généraux et anomalies au site d'administration</i></p>
</td>
<td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Fréquence Indéterminée :</p>
</td>
<td width=374 valign=top style='width:280.2pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>fièvre</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=204 valign=top style='width:152.85pt;border-top:none;border-left:
solid windowtext 1.0pt;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i>Affections hépato-biliaires</i></p>
</td>
<td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Fréquence Indéterminée :</p>
</td>
<td width=374 valign=top style='width:280.2pt;border-top:none;border-left:
none;border-bottom:none black 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>ictère (ictère cholestatique intra-hépatique)</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
<tr style='height:12.0pt'>
<td width=204 valign=top style='width:152.85pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><i>Affections psychiatriques</i></p>
</td>
<td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Fréquence Indéterminée :</p>
</td>
<td width=374 valign=top style='width:280.2pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt;height:12.0pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>dépression, troubles du sommeil</p>
</td>
<td style='height:12.0pt;border:none' width=0 height=16></td>
</tr>
</thead>
</table>
<p class=AmmCorpsTexte>Les événements indésirables dose-dépendants de l'hydrochlorothiazide (particulièrement les déséquilibres électrolytiques) peuvent être majorés lors d'une augmentation de la dose d'hydrochlorothiazide.</p>
<p class="AmmAnnexeTitre2"><a name="RcpSurdosage">4.9. Surdosage</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278931">Aucune<span style='letter-spacing:-.35pt'> </span>info<span style='letter-spacing:-.05pt'>r</span>mation<span style='letter-spacing:-.5pt'> </span>spéci<span style='letter-spacing:.05pt'>f</span>ique<span style='letter-spacing:-.4pt'> </span>n<span style='letter-spacing:.05pt'>’</span>est<span style='letter-spacing:-.2pt'> </span>disponible<span style='letter-spacing: -.45pt'> </span>sur<span style='letter-spacing:-.15pt'> </span>le<span style='letter-spacing:-.1pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.4pt'> </span>en cas<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>surdosage<span style='letter-spacing:-.45pt'> </span>par<span style='letter-spacing:-.15pt'> </span>IRBESARTAN/HYDROCHLOROTHIAZIDE SET. Le<span style='letter-spacing:-.1pt'> </span>patient<span style='letter-spacing:-.3pt'> </span>doit<span style='letter-spacing:-.15pt'> </span>être<span style='letter-spacing:-.15pt'> </span>placé<span style='letter-spacing:-.25pt'> </span>s<span style='letter-spacing:.1pt'>o</span>us<span style='letter-spacing: -.2pt'> </span>étroite<span style='letter-spacing:-.3pt'> </span>surveillance,<span style='letter-spacing:-.6pt'> </span>un<span style='letter-spacing:-.15pt'> </span>traitement<span style='letter-spacing:-.4pt'> </span>sy<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>t<span style='letter-spacing:.1pt'>o</span>matique<span style='letter-spacing:-.7pt'> </span>et le<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:-.1pt'>m</span>aintien<span style='letter-spacing:-.25pt'> </span>des fonctions<span style='letter-spacing:-.4pt'> </span>vit<span style='letter-spacing:-.05pt'>a</span>les<span style='letter-spacing:-.3pt'> </span>se<span style='letter-spacing:.05pt'>r</span>a<span style='letter-spacing:-.15pt'> </span>inst<span style='letter-spacing:.05pt'>au</span>ré.<span style='letter-spacing:-.4pt'> </span>Les<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.05pt'>e</span>sures<span style='letter-spacing:-.3pt'> </span>à prend<span style='letter-spacing:.05pt'>r</span>e<span style='letter-spacing:-.3pt'> </span>dépendent<span style='letter-spacing:-.45pt'> </span>du<span style='letter-spacing:-.1pt'> </span>te<span style='letter-spacing: -.05pt'>m</span><span style='letter-spacing:.05pt'>p</span>s<span style='letter-spacing:-.25pt'> </span>passé<span style='letter-spacing:-.25pt'> </span>depuis<span style='letter-spacing:-.3pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>ingestion<span style='letter-spacing: -.4pt'> </span>et de<span style='letter-spacing:-.1pt'> </span>la sévérité<span style='letter-spacing:-.25pt'> </span>des<span style='letter-spacing:-.15pt'> </span>s<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>t<span style='letter-spacing:.1pt'>ô</span>mes.<span style='letter-spacing:-.55pt'> </span>Des<span style='letter-spacing:-.1pt'> </span>mesures<span style='letter-spacing:-.35pt'> </span>telles<span style='letter-spacing:-.05pt'> </span>que<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing: -.05pt'>'</span>induction<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>vo<span style='letter-spacing:-.1pt'>m</span>issements<span style='letter-spacing:-.6pt'> </span>et/ou<span style='letter-spacing:-.2pt'> </span>le lavage gastrique<span style='letter-spacing:-.4pt'> </span>sont<span style='letter-spacing:-.25pt'> </span>suggérées.<span style='letter-spacing: -.45pt'> </span>Le<span style='letter-spacing:-.1pt'> </span>charbon<span style='letter-spacing:-.35pt'> </span>activé<span style='letter-spacing:-.25pt'> </span>peut<span style='letter-spacing:-.2pt'> </span>ê<span style='letter-spacing: -.05pt'>t</span>re<span style='letter-spacing:-.1pt'> </span>utile dans<span style='letter-spacing:-.2pt'> </span>le traitement<span style='letter-spacing: -.4pt'> </span>du<span style='letter-spacing:-.15pt'> </span>surdosage.<span style='letter-spacing:-.45pt'> </span>Les dosages<span style='letter-spacing: -.35pt'> </span>sanguins<span style='letter-spacing:-.4pt'> </span>des<span style='letter-spacing:-.15pt'> </span>élec<span style='letter-spacing:.1pt'>t</span>ro<span style='letter-spacing:-.05pt'>l</span><span style='letter-spacing:.1pt'>y</span>tes<span style='letter-spacing:-.3pt'> </span>et de<span style='letter-spacing:-.1pt'> </span>la créatinine<span style='letter-spacing:-.45pt'> </span>devront<span style='letter-spacing:-.35pt'> </span>être<span style='letter-spacing:-.15pt'> </span>p<span style='letter-spacing:-.05pt'>r</span>atiqués<span style='letter-spacing:-.4pt'> </span>fréquemment.<span style='letter-spacing:-.55pt'> </span>En<span style='letter-spacing:-.1pt'> </span>cas d’h<span style='letter-spacing:.1pt'>y</span>potension,<span style='letter-spacing:-.65pt'> </span>le patient<span style='letter-spacing: -.3pt'> </span>devra<span style='letter-spacing:-.25pt'> </span>être<span style='letter-spacing:-.15pt'> </span>pla<span style='letter-spacing:.05pt'>c</span>é<span style='letter-spacing:-.2pt'> </span>en<span style='letter-spacing:-.1pt'> </span>decubitus<span style='letter-spacing:-.4pt'> </span>et un<span style='letter-spacing:-.1pt'> </span>re<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>l<span style='letter-spacing:.05pt'>i</span>ssage<span style='letter-spacing:-.45pt'> </span>vol<span style='letter-spacing:.05pt'>é</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>i</span>que<span style='letter-spacing:-.45pt'> </span>h<span style='letter-spacing:.1pt'>y</span>drosodé effectué<span style='letter-spacing: -.3pt'> </span>rapi<span style='letter-spacing:.1pt'>d</span><span style='letter-spacing:.05pt'>e</span><span style='letter-spacing:-.1pt'>m</span>ent.</a></p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.15pt'> </span>signes<span style='letter-spacing:-.25pt'> </span>cl<span style='letter-spacing:.05pt'>in</span>iques<span style='letter-spacing:-.3pt'> </span>les<span style='letter-spacing:-.1pt'> </span>plus<span style='letter-spacing:-.2pt'> </span>probables<span style='letter-spacing:-.45pt'> </span>d<span style='letter-spacing:.05pt'>’</span>un<span style='letter-spacing: -.2pt'> </span>surd<span style='letter-spacing:.1pt'>o</span>sage<span style='letter-spacing:-.5pt'> </span>par<span style='letter-spacing:-.15pt'> </span>irbésart<span style='letter-spacing:.05pt'>a</span>n<span style='letter-spacing:-.45pt'> </span>seraient<span style='letter-spacing:-.35pt'> </span>une<span style='letter-spacing:-.15pt'> </span>h<span style='letter-spacing:.1pt'>y</span>potension<span style='letter-spacing:-.6pt'> </span>et une tach<span style='letter-spacing:.1pt'>y</span>cardie.<span style='letter-spacing:-.6pt'> </span>Une<span style='letter-spacing:-.2pt'> </span>brad<span style='letter-spacing:.1pt'>y</span>card<span style='letter-spacing:.05pt'>i</span>e<span style='letter-spacing:-.45pt'> </span>pourrait<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.05pt'>é</span><span style='letter-spacing: .05pt'>g</span>al<span style='letter-spacing:.05pt'>e</span><span style='letter-spacing:-.1pt'>m</span>ent<span style='letter-spacing:-.25pt'> </span>su<span style='letter-spacing:.05pt'>rv</span>enir.</p>
<p class=AmmCorpsTexte>Le<span style='letter-spacing:-.1pt'> </span>surdosage<span style='letter-spacing:-.45pt'> </span>d’h<span style='letter-spacing:.1pt'>y</span>drochlorothiazide<span style='letter-spacing:-1.0pt'> </span>est<span style='letter-spacing:-.1pt'> </span>associé<span style='letter-spacing:-.2pt'> </span>à un<span style='letter-spacing:-.1pt'> </span>déficit<span style='letter-spacing:-.3pt'> </span>électro<span style='letter-spacing:.1pt'>ly</span>tique<span style='letter-spacing:-.6pt'> </span>(hypokali<span style='letter-spacing:.05pt'>é</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>i</span>e, h<span style='letter-spacing:.1pt'>y</span>pochloré<span style='letter-spacing: -.05pt'>m</span><span style='letter-spacing:.05pt'>i</span>e,<span style='letter-spacing:-.6pt'> </span>h<span style='letter-spacing:.1pt'>y</span>ponatrémie)<span style='letter-spacing:-.65pt'> </span>ainsi<span style='letter-spacing:-.2pt'> </span>qu'à<span style='letter-spacing:-.2pt'> </span>une<span style='letter-spacing:-.15pt'> </span>désh<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:.05pt'>d</span>ratation<span style='letter-spacing:-.65pt'> </span>résultant<span style='letter-spacing: -.4pt'> </span>d'une<span style='letter-spacing:-.25pt'> </span>diurèse<span style='letter-spacing:-.3pt'> </span>ex<span style='letter-spacing:.05pt'>c</span>essiv<span style='letter-spacing:.05pt'>e</span>.<span style='letter-spacing:-.45pt'> </span>Les signes<span style='letter-spacing:-.25pt'> </span>et s<span style='letter-spacing: .1pt'>y</span>mptô<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.05pt'>e</span>s<span style='letter-spacing:-.45pt'> </span>les<span style='letter-spacing:-.1pt'> </span>plus<span style='letter-spacing:-.2pt'> </span>courants<span style='letter-spacing:-.35pt'> </span>d<span style='letter-spacing:.05pt'>’</span>un<span style='letter-spacing:-.15pt'> </span>surdosage<span style='letter-spacing: -.5pt'> </span>sont<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>nausées<span style='letter-spacing:-.35pt'> </span>et la<span style='letter-spacing:.1pt'> </span>s<span style='letter-spacing: .1pt'>o</span>mnolence. L<span style='letter-spacing:-.05pt'>'</span>h<span style='letter-spacing:.1pt'>y</span>p<span style='letter-spacing:-.05pt'>o</span>kaliémie<span style='letter-spacing:-.65pt'> </span>peut<span style='letter-spacing:-.2pt'> </span>pro<span style='letter-spacing:-.05pt'>vo</span>quer<span style='letter-spacing:-.45pt'> </span>des<span style='letter-spacing:-.15pt'> </span>spasmes<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.1pt'>u</span>sculaires<span style='letter-spacing:-.5pt'> </span>et/ou<span style='letter-spacing:-.2pt'> </span>aggraver<span style='letter-spacing:-.4pt'> </span>les<span style='letter-spacing:-.1pt'> </span>troubles<span style='letter-spacing:-.35pt'> </span>du<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>r</span><span style='letter-spacing:.1pt'>y</span>th<span style='letter-spacing:-.1pt'>m</span>e cardiaque<span style='letter-spacing: -.4pt'> </span>liés à l<span style='letter-spacing:-.05pt'>'</span>utilisation<span style='letter-spacing:-.4pt'> </span>conco<span style='letter-spacing:-.05pt'>m</span>itan<span style='letter-spacing:.1pt'>t</span>e<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>digit<span style='letter-spacing:-.1pt'>a</span>liques<span style='letter-spacing:-.5pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>certains<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.1pt'>m</span>édicaments<span style='letter-spacing:-.55pt'> </span>antiar<span style='letter-spacing:.1pt'>y</span>thmiques.</p>
<p class=AmmCorpsTexte>L<span style='letter-spacing:.05pt'>’</span>irbésartan<span style='letter-spacing:-.5pt'> </span>n<span style='letter-spacing:-.05pt'>'</span>est<span style='letter-spacing:-.2pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>hémodia<span style='letter-spacing:-.05pt'>l</span><span style='letter-spacing:.1pt'>y</span>sable.<span style='letter-spacing:-.7pt'> </span>La<span style='letter-spacing:-.1pt'> </span>proport<span style='letter-spacing:-.05pt'>i</span>on<span style='letter-spacing:-.55pt'> </span>d’h<span style='letter-spacing:.1pt'>y</span>d<span style='letter-spacing:-.05pt'>r</span>ochlo<span style='letter-spacing:-.05pt'>r</span>othiazide<span style='letter-spacing: -.95pt'> </span>éliminée<span style='letter-spacing:-.35pt'> </span>par<span style='letter-spacing:-.15pt'> </span>hé<span style='letter-spacing:-.1pt'>m</span>odial<span style='letter-spacing:.1pt'>y</span>se n<span style='letter-spacing:.05pt'>’</span>a<span style='letter-spacing:-.1pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>été déte<span style='letter-spacing:.05pt'>r</span><span style='letter-spacing: -.1pt'>m</span>inée.</p>
<p class="AmmAnnexeTitre1"><a name="RcpPropPharmacologie">5. PROPRIETES PHARMACOLOGIQUES</a></p>
<p class="AmmAnnexeTitre2"><a name="RcpPropPharmacodynamie">5.1. Propriétés pharmacodynamiques</a></p>
<p class=AmmCorpsTexteGras><a name="_Toc142278933">Classe<span style='letter-spacing:-.3pt'> </span>pha<span style='letter-spacing:.05pt'>r</span>macothérapeutique :<span style='letter-spacing:-1.0pt'> </span>antagon<span style='letter-spacing: -.05pt'>i</span>stes<span style='letter-spacing:-.55pt'> </span>des<span style='letter-spacing:-.15pt'> </span>r<span style='letter-spacing:.05pt'>é</span>ce<span style='letter-spacing:.1pt'>p</span>teurs<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>ang<span style='letter-spacing:.05pt'>i</span>otensine-II,<span style='letter-spacing: -.7pt'> </span>associations</a></p>
<p class=AmmCorpsTexteGras>Code<span style='letter-spacing:-.25pt'> </span>ATC:<span style='letter-spacing:-.25pt'> </span>C09DA04.</p>
<p class=AmmCorpsTexte>IRBESARTAN/HYDROCHLOROTHIAZIDE SET<span style='letter-spacing:-.5pt'> </span>est<span style='letter-spacing:-.1pt'> </span>l'association<span style='letter-spacing:-.55pt'> </span>d’un<span style='letter-spacing:-.2pt'> </span>antagoniste<span style='letter-spacing:-.5pt'> </span>des<span style='letter-spacing:-.15pt'> </span>réc<span style='letter-spacing:-.1pt'>e</span>pteurs<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l'ang<span style='letter-spacing:.05pt'>i</span>otensin<span style='letter-spacing:-.05pt'>e</span>-II,<span style='letter-spacing:-.75pt'> </span>l'<span style='letter-spacing:.05pt'>i</span>rbésartan,<span style='letter-spacing:-.45pt'> </span>et<span style='letter-spacing:.1pt'> </span>d’un diurétique<span style='letter-spacing:-.4pt'> </span>th<span style='letter-spacing: -.05pt'>i</span>azidique,<span style='letter-spacing:-.45pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>hydrochloro<span style='letter-spacing: -.05pt'>t</span>hiazide.<span style='letter-spacing:-.9pt'> </span>L<span style='letter-spacing:-.05pt'>'</span>assoc<span style='letter-spacing:.05pt'>i</span>ation<span style='letter-spacing:-.55pt'> </span>de<span style='letter-spacing:-.1pt'> </span>ces<span style='letter-spacing:-.15pt'> </span>co<span style='letter-spacing:-.1pt'>m</span>posants<span style='letter-spacing:-.5pt'> </span>a<span style='letter-spacing:.1pt'> </span>un<span style='letter-spacing:-.1pt'> </span>effet antih<span style='letter-spacing: .1pt'>y</span><span style='letter-spacing:.05pt'>p</span>ertenseur<span style='letter-spacing:-.75pt'> </span>additif,<span style='letter-spacing:-.3pt'> </span>p<span style='letter-spacing:-.05pt'>r</span>oduisant<span style='letter-spacing:-.45pt'> </span>une<span style='letter-spacing:-.15pt'> </span>baisse<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:.1pt'>p</span>ression<span style='letter-spacing:-.35pt'> </span>artér<span style='letter-spacing:.1pt'>i</span>elle<span style='letter-spacing:-.25pt'> </span>plus<span style='letter-spacing:-.2pt'> </span>i<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.1pt'>p</span><span style='letter-spacing:.05pt'>o</span>rtante<span style='letter-spacing:-.5pt'> </span>que<span style='letter-spacing:-.15pt'> </span>chacun<span style='letter-spacing:-.3pt'> </span>de ces<span style='letter-spacing:-.15pt'> </span>c<span style='letter-spacing:.1pt'>o</span><span style='letter-spacing:-.1pt'>m</span>posants<span style='letter-spacing:-.5pt'> </span>utilisés<span style='letter-spacing:-.3pt'> </span>se<span style='letter-spacing:.1pt'>u</span>ls.</p>
<p class=AmmCorpsTexte>L'irbésartan<span style='letter-spacing:-.5pt'> </span>est<span style='letter-spacing:-.1pt'> </span>un<span style='letter-spacing:-.1pt'> </span>antagoniste<span style='letter-spacing:-.5pt'> </span>sélectif<span style='letter-spacing:-.3pt'> </span>puissant<span style='letter-spacing:-.35pt'> </span>des<span style='letter-spacing:-.15pt'> </span>récept<span style='letter-spacing:-.05pt'>e</span>urs<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l'angiotensine-II<span style='letter-spacing:-.7pt'> </span>(type<span style='letter-spacing:-.25pt'> </span>AT<sub><span style='font-size:7.0pt;letter-spacing:.05pt'>1</span></sub>),<span style='letter-spacing:-.2pt'> </span>actif par voie<span style='letter-spacing: -.2pt'> </span>orale.<span style='letter-spacing:-.25pt'> </span>Il<span style='letter-spacing:-.1pt'> </span>bloque<span style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>t</span>ous<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.05pt'>l</span>es<span style='letter-spacing:-.1pt'> </span>effets<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l'angiotensine-II<span style='letter-spacing:-.7pt'> </span>faisant<span style='letter-spacing:-.3pt'> </span>intervenir<span style='letter-spacing:-.45pt'> </span>les<span style='letter-spacing:-.1pt'> </span>récepteurs<span style='letter-spacing: -.45pt'> </span>AT<sub><span style='font-size:7.0pt;letter-spacing:.05pt'>1</span></sub>, indépendamment<span style='letter-spacing:-.7pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>ori<span style='letter-spacing:.1pt'>g</span>ine<span style='letter-spacing:-.3pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la<span style='letter-spacing:-.05pt'> </span>voie<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>synth<span style='letter-spacing:-.05pt'>è</span>se<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l'angiotensine-II.<span style='letter-spacing:-.75pt'> </span>L'antagonis<span style='letter-spacing: -.05pt'>m</span>e<span style='letter-spacing:-.6pt'> </span>sélectif<span style='letter-spacing:-.3pt'> </span>des récepteurs<span style='letter-spacing: -.45pt'> </span>de l'angiotensine-II<span style='letter-spacing:-.7pt'> </span>(A<span style='letter-spacing:.05pt'>T</span><sub><span style='font-size:7.0pt; letter-spacing:.05pt'>1</span></sub>)<span style='letter-spacing:-.2pt'> </span>pr<span style='letter-spacing:-.05pt'>o</span>voque<span style='letter-spacing:-.4pt'> </span><span style='letter-spacing:-.05pt'>u</span><span style='letter-spacing:.05pt'>n</span>e<span style='letter-spacing:-.1pt'> </span>élévation<span style='letter-spacing:-.35pt'> </span>des<span style='letter-spacing:-.15pt'> </span>ta<span style='letter-spacing: -.05pt'>u</span>x<span style='letter-spacing:-.15pt'> </span>plasmatiques<span style='letter-spacing:-.55pt'> </span>de<span style='letter-spacing:-.1pt'> </span>rénine<span style='letter-spacing:-.25pt'> </span>et des taux d'angiotensine-II<span style='letter-spacing:-.75pt'> </span>et une<span style='letter-spacing:-.15pt'> </span>baisse<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:.05pt'>l</span>a concentrat<span style='letter-spacing:.1pt'>i</span>on<span style='letter-spacing: -.6pt'> </span>plas<span style='letter-spacing:-.1pt'>m</span>ati<span style='letter-spacing:.1pt'>q</span>ue<span style='letter-spacing:-.6pt'> </span>d'aldostér<span style='letter-spacing:.1pt'>o</span>ne.<span style='letter-spacing:-.6pt'> </span>La<span style='letter-spacing:-.1pt'> </span>kaliémie<span style='letter-spacing:-.35pt'> </span>n'est pas<span style='letter-spacing:-.1pt'> m</span>odifiée<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>façon<span style='letter-spacing:-.25pt'> </span>significative<span style='letter-spacing: -.55pt'> </span>par<span style='letter-spacing:-.15pt'> </span>l'irbésartan<span style='letter-spacing:-.5pt'> </span>se<span style='letter-spacing:.1pt'>u</span>l<span style='letter-spacing:-.15pt'> </span>aux<span style='letter-spacing:-.15pt'> </span>doses<span style='letter-spacing:-.25pt'> </span>rec<span style='letter-spacing:.1pt'>o</span>mmandées<span style='letter-spacing:-.55pt'> </span>en<span style='letter-spacing:-.1pt'> </span>dehors<span style='letter-spacing:-.3pt'> </span>des patients<span style='letter-spacing: -.35pt'> </span>à risque<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>pertub<span style='letter-spacing:-.05pt'>a</span>tion<span style='letter-spacing:-.5pt'> </span>électro<span style='letter-spacing:-.05pt'>l</span><span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.05pt'>t</span>ique<span style='letter-spacing:-.55pt'> </span>(voir<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.05pt'>r</span><span style='letter-spacing: .05pt'>u</span><span style='letter-spacing:-.05pt'>b</span>riques<span style='letter-spacing:-.4pt'> </span>4.4<span style='letter-spacing:-.15pt'> </span>et<span style='letter-spacing:-.05pt'> </span>4.5).<span style='letter-spacing:-.2pt'> </span>L<span style='letter-spacing:-.05pt'>'</span>irbésartan<span style='letter-spacing: -.45pt'> </span>n<span style='letter-spacing:-.05pt'>'</span>inhibe<span style='letter-spacing:-.3pt'> </span>pas l<span style='letter-spacing:-.05pt'>'</span>ECA<span style='letter-spacing:-.2pt'> </span>(kininase-II),<span style='letter-spacing: -.6pt'> </span>enz<span style='letter-spacing:.1pt'>y</span>me<span style='letter-spacing:-.35pt'> </span>qui<span style='letter-spacing:-.15pt'> </span>génère<span style='letter-spacing:-.3pt'> </span>la fo<span style='letter-spacing:.05pt'>r</span><span style='letter-spacing:-.1pt'>m</span>ation<span style='letter-spacing:-.3pt'> </span>d'angiotensine-II<span style='letter-spacing:-.75pt'> </span>et qui<span style='letter-spacing:-.15pt'> </span>dég<span style='letter-spacing:-.05pt'>r</span>ade<span style='letter-spacing:-.35pt'> </span>égaleme<span style='letter-spacing:.1pt'>n</span>t<span style='letter-spacing:-.4pt'> </span>la brad<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:.05pt'>k</span>inine<span style='letter-spacing:-.5pt'> </span>en<span style='letter-spacing:-.1pt'> m</span>é<span style='letter-spacing:.05pt'>t</span>abolites<span style='letter-spacing:-.4pt'> </span>inactifs.<span style='letter-spacing:-.35pt'> </span>L<span style='letter-spacing:-.05pt'>'</span>i<span style='letter-spacing: .05pt'>r</span>bésartan<span style='letter-spacing:-.5pt'> </span>ne<span style='letter-spacing:-.2pt'> </span>nécessite<span style='letter-spacing:-.4pt'> </span>pas<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing: .1pt'>d</span><span style='letter-spacing:.05pt'>’</span>activation<span style='letter-spacing:-.45pt'> </span><span style='letter-spacing:-.1pt'>m</span>étabolique<span style='letter-spacing:-.5pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>être actif.</p>
<p class=AmmCorpsTexte>L’<span style='letter-spacing:-.05pt'>h</span>ydroch<span style='letter-spacing:-.05pt'>l</span>o<span style='letter-spacing:-.05pt'>r</span>othiazide<span style='letter-spacing:-.95pt'> </span>est<span style='letter-spacing:-.1pt'> </span>un<span style='letter-spacing:-.1pt'> </span>d<span style='letter-spacing:-.05pt'>i</span>urétique<span style='letter-spacing:-.5pt'> </span>thiaz<span style='letter-spacing:-.05pt'>i</span>dique.<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.05pt'>L</span>e <span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>é</span>canisme<span style='letter-spacing:-.35pt'> </span>d<span style='letter-spacing:-.05pt'>'</span>action<span style='letter-spacing:-.3pt'> </span>des<span style='letter-spacing:-.15pt'> </span>diurétiques thiazidiques<span style='letter-spacing:-.55pt'> </span>n<span style='letter-spacing:-.05pt'>'</span>est<span style='letter-spacing:-.2pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>c<span style='letter-spacing:.1pt'>o</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.1pt'>p</span>lètement<span style='letter-spacing:-.55pt'> </span>connu.<span style='letter-spacing:-.3pt'> </span>Les<span style='letter-spacing:-.1pt'> </span>thiazidiques<span style='letter-spacing:-.5pt'> </span>agissent<span style='letter-spacing:-.35pt'> </span>sur<span style='letter-spacing:-.15pt'> </span>les<span style='letter-spacing:-.1pt'> </span>mécanis<span style='letter-spacing:-.05pt'>m</span>es<span style='letter-spacing:-.55pt'> </span>de réabsorption<span style='letter-spacing: -.6pt'> </span>électrol<span style='letter-spacing:.1pt'>y</span>ti<span style='letter-spacing:-.05pt'>q</span>ue<span style='letter-spacing:-.6pt'> </span>par<span style='letter-spacing:-.15pt'> </span>les<span style='letter-spacing:-.1pt'> </span>tubu<span style='letter-spacing:-.05pt'>l</span>es<span style='letter-spacing:-.3pt'> </span>du<span style='letter-spacing:-.1pt'> </span>rein<span style='letter-spacing:-.15pt'> </span>en<span style='letter-spacing:-.2pt'> </span>augmentant<span style='letter-spacing: -.45pt'> </span>directement<span style='letter-spacing:-.45pt'> </span>l'éli<span style='letter-spacing:-.05pt'>m</span>ination<span style='letter-spacing:-.25pt'> </span>du<span style='letter-spacing:-.1pt'> </span>sodium et du<span style='letter-spacing:-.1pt'> </span>chlore<span style='letter-spacing:-.25pt'> </span>en<span style='letter-spacing:-.1pt'> </span>quantité<span style='letter-spacing:-.3pt'> </span>approxi<span style='letter-spacing:-.05pt'>m</span>ativement<span style='letter-spacing:-.75pt'> </span>égales.<span style='letter-spacing:-.3pt'> </span>En<span style='letter-spacing:-.1pt'> </span>favorisant<span style='letter-spacing:-.45pt'> </span>la diurèse,<span style='letter-spacing: -.35pt'> </span>l<span style='letter-spacing:-.05pt'>'</span><span style='letter-spacing:.1pt'>h</span>ydrochlorothiazide di<span style='letter-spacing:-.1pt'>m</span>inue<span style='letter-spacing:-.35pt'> </span>le volume<span style='letter-spacing:-.35pt'> </span>pla<span style='letter-spacing: .05pt'>s</span>ma<span style='letter-spacing:.05pt'>t</span>ique,<span style='letter-spacing:-.55pt'> </span>sti<span style='letter-spacing:-.1pt'>m</span>ule<span style='letter-spacing:-.2pt'> </span>l'<span style='letter-spacing:.05pt'>a</span>ctivité de<span style='letter-spacing:-.15pt'> </span>la rénine<span style='letter-spacing: -.25pt'> </span>pla<span style='letter-spacing:.05pt'>s</span>matique,<span style='letter-spacing:-.55pt'> </span>augmente<span style='letter-spacing:-.45pt'> </span>la séc<span style='letter-spacing:.05pt'>r</span>ét<span style='letter-spacing:.05pt'>i</span>on d<span style='letter-spacing:.05pt'>’</span>aldostérone,<span style='letter-spacing:-.65pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>conséquence<span style='letter-spacing: -.55pt'> </span>l'augmentation<span style='letter-spacing:-.6pt'> </span>de<span style='letter-spacing:-.15pt'> </span>la kaliurèse,<span style='letter-spacing: -.4pt'> </span>la perte<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>bicarbonate<span style='letter-spacing: -.5pt'> </span>et la di<span style='letter-spacing:-.1pt'>m</span>inution<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la kali<span style='letter-spacing:.05pt'>é</span><span style='letter-spacing: -.1pt'>m</span><span style='letter-spacing:.05pt'>i</span>e.<span style='letter-spacing:-.4pt'> </span>L'a<span style='letter-spacing:.1pt'>d</span><span style='letter-spacing:-.1pt'>m</span>inist<span style='letter-spacing:.05pt'>r</span>a<span style='letter-spacing:.05pt'>t</span>ion<span style='letter-spacing:-.6pt'> </span><span style='letter-spacing:-.1pt'>c</span>onco<span style='letter-spacing:-.1pt'>m</span>itante<span style='letter-spacing:-.25pt'> </span>d<span style='letter-spacing:.05pt'>’</span>irbésartan<span style='letter-spacing:-.5pt'> </span>(probabl<span style='letter-spacing:-.05pt'>e</span>ment<span style='letter-spacing:-.65pt'> </span>grâce<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:.05pt'>a</span>u bloquage<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l'axe<span style='letter-spacing:-.2pt'> </span>rénine-angiote<span style='letter-spacing: .05pt'>n</span>sine-aldostérone)<span style='letter-spacing:-1.45pt'> </span>tend<span style='letter-spacing:-.2pt'> </span>à réduire<span style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>l</span>es<span style='letter-spacing: -.1pt'> </span>pertes<span style='letter-spacing:-.25pt'> </span>potassiques<span style='letter-spacing:-.5pt'> </span>indui<span style='letter-spacing:-.05pt'>t</span>es<span style='letter-spacing:-.35pt'> par ces </span>diurétiques.<span style='letter-spacing:-.5pt'> </span>La<span style='letter-spacing:-.1pt'> </span>diurèse<span style='letter-spacing:-.3pt'> </span>c<span style='letter-spacing:.1pt'>o</span>mmence<span style='letter-spacing:-.5pt'> </span>d<span style='letter-spacing:.05pt'>e</span>ux<span style='letter-spacing:-.2pt'> </span>heures<span style='letter-spacing:-.3pt'> </span>après<span style='letter-spacing:-.25pt'> </span>une<span style='letter-spacing:-.15pt'> </span>a<span style='letter-spacing:.1pt'>d</span><span style='letter-spacing:-.1pt'>m</span>inistration<span style='letter-spacing:-.6pt'> </span>orale d’<span style='letter-spacing:-.05pt'>h</span><span style='letter-spacing:.1pt'>y</span>d<span style='letter-spacing:-.05pt'>r</span>ochlo<span style='letter-spacing:-.05pt'>r</span>othiazide;<span style='letter-spacing: -.95pt'> </span>elle<span style='letter-spacing:.05pt'> </span>atteint<span style='letter-spacing:.05pt'> </span>son<span style='letter-spacing:-.15pt'> </span>maxi<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.1pt'>u</span>m<span style='letter-spacing:-.45pt'> </span><span style='letter-spacing:-.05pt'>e</span>nviron<span style='letter-spacing:-.35pt'> </span>4<span style='letter-spacing:-.05pt'> </span>heur<span style='letter-spacing:-.05pt'>e</span>s<span style='letter-spacing:-.3pt'> </span>après<span style='letter-spacing:-.25pt'> </span>la prise<span style='letter-spacing:-.2pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>se<span style='letter-spacing: -.1pt'> </span>maintenir pendant<span style='letter-spacing:-.3pt'> </span>envi<span style='letter-spacing:-.05pt'>r</span>on<span style='letter-spacing:-.35pt'> </span>6<span style='letter-spacing:-.05pt'> </span>à <span style='letter-spacing:-.05pt'>1</span>2<span style='letter-spacing:-.05pt'> </span>he<span style='letter-spacing:-.05pt'>u</span>res.</p>
<p class=AmmCorpsTexte>La<span style='letter-spacing:-.1pt'> </span>baisse<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:.05pt'>l</span>a pression<span style='letter-spacing: -.35pt'> </span>artérielle<span style='letter-spacing:.05pt'> </span>av<span style='letter-spacing:.05pt'>e</span>c<span style='letter-spacing:-.15pt'> </span>l'ass<span style='letter-spacing:-.05pt'>o</span>ciation<span style='letter-spacing:-.55pt'> </span>irbésartan/h<span style='letter-spacing:.1pt'>y</span>drochlorothiazide<span style='letter-spacing:-1.3pt'> </span>est<span style='letter-spacing:-.1pt'> </span>dose dépendante<span style='letter-spacing:-.5pt'> </span>aux<span style='letter-spacing: -.15pt'> </span>doses<span style='letter-spacing:-.25pt'> </span>thérapeutiques<span style='letter-spacing:-.65pt'> </span>rec<span style='letter-spacing:.1pt'>o</span>mmandées.<span style='letter-spacing:-.6pt'> </span>L<span style='letter-spacing:-.05pt'>'</span>addition<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>12,5<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span>g<span style='letter-spacing:-.1pt'> </span>d<span style='letter-spacing:.05pt'>’</span>hydrochlorothiazide<span style='letter-spacing:-.95pt'> </span>à 300<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>g<span style='letter-spacing: -.1pt'> </span>d<span style='letter-spacing:.05pt'>’</span>i<span style='letter-spacing:-.05pt'>r</span>bésartan<span style='letter-spacing:-.5pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.25pt'> </span>mal<span style='letter-spacing:-.15pt'> </span>contrôlés<span style='letter-spacing:-.45pt'> </span>par<span style='letter-spacing:-.15pt'> </span>la dose<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing: -.1pt'> </span>300<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>g<span style='letter-spacing:-.1pt'> </span>d<span style='letter-spacing:.05pt'>’</span>i<span style='letter-spacing:-.05pt'>r</span>bésartan<span style='letter-spacing:-.5pt'> </span>seul,<span style='letter-spacing:-.2pt'> </span>en<span style='letter-spacing:-.1pt'> </span>une prise<span style='letter-spacing:-.2pt'> </span>par<span style='letter-spacing:-.15pt'> </span>jour,<span style='letter-spacing:-.2pt'> </span>produit<span style='letter-spacing:-.3pt'> </span>une<span style='letter-spacing:-.2pt'> </span>baisse<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la p<span style='letter-spacing:.05pt'>r</span>ession<span style='letter-spacing: -.35pt'> </span>artérie<span style='letter-spacing:.05pt'>l</span>le<span style='letter-spacing:-.15pt'> </span>diastolique<span style='letter-spacing: -.5pt'> </span>supplé<span style='letter-spacing:-.1pt'>m</span>enta<span style='letter-spacing:.1pt'>i</span>re<span style='letter-spacing:-.6pt'> </span>(24<span style='letter-spacing:-.15pt'> </span>heures<span style='letter-spacing:-.3pt'> </span>après la prise)<span style='letter-spacing:-.25pt'> </span>d<span style='letter-spacing:.05pt'>’</span>au<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>ins<span style='letter-spacing:-.25pt'> </span>6,1<span style='letter-spacing:-.05pt'> </span>mm<span style='letter-spacing:-.15pt'> </span>Hg,<span style='letter-spacing:-.15pt'> </span>effet<span style='letter-spacing:-.2pt'> </span>placebo<span style='letter-spacing:-.35pt'> </span>dédu<span style='letter-spacing:-.05pt'>i</span>t.<span style='letter-spacing:-.3pt'> </span>L'a<span style='letter-spacing:.05pt'>s</span>sociati<span style='letter-spacing:.1pt'>o</span>n<span style='letter-spacing:-.55pt'> </span>de<span style='letter-spacing:-.1pt'> </span>300<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span>g<span style='letter-spacing:-.1pt'> </span>d<span style='letter-spacing:.05pt'>’</span>irbésartan<span style='letter-spacing: -.5pt'> </span><span style='letter-spacing:.05pt'>e</span>t de 12,5<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span>g<span style='letter-spacing:-.1pt'> </span>d<span style='letter-spacing:.05pt'>’</span>hydrochloro<span style='letter-spacing:-.05pt'>t</span>hiazide<span style='letter-spacing:-.95pt'> </span>a pe<span style='letter-spacing:.05pt'>r</span><span style='letter-spacing: -.1pt'>m</span>is<span style='letter-spacing:-.2pt'> </span>une<span style='letter-spacing:-.15pt'> </span>r<span style='letter-spacing:-.05pt'>é</span>duction<span style='letter-spacing:-.4pt'> </span>globale<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la<span style='letter-spacing: -.05pt'> </span>pression<span style='letter-spacing:-.35pt'> </span>artérielle<span style='letter-spacing:.05pt'> </span>pouvant atteindre<span style='letter-spacing: -.35pt'> </span>13,<span style='letter-spacing:-.05pt'>6</span>/11,5<span style='letter-spacing:-.4pt'> </span>mm<span style='letter-spacing:-.2pt'> </span>Hg<span style='letter-spacing:-.15pt'> </span>(PAS/PAD),<span style='letter-spacing: -.5pt'> </span>effet<span style='letter-spacing:-.2pt'> </span>placebo<span style='letter-spacing:-.35pt'> </span>déduit.</p>
<p class=AmmCorpsTexte>Des<span style='letter-spacing:-.15pt'> </span>données<span style='letter-spacing:-.25pt'> </span>cliniques<span style='letter-spacing: -.4pt'> </span>li<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.05pt'>i</span>tées<span style='letter-spacing:-.15pt'> </span>(7<span style='letter-spacing:-.1pt'> </span>sur<span style='letter-spacing:-.15pt'> </span>22<span style='letter-spacing:-.1pt'> </span>patients)<span style='letter-spacing:-.35pt'> </span>suggèrent<span style='letter-spacing:-.45pt'> </span>que<span style='letter-spacing:-.15pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.35pt'> </span>non<span style='letter-spacing:-.2pt'> </span>contrôlés<span style='letter-spacing:-.4pt'> </span>par l<span style='letter-spacing:-.05pt'>'</span>association<span style='letter-spacing:-.45pt'> </span>à la dose<span style='letter-spacing: -.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>300<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/12,5<span style='letter-spacing:-.4pt'> </span><span style='letter-spacing:-.1pt'>m</span>g<span style='letter-spacing:-.1pt'> </span>peuvent<span style='letter-spacing:-.35pt'> </span>répondre<span style='letter-spacing:-.4pt'> </span>à u<span style='letter-spacing:-.05pt'>n</span>e<span style='letter-spacing: -.1pt'> </span>dose<span style='letter-spacing:-.2pt'> </span>plus<span style='letter-spacing:-.2pt'> </span>élevée<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>300<span style='letter-spacing: -.2pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/25<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>. Chez<span style='letter-spacing:-.25pt'> </span>ces<span style='letter-spacing: -.15pt'> </span>patients,<span style='letter-spacing:-.35pt'> </span>une<span style='letter-spacing:-.15pt'> </span>diminution<span style='letter-spacing: -.45pt'> </span>supp<span style='letter-spacing:-.05pt'>l</span>é<span style='letter-spacing:-.1pt'>m</span>entai<span style='letter-spacing:.05pt'>r</span>e<span style='letter-spacing:-.6pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la<span style='letter-spacing:-.05pt'> </span>pression<span style='letter-spacing:-.35pt'> </span>artérielle<span style='letter-spacing:.05pt'> </span>a é<span style='letter-spacing:.05pt'>t</span>é observée<span style='letter-spacing: -.4pt'> </span>à la<span style='letter-spacing:.1pt'> </span>fois<span style='letter-spacing:-.15pt'> </span>pour la pression<span style='letter-spacing: -.35pt'> </span>artérielle<span style='letter-spacing:.05pt'> </span>s<span style='letter-spacing:.1pt'>y</span>stolique<span style='letter-spacing:-.45pt'> </span>(PAS)<span style='letter-spacing:-.25pt'> </span>et la pression<span style='letter-spacing:-.35pt'> </span>artérielle<span style='letter-spacing: .05pt'> </span>diast<span style='letter-spacing:.1pt'>o</span>lique<span style='letter-spacing:-.5pt'> </span>(PAD)<span style='letter-spacing:-.3pt'> </span>(13,3<span style='letter-spacing:-.25pt'> </span>et<span style='letter-spacing:-.05pt'> </span>8,3<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>m<span style='letter-spacing:-.15pt'> </span>Hg respectiv<span style='letter-spacing: .05pt'>e</span>m<span style='letter-spacing:.05pt'>en</span>t).</p>
<p class=AmmCorpsTexte>Une<span style='letter-spacing:-.2pt'> </span>dose<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>150<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>g<span style='letter-spacing:-.1pt'> </span>d<span style='letter-spacing:.05pt'>’</span>i<span style='letter-spacing:-.05pt'>r</span>bésartan<span style='letter-spacing:-.5pt'> </span>et de 12,5<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span>g<span style='letter-spacing:-.1pt'> </span>d’hydrochloro<span style='letter-spacing:-.05pt'>t</span>hiazide,<span style='letter-spacing:-.95pt'> </span>en<span style='letter-spacing:-.1pt'> </span>une<span style='letter-spacing: -.15pt'> </span>prise<span style='letter-spacing:-.2pt'> </span>quotidienne,<span style='letter-spacing:-.5pt'> </span>a per<span style='letter-spacing:-.1pt'>m</span>is<span style='letter-spacing:-.25pt'> </span>une<span style='letter-spacing:-.1pt'> </span>réduction<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span><span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.05pt'>e</span>nne<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.05pt'> </span>12<span style='letter-spacing:-.05pt'>,</span>9/<span style='letter-spacing:-.05pt'>6</span>,9<span style='letter-spacing:-.3pt'> </span>mm<span style='letter-spacing:-.15pt'> </span>Hg<span style='letter-spacing:-.2pt'> </span>(PAS/PAD)<span style='letter-spacing:-.55pt'> </span>(24<span style='letter-spacing:-.15pt'> </span>heures<span style='letter-spacing:-.3pt'> </span>après<span style='letter-spacing:-.15pt'> </span>la prise),<span style='letter-spacing:-.3pt'> </span>effet<span style='letter-spacing: -.25pt'> </span>placebo dédu<span style='letter-spacing:-.05pt'>i</span>t,<span style='letter-spacing:-.3pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.35pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing: -.25pt'> </span><span style='letter-spacing:-.05pt'>un</span>e<span style='letter-spacing:-.1pt'> </span>hypertension<span style='letter-spacing: -.55pt'> </span>artérielle<span style='letter-spacing:.05pt'> </span>légère<span style='letter-spacing:-.25pt'> </span>à<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:-.1pt'>m</span>odérée.<span style='letter-spacing:-.4pt'> </span>L'effet<span style='letter-spacing:-.2pt'> </span>maxi<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.1pt'>u</span>m<span style='letter-spacing:-.45pt'> </span>survient entre<span style='letter-spacing: -.2pt'> </span>3<span style='letter-spacing:-.05pt'> </span>et 6<span style='letter-spacing:-.05pt'> </span>heures.<span style='letter-spacing:-.3pt'> </span>Lors<span style='letter-spacing:-.2pt'> </span>d<span style='letter-spacing: .05pt'>’</span>un<span style='letter-spacing:-.2pt'> </span>enregistrement<span style='letter-spacing:-.65pt'> </span><span style='letter-spacing:.05pt'>a</span><span style='letter-spacing:-.1pt'>m</span>bulatoire<span style='letter-spacing:-.5pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la pression<span style='letter-spacing:-.35pt'> </span>artérielle<span style='letter-spacing: .05pt'> </span>(<span style='letter-spacing:.1pt'>M</span>APA), l<span style='letter-spacing:-.05pt'>'</span>association<span style='letter-spacing: -.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>150<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>g<span style='letter-spacing:-.1pt'> </span>d<span style='letter-spacing:.05pt'>’</span><span style='letter-spacing:-.05pt'>i</span>rbésartan<span style='letter-spacing: -.5pt'> </span>et de<span style='letter-spacing:-.1pt'> </span>12,5<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span>g<span style='letter-spacing:-.1pt'> </span>d<span style='letter-spacing:-.1pt'>’</span>hydrochlo<span style='letter-spacing:-.05pt'>r</span>oth<span style='letter-spacing:-.05pt'>i</span>azide<span style='letter-spacing:-.95pt'> </span>en<span style='letter-spacing:-.1pt'> </span>une<span style='letter-spacing:-.15pt'> </span>seule<span style='letter-spacing:-.25pt'> </span>prise<span style='letter-spacing:-.2pt'> </span>par<span style='letter-spacing:-.15pt'> </span>jour,<span style='letter-spacing:-.2pt'> </span>a produit<span style='letter-spacing:-.35pt'> </span>une<span style='letter-spacing: -.15pt'> </span>baisse<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la p<span style='letter-spacing:.05pt'>r</span>ession<span style='letter-spacing:-.35pt'> </span>artérie<span style='letter-spacing:.1pt'>l</span>le<span style='letter-spacing:-.3pt'> </span>sur<span style='letter-spacing:-.15pt'> </span>24<span style='letter-spacing:-.2pt'> </span>heu<span style='letter-spacing:-.05pt'>r</span>es<span style='letter-spacing:-.3pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>une<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.05pt'>r</span>éduction<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.1pt'>m</span>oyenne<span style='letter-spacing:-.4pt'> </span>sur<span style='letter-spacing:-.15pt'> </span>24<span style='letter-spacing:-.1pt'> </span>heures<span style='letter-spacing:-.3pt'> </span>de 15,8<span style='letter-spacing:-.05pt'>/</span>10,0<span style='letter-spacing: -.4pt'> </span>mm<span style='letter-spacing:-.15pt'> </span>Hg<span style='letter-spacing:-.15pt'> </span>(PAS/PAD),<span style='letter-spacing: -.55pt'> </span>effet<span style='letter-spacing:-.2pt'> </span>placebo<span style='letter-spacing:-.35pt'> </span>déduit.<span style='letter-spacing:-.35pt'> </span>Le<span style='letter-spacing:-.1pt'> </span>rapport<span style='letter-spacing:-.3pt'> </span>v<span style='letter-spacing:-.05pt'>a</span>llée-pic<span style='letter-spacing:-.4pt'> </span>sous IRBESARTAN/HYDROCHLOROTHIAZIDE SET<span style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>1</span>50<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/12,5<span style='letter-spacing:-.4pt'> </span><span style='letter-spacing:-.1pt'>m</span>g<span style='letter-spacing:-.1pt'> </span>était<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>100<span style='letter-spacing:-.05pt'>%</span>,<span style='letter-spacing:-.3pt'> </span>mesures<span style='letter-spacing:-.35pt'> </span>faites<span style='letter-spacing:-.2pt'> </span>par<span style='letter-spacing:-.15pt'> </span>l<span style='letter-spacing: -.05pt'>'</span>enregistre<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.6pt'> </span>a<span style='letter-spacing:-.1pt'>m</span>bulatoire<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la pression<span style='letter-spacing:-.35pt'> </span>arté<span style='letter-spacing: .05pt'>r</span>ielle.<span style='letter-spacing:-.2pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>ra<span style='letter-spacing:.1pt'>p</span>ports<span style='letter-spacing:-.35pt'> </span>vallée-pic<span style='letter-spacing: -.4pt'> </span>ont<span style='letter-spacing:-.2pt'> </span>été respectiv<span style='letter-spacing:.05pt'>e</span>ment<span style='letter-spacing:-.65pt'> </span>de<span style='letter-spacing:-.1pt'> </span>68%<span style='letter-spacing:-.2pt'> </span>et 76%<span style='letter-spacing:-.2pt'> </span>sous IRBESARTAN/HYDROCHLOROTHIAZIDE SET<span style='letter-spacing:-.5pt'> </span>150<span style='letter-spacing: -.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/12,5<span style='letter-spacing:-.4pt'> </span><span style='letter-spacing:-.1pt'>m</span>g<span style='letter-spacing:-.1pt'> </span>et<span style='letter-spacing:.1pt'> </span>IRBESARTAN/HYDROCHLOROTHIAZIDE SET<span style='letter-spacing:-.5pt'> </span>300<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/12<span style='letter-spacing:-.05pt'>,</span>5<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.1pt'>m</span>g<span style='letter-spacing:-.1pt'> </span>lorsque<span style='letter-spacing:-.3pt'> </span>les<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>e</span>sur<span style='letter-spacing:.05pt'>e</span>s<span style='letter-spacing:-.3pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été prises<span style='letter-spacing: -.25pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le cabinet<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span>édi<span style='letter-spacing:.05pt'>c</span>al<span style='letter-spacing:-.2pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>un<span style='letter-spacing:-.1pt'> </span>brassard.<span style='letter-spacing:-.4pt'> </span></p>
<p class=AmmCorpsTexte>Ces<span style='letter-spacing:-.05pt'> </span>ef<span style='letter-spacing:.05pt'>f</span>ets<span style='letter-spacing:-.2pt'> </span>sur<span style='letter-spacing:-.15pt'> </span>24<span style='letter-spacing:-.1pt'> </span>h<span style='letter-spacing:-.1pt'>e</span>ures<span style='letter-spacing:-.3pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été observés<span style='letter-spacing: -.4pt'> </span><span style='letter-spacing:.05pt'>s</span>ans<span style='letter-spacing:-.15pt'> </span>baisse<span style='letter-spacing:-.2pt'> </span>exce<span style='letter-spacing:.05pt'>s</span>sive<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la pression<span style='letter-spacing:-.35pt'> </span>arté<span style='letter-spacing: .05pt'>r</span>ielle<span style='letter-spacing:-.2pt'> </span>au<span style='letter-spacing:-.1pt'> </span>pic<span style='letter-spacing:-.15pt'> </span>et sont<span style='letter-spacing:-.2pt'> </span>co<span style='letter-spacing: -.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>at<span style='letter-spacing:.05pt'>ib</span>les<span style='letter-spacing:-.4pt'> </span>a<span style='letter-spacing:-.05pt'>v</span>ec<span style='letter-spacing:-.1pt'> </span>une<span style='letter-spacing:-.15pt'> </span>réduction<span style='letter-spacing: -.4pt'> </span>de<span style='letter-spacing:-.15pt'> </span>la pression<span style='letter-spacing:-.35pt'> </span>artérielle<span style='letter-spacing: .05pt'> </span>sûre<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>e</span>t efficace,<span style='letter-spacing: -.3pt'> </span>tout<span style='letter-spacing:-.15pt'> </span>au<span style='letter-spacing:-.1pt'> </span>long<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>intervalle<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.2pt'> </span>prise<span style='letter-spacing:-.2pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>une<span style='letter-spacing:-.05pt'> </span>a<span style='letter-spacing:.1pt'>d</span><span style='letter-spacing:-.1pt'>m</span>inistration<span style='letter-spacing: -.55pt'> </span>q<span style='letter-spacing:-.05pt'>u</span>otidienn<span style='letter-spacing:-.05pt'>e</span>.</p>
<p class=AmmCorpsTexte>Chez<span style='letter-spacing:-.25pt'> </span>les<span style='letter-spacing:-.1pt'> </span>pat<span style='letter-spacing:.05pt'>i</span>ents<span style='letter-spacing:-.35pt'> </span>qui<span style='letter-spacing:-.15pt'> </span>ne<span style='letter-spacing:-.1pt'> </span>sont<span style='letter-spacing:-.2pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>suffisamment<span style='letter-spacing: -.65pt'> </span>contrôlés<span style='letter-spacing:-.4pt'> </span>par<span style='letter-spacing:-.15pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>h<span style='letter-spacing:.1pt'>y</span>d<span style='letter-spacing:-.05pt'>r</span>ochlorothiaz<span style='letter-spacing:-.05pt'>i</span>de<span style='letter-spacing:-.9pt'> </span>25<span style='letter-spacing:-.1pt'> m</span>g<span style='letter-spacing:-.1pt'> </span>seul, l'addition<span style='letter-spacing:-.4pt'> </span>d<span style='letter-spacing: .05pt'>’</span>irbésartan<span style='letter-spacing:-.5pt'> </span>a en<span style='letter-spacing:.05pt'>t</span>raîné<span style='letter-spacing:-.25pt'> </span>une<span style='letter-spacing:-.15pt'> </span>réduction<span style='letter-spacing: -.4pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span><span style='letter-spacing:.1pt'>y</span>enne<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>PAS/PAD<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>11,1/7,2<span style='letter-spacing:-.35pt'> </span>mm<span style='letter-spacing:-.15pt'> </span>Hg. L<span style='letter-spacing:.05pt'>’</span>effet<span style='letter-spacing: -.3pt'> </span>antihypertenseur<span style='letter-spacing:-.75pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l'irbé<span style='letter-spacing:.05pt'>s</span>artan<span style='letter-spacing:-.45pt'> </span><span style='letter-spacing:.05pt'>e</span>n assoc<span style='letter-spacing:-.05pt'>i</span>ation<span style='letter-spacing: -.5pt'> </span>avec<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>l</span><span style='letter-spacing:-.05pt'>'</span>h<span style='letter-spacing:.1pt'>y</span>drochlorothiazide<span style='letter-spacing: -.95pt'> </span>apparaît<span style='letter-spacing:-.35pt'> </span>dès<span style='letter-spacing:-.15pt'> </span>la pre<span style='letter-spacing:-.1pt'>m</span>ière<span style='letter-spacing:-.4pt'> </span>dose,<span style='letter-spacing:-.25pt'> </span>il devient<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing: -.05pt'>n</span><span style='letter-spacing:.05pt'>o</span>table<span style='letter-spacing:-.25pt'> </span>en<span style='letter-spacing:-.1pt'> </span>1<span style='letter-spacing:-.05pt'> </span>à<span style='letter-spacing:-.05pt'> </span>2<span style='letter-spacing:-.05pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines,<span style='letter-spacing:-.4pt'> </span><span style='letter-spacing:.05pt'>l</span>'effet<span style='letter-spacing:-.1pt'> </span>max<span style='letter-spacing:.05pt'>i</span><span style='letter-spacing:-.1pt'>m</span>al<span style='letter-spacing:-.2pt'> </span>étant<span style='letter-spacing:-.2pt'> </span>observé<span style='letter-spacing:-.35pt'> </span>6<span style='letter-spacing:-.05pt'> </span>à 8<span style='letter-spacing: -.05pt'> </span>semaines<span style='letter-spacing:-.4pt'> après le </span>début<span style='letter-spacing:-.25pt'> </span>du<span style='letter-spacing:-.1pt'> </span>t<span style='letter-spacing:-.05pt'>r</span>aitement.<span style='letter-spacing: -.4pt'> </span>Lors<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>études<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>suivi<span style='letter-spacing:-.2pt'> </span>à long<span style='letter-spacing:-.2pt'> </span>te<span style='letter-spacing:.05pt'>r</span><span style='letter-spacing:-.1pt'>m</span>e,<span style='letter-spacing:-.3pt'> </span>les ef<span style='letter-spacing:.05pt'>f</span>ets<span style='letter-spacing:-.2pt'> </span>de l<span style='letter-spacing:-.05pt'>'</span>irbésartan/hydrochlo<span style='letter-spacing:-.05pt'>r</span>oth<span style='letter-spacing:-.05pt'>i</span>azide<span style='letter-spacing:-1.3pt'> </span>se<span style='letter-spacing:-.1pt'> </span>sont<span style='letter-spacing:-.1pt'> </span>maintenus<span style='letter-spacing:-.4pt'> </span>au-delà<span style='letter-spacing:-.15pt'> </span>d’<span style='letter-spacing:-.05pt'>u</span>n<span style='letter-spacing:-.15pt'> </span>an.<span style='letter-spacing:-.2pt'> </span>Quoique<span style='letter-spacing:-.4pt'> </span>n<span style='letter-spacing:-.05pt'>o</span>n<span style='letter-spacing: -.2pt'> </span>spécifique<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.05pt'>e</span>nt<span style='letter-spacing:-.6pt'> </span>étudié avec<span style='letter-spacing:-.2pt'> </span>IRBESARTAN/HYDROCHLOROTHIAZIDE SET,<span style='letter-spacing:-.5pt'> </span>un<span style='letter-spacing: -.15pt'> </span>phénomène<span style='letter-spacing:-.5pt'> </span>de<span style='letter-spacing:-.1pt'> </span>rebond<span style='letter-spacing:-.3pt'> </span>n<span style='letter-spacing:.05pt'>’</span>a<span style='letter-spacing:-.1pt'> </span>pas<span style='letter-spacing:-.1pt'> </span>été observé<span style='letter-spacing: -.35pt'> </span>que<span style='letter-spacing:-.2pt'> </span>ce soit<span style='letter-spacing:-.15pt'> </span>avec<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>l</span>'irbésartan<span style='letter-spacing: -.45pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>avec l<span style='letter-spacing:-.05pt'>'</span>h<span style='letter-spacing:.1pt'>y</span>droch<span style='letter-spacing:-.05pt'>l</span>or<span style='letter-spacing:-.05pt'>o</span>thiazide.</p>
<p class=AmmCorpsTexte>L’effet<span style='letter-spacing:-.25pt'> </span>sur<span style='letter-spacing:-.15pt'> </span>la <span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>rbidité<span style='letter-spacing:-.4pt'> </span>et la<span style='letter-spacing:.1pt'> </span><span style='letter-spacing: -.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>rtalité<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>assoc<span style='letter-spacing:-.1pt'>i</span>ation<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>irbésartan<span style='letter-spacing: -.4pt'> </span>et de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>hyd<span style='letter-spacing:-.05pt'>r</span>ochlorothiaz<span style='letter-spacing:-.05pt'>i</span>de<span style='letter-spacing:-.9pt'> </span>n’a pas<span style='letter-spacing:-.15pt'> </span>été étudié.<span style='letter-spacing:-.3pt'> </span>Des<span style='letter-spacing:-.15pt'> </span>études<span style='letter-spacing:-.3pt'> </span>épidé<span style='letter-spacing:-.05pt'>m</span>iologiques<span style='letter-spacing:-.8pt'> </span>ont<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>ontré<span style='letter-spacing:-.3pt'> </span>que<span style='letter-spacing:-.15pt'> </span>le traitement<span style='letter-spacing: -.4pt'> </span>à long<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.05pt'>t</span>er<span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:-.1pt'> </span>par l<span style='letter-spacing:-.05pt'>'</span>h<span style='letter-spacing:.1pt'>y</span>drochlorothiazide<span style='letter-spacing: -.85pt'> </span>réduit<span style='letter-spacing:-.25pt'> </span>le<span style='letter-spacing:-.05pt'> </span>risque<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing: .05pt'>o</span>r<span style='letter-spacing:.05pt'>t</span>alité<span style='letter-spacing:-.2pt'> </span>et de <span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>rbidité<span style='letter-spacing:-.45pt'> </span>cardiovasculaires.</p>
<p class=AmmCorpsTexte>L<span style='letter-spacing:-.05pt'>'</span>efficacité<span style='letter-spacing:-.45pt'> </span>d’IRBESARTAN/HYDROCHLOROTHIAZIDE SET<span style='letter-spacing:-.5pt'> </span>est<span style='letter-spacing:-.1pt'> </span>indépendante<span style='letter-spacing:-.55pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.1pt'>'</span>âge<span style='letter-spacing:-.15pt'> </span>et<span style='letter-spacing:.1pt'> </span>du<span style='letter-spacing:-.1pt'> </span>sexe.<span style='letter-spacing:-.2pt'> </span>Comme<span style='letter-spacing:-.25pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>l<span style='letter-spacing:.05pt'>e</span>s autres<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing: -.1pt'>m</span>édi<span style='letter-spacing:.05pt'>ca</span><span style='letter-spacing:-.1pt'>m</span>ents agissant<span style='letter-spacing: -.35pt'> </span>sur<span style='letter-spacing:-.15pt'> </span>le s<span style='letter-spacing:.1pt'>y</span>stème<span style='letter-spacing:-.35pt'> </span>ré<span style='letter-spacing:.1pt'>n</span>ine-angiotensine,<span style='letter-spacing: -.85pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.35pt'> </span>h<span style='letter-spacing:.1pt'>y</span>pertendus<span style='letter-spacing:-.55pt'> </span>noirs<span style='letter-spacing:-.2pt'> </span>présentent<span style='letter-spacing:-.45pt'> </span>une<span style='letter-spacing:-.15pt'> </span>réponse sensiblement<span style='letter-spacing:-.5pt'> </span>plus<span style='letter-spacing:-.2pt'> </span>faible<span style='letter-spacing:-.25pt'> </span>à une<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing: -.1pt'>m</span>onothérapie<span style='letter-spacing:-.55pt'> </span>par<span style='letter-spacing:-.15pt'> </span>irbésartan.<span style='letter-spacing: -.45pt'> </span>Quand<span style='letter-spacing:-.3pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>irbésartan<span style='letter-spacing: -.4pt'> </span>est<span style='letter-spacing:-.1pt'> </span>ad<span style='letter-spacing:-.1pt'>m</span>inist<span style='letter-spacing:.05pt'>r</span>é<span style='letter-spacing:-.4pt'> </span>en association<span style='letter-spacing: -.5pt'> </span><span style='letter-spacing:.05pt'>av</span>ec<span style='letter-spacing:-.05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>faibles<span style='letter-spacing:-.25pt'> </span>doses<span style='letter-spacing:-.25pt'> </span>d’h<span style='letter-spacing:.1pt'>y</span>drochlorothiazide<span style='letter-spacing:-1.0pt'> </span>(telles<span style='letter-spacing:-.25pt'> </span>que<span style='letter-spacing:-.15pt'> </span>12,5<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span>g<span style='letter-spacing:-.1pt'> </span>par<span style='letter-spacing:-.15pt'> </span>jour),<span style='letter-spacing:-.25pt'> </span>la réponse antih<span style='letter-spacing: .1pt'>y</span><span style='letter-spacing:.05pt'>p</span>ertensive<span style='letter-spacing:-.75pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing:-.35pt'> </span>noirs<span style='letter-spacing:-.2pt'> </span>se<span style='letter-spacing:-.1pt'> </span>rapp<span style='letter-spacing:.05pt'>r</span>oche<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>celle des<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing: -.35pt'> </span>non<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.05pt'>n</span><span style='letter-spacing:.05pt'>o</span>irs.</p>
<p class=AmmCorpsTexte>L’efficacité<span style='letter-spacing:-.45pt'> </span>et la tolérance<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> l'</span>IRBESARTAN/HYDROCHLOROTHIAZIDE SET<span style='letter-spacing:-.5pt'> </span>en<span style='letter-spacing:-.1pt'> </span>t<span style='letter-spacing:-.05pt'>r</span>aite<span style='letter-spacing:-.05pt'>m</span>e<span style='letter-spacing:.1pt'>n</span>t<span style='letter-spacing:-.1pt'> </span>initial<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>hypertension<span style='letter-spacing: -.55pt'> </span>artérielle<span style='letter-spacing:.05pt'> </span>sé<span style='letter-spacing:.1pt'>v</span>ère<span style='letter-spacing:-.3pt'> </span>(définie par<span style='letter-spacing:-.15pt'> </span>une<span style='letter-spacing: -.15pt'> </span>PAD<span style='letter-spacing:-.2pt'> </span>&#8805; 110<span style='letter-spacing:-.15pt'> </span>mmHg)<span style='letter-spacing:-.35pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été évaluées<span style='letter-spacing:-.3pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>une<span style='letter-spacing:-.15pt'> </span>étude<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing: .05pt'>u</span>lticentrique,<span style='letter-spacing:-.6pt'> </span>rando<span style='letter-spacing:-.1pt'>m</span>isée,<span style='letter-spacing:-.55pt'> </span>en double-aveugle<span style='letter-spacing:-.6pt'> </span>et bras<span style='letter-spacing:-.2pt'> </span>parallèles<span style='letter-spacing: -.35pt'> </span>contre<span style='letter-spacing:-.15pt'> </span>produit<span style='letter-spacing:-.35pt'> </span>actif<span style='letter-spacing:-.05pt'> </span>pendant<span style='letter-spacing:-.35pt'> </span>8<span style='letter-spacing:-.05pt'> </span>s<span style='letter-spacing:-.05pt'>e</span>maines.<span style='letter-spacing:-.45pt'> </span>Au<span style='letter-spacing:-.15pt'> </span>total,<span style='letter-spacing:-.2pt'> </span>697<span style='letter-spacing:-.2pt'> </span>patients<span style='letter-spacing:-.35pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été rando<span style='letter-spacing:-.1pt'>m</span>isés<span style='letter-spacing: -.5pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>un<span style='letter-spacing:-.1pt'> </span>rappo<span style='letter-spacing:-.05pt'>r</span>t<span style='letter-spacing:-.25pt'> </span>2:1<span style='letter-spacing:-.1pt'> </span>soit<span style='letter-spacing:-.25pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le groupe<span style='letter-spacing:-.3pt'> </span>i<span style='letter-spacing: -.05pt'>r</span>bésartan/h<span style='letter-spacing:.1pt'>y</span>d<span style='letter-spacing:-.05pt'>r</span>ochlorothiaz<span style='letter-spacing: -.05pt'>i</span>de<span style='letter-spacing:-1.35pt'> </span>150<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/12,5<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.1pt'>m</span>g soit<span style='letter-spacing:-.15pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le g<span style='letter-spacing:-.05pt'>r</span>oupe<span style='letter-spacing:-.3pt'> </span>irbésartan<span style='letter-spacing:-.45pt'> </span>150<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>.<span style='letter-spacing:-.15pt'> </span>Après<span style='letter-spacing:-.25pt'> </span>une<span style='letter-spacing:-.15pt'> </span>semaine<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>traitement,<span style='letter-spacing:-.4pt'> </span>les<span style='letter-spacing:-.1pt'> </span>doses<span style='letter-spacing:-.25pt'> </span>reçues<span style='letter-spacing:-.3pt'> </span>par<span style='letter-spacing:-.15pt'> les patients </span>ont<span style='letter-spacing:-.15pt'> </span>été s<span style='letter-spacing:.1pt'>y</span>stématique<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.75pt'> </span>au<span style='letter-spacing:.1pt'>g</span>mentées<span style='letter-spacing:-.5pt'> </span>par<span style='letter-spacing:-.15pt'> </span>tit<span style='letter-spacing:.05pt'>r</span>ation<span style='letter-spacing:-.2pt'> </span>forcée<span style='letter-spacing:-.25pt'> </span>(avant<span style='letter-spacing:-.25pt'> </span>d<span style='letter-spacing:.05pt'>’</span>évaluer<span style='letter-spacing:-.4pt'> </span>la réponse<span style='letter-spacing:-.35pt'> </span>à la dose plus<span style='letter-spacing:-.2pt'> </span>faible),<span style='letter-spacing:-.3pt'> </span>respectiveme<span style='letter-spacing:.1pt'>n</span>t<span style='letter-spacing:-.65pt'> </span>à irbésartan<span style='letter-spacing: .1pt'>/</span>h<span style='letter-spacing:.1pt'>y</span>d<span style='letter-spacing:-.05pt'>r</span>och<span style='letter-spacing:-.05pt'>l</span>oro<span style='letter-spacing:-.05pt'>t</span>hiazide<span style='letter-spacing:-1.3pt'> </span>300<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing: -.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/25<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span>g<span style='letter-spacing:-.1pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>irbésartan<span style='letter-spacing:-.4pt'> </span>300<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>.</p>
<p class=AmmCorpsTexte>L<span style='letter-spacing:.05pt'>’</span>étude<span style='letter-spacing:-.35pt'> </span>a recruté<span style='letter-spacing: -.3pt'> </span>58%<span style='letter-spacing:-.2pt'> </span>d<span style='letter-spacing:.05pt'>’</span>homm<span style='letter-spacing:.05pt'>e</span>s.<span style='letter-spacing:-.5pt'> </span>L'âge<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span><span style='letter-spacing:.1pt'>y</span>en<span style='letter-spacing:-.25pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing:-.35pt'> </span>était de<span style='letter-spacing:-.1pt'> </span>52,5<span style='letter-spacing:-.2pt'> </span>ans,<span style='letter-spacing:-.15pt'> </span>13%<span style='letter-spacing:-.2pt'> </span>éta<span style='letter-spacing:.1pt'>i</span>ent<span style='letter-spacing:-.15pt'> </span>âgés de<span style='letter-spacing:-.1pt'> </span>65<span style='letter-spacing:-.1pt'> </span>ans<span style='letter-spacing: -.15pt'> </span>ou<span style='letter-spacing:-.2pt'> </span>plus,<span style='letter-spacing:-.2pt'> </span>et seulement<span style='letter-spacing: -.4pt'> </span>2%<span style='letter-spacing:-.15pt'> </span>étaient<span style='letter-spacing:.05pt'> </span>agés<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>75<span style='letter-spacing:-.1pt'> </span>ans<span style='letter-spacing:-.15pt'> </span>ou<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>p</span>lus.<span style='letter-spacing:-.25pt'> </span>Douze<span style='letter-spacing:-.3pt'> </span>pour<span style='letter-spacing:-.25pt'> </span>cent<span style='letter-spacing:-.2pt'> </span>(12<span style='letter-spacing:-.05pt'>%</span>)<span style='letter-spacing:-.25pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patients présentaient<span style='letter-spacing:-.55pt'> </span>un<span style='letter-spacing:-.1pt'> </span>diabète,<span style='letter-spacing:-.35pt'> </span>34%<span style='letter-spacing:-.2pt'> </span>une<span style='letter-spacing: -.15pt'> </span>h<span style='letter-spacing:.1pt'>y</span>perlipidé<span style='letter-spacing:-.05pt'>m</span>ie<span style='letter-spacing:-.5pt'> </span>et la<span style='letter-spacing:.05pt'> </span>patholgie<span style='letter-spacing: -.4pt'> </span>cardiovasculaire<span style='letter-spacing:-.65pt'> </span>la plus<span style='letter-spacing:-.2pt'> </span>fréquente<span style='letter-spacing: -.4pt'> </span>était un<span style='letter-spacing:-.1pt'> </span>angor<span style='letter-spacing:-.3pt'> </span>stable<span style='letter-spacing:-.25pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>3,5%<span style='letter-spacing:-.25pt'> </span>des<span style='letter-spacing:-.15pt'> </span>participants<span style='letter-spacing:-.45pt'> </span>à l'étude.</p>
<p class=AmmCorpsTexte>L’<span style='letter-spacing:-.05pt'>o</span><span style='letter-spacing:.05pt'>b</span>jectif<span style='letter-spacing:-.2pt'> </span>pr<span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.05pt'>n</span>cipal<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>cette étude<span style='letter-spacing:-.25pt'> </span>était de<span style='letter-spacing:-.1pt'> </span>c<span style='letter-spacing:.1pt'>o</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:-.05pt'>p</span>arer<span style='letter-spacing:-.4pt'> </span>le pourcentage<span style='letter-spacing: -.6pt'> </span>de<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.35pt'> </span>d<span style='letter-spacing:-.05pt'>o</span>nt<span style='letter-spacing:-.2pt'> </span>la PAD<span style='letter-spacing:-.2pt'> </span>était controlée<span style='letter-spacing:-.4pt'> </span>(PAD<span style='letter-spacing: -.25pt'> </span>&lt;<span style='letter-spacing:-.05pt'> </span>90<span style='letter-spacing:-.1pt'> </span>mm<span style='letter-spacing:.05pt'>H</span>g)<span style='letter-spacing:-.35pt'> </span>après<span style='letter-spacing:-.25pt'> </span>5<span style='letter-spacing:-.05pt'> </span>semaines<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>tr<span style='letter-spacing:.05pt'>a</span>it<span style='letter-spacing:.05pt'>e</span><span style='letter-spacing:-.1pt'>m</span>ent.<span style='letter-spacing:-.25pt'> </span>Qua<span style='letter-spacing:.05pt'>r</span>ante<span style='letter-spacing:-.4pt'> </span>sept<span style='letter-spacing:-.2pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>cent<span style='letter-spacing:-.2pt'> </span>(47,2%)<span style='letter-spacing:-.35pt'> </span>des patients<span style='letter-spacing:-.35pt'> </span>traités<span style='letter-spacing:-.25pt'> </span>par<span style='letter-spacing:-.15pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>association<span style='letter-spacing: -.5pt'> </span><span style='letter-spacing:-.05pt'>o</span><span style='letter-spacing:.05pt'>n</span>t<span style='letter-spacing:-.1pt'> </span>eu<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>un</span>e<span style='letter-spacing:-.1pt'> </span>PAD<span style='letter-spacing:-.2pt'> </span>&lt;<span style='letter-spacing:-.05pt'> </span>90<span style='letter-spacing:-.1pt'> </span>mmHg<span style='letter-spacing:-.3pt'> </span>à la vallée<span style='letter-spacing: -.25pt'> </span>c<span style='letter-spacing:.1pt'>o</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>aré<span style='letter-spacing:-.4pt'> </span>à 33,2%<span style='letter-spacing:-.3pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patients sous<span style='letter-spacing:-.2pt'> </span>irbésart<span style='letter-spacing:.05pt'>a</span>n<span style='letter-spacing:-.45pt'> </span>(p<span style='letter-spacing:-.1pt'> </span>=<span style='letter-spacing:-.05pt'> </span>0,0005).<span style='letter-spacing:-.35pt'> </span>La<span style='letter-spacing:-.1pt'> </span>pression<span style='letter-spacing:-.35pt'> </span>artérielle <span style='letter-spacing: -.1pt'>m</span><span style='letter-spacing:.1pt'>oy</span>enne<span style='letter-spacing:-.35pt'> </span>avant<span style='letter-spacing:-.25pt'> </span>trait<span style='letter-spacing:.05pt'>e</span>ment<span style='letter-spacing:-.2pt'> </span>éta<span style='letter-spacing:.1pt'>i</span>t approxi<span style='letter-spacing:-.05pt'>m</span>at<span style='letter-spacing: .05pt'>i</span>v<span style='letter-spacing:.05pt'>e</span><span style='letter-spacing:-.1pt'>m</span>ent de<span style='letter-spacing:-.05pt'> </span>172<span style='letter-spacing:-.05pt'>/</span>113<span style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.1pt'>m</span>mHg<span style='letter-spacing:-.3pt'> </span>dans<span style='letter-spacing:-.15pt'> </span>chaque<span style='letter-spacing:-.25pt'> </span>groupe<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>traite<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>et la di<span style='letter-spacing:-.1pt'>m</span>inution<span style='letter-spacing: -.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la PAS<span style='letter-spacing:-.05pt'>/</span>PAD<span style='letter-spacing:-.45pt'> </span>à 5<span style='letter-spacing:-.05pt'> </span>semaines était<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>30,8<span style='letter-spacing:-.05pt'>/</span>24,0<span style='letter-spacing:-.4pt'> </span>m<span style='letter-spacing:-.1pt'>m</span>Hg<span style='letter-spacing:-.3pt'> </span>et<span style='letter-spacing:.05pt'> </span>21,1<span style='letter-spacing:-.05pt'>/</span>19<span style='letter-spacing:-.05pt'>,</span>3<span style='letter-spacing:-.4pt'> </span>mmHg<span style='letter-spacing:-.3pt'> </span>respective<span style='letter-spacing: -.05pt'>m</span>ent<span style='letter-spacing:-.6pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>groupes irbésartan/hydrochloro<span style='letter-spacing:-.05pt'>t</span>hiazide<span style='letter-spacing:-1.35pt'> </span>et irbésartan<span style='letter-spacing: -.45pt'> </span>(p<span style='letter-spacing:-.1pt'> </span>&lt;<span style='letter-spacing:-.05pt'> </span>0,0001).</p>
<p class=AmmCorpsTexte>La<span style='letter-spacing:-.1pt'> </span>nature<span style='letter-spacing:-.25pt'> </span>et l'incidence<span style='letter-spacing: -.4pt'> </span>des<span style='letter-spacing:-.15pt'> </span>événe<span style='letter-spacing:-.05pt'>m</span>ents<span style='letter-spacing:-.5pt'> </span><span style='letter-spacing:.05pt'>i</span>ndésir<span style='letter-spacing:-.1pt'>a</span>bles<span style='letter-spacing:-.5pt'> </span>rapportés<span style='letter-spacing:-.4pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.35pt'> </span>traités<span style='letter-spacing:-.25pt'> </span>par<span style='letter-spacing:-.15pt'> </span>l'ass<span style='letter-spacing:.1pt'>o</span>ciation étaient<span style='letter-spacing:.05pt'> </span>si<span style='letter-spacing: -.1pt'>m</span>ilaires<span style='letter-spacing:-.4pt'> </span>à ceux<span style='letter-spacing:-.2pt'> </span>du<span style='letter-spacing:-.1pt'> </span>profil<span style='letter-spacing:-.25pt'> </span>des<span style='letter-spacing:-.15pt'> </span>é<span style='letter-spacing:-.05pt'>v</span>éne<span style='letter-spacing:-.05pt'>m</span>ents<span style='letter-spacing:-.55pt'> </span>indésirables<span style='letter-spacing: -.5pt'> </span>rapporté<span style='letter-spacing:-.35pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les patients<span style='letter-spacing: -.35pt'> </span>sous <span style='letter-spacing:-.1pt'>m</span>onothérapie.<span style='letter-spacing:-.6pt'> </span>Pendant<span style='letter-spacing:-.35pt'> </span>les<span style='letter-spacing:-.1pt'> </span>8<span style='letter-spacing: -.05pt'> </span>se<span style='letter-spacing:-.1pt'>m</span>aines<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:.1pt'>d</span>e<span style='letter-spacing:-.05pt'> </span>l'étude,<span style='letter-spacing:-.3pt'> </span>il <span style='letter-spacing:-.05pt'>n</span>’y<span style='letter-spacing: -.15pt'> </span>a pas<span style='letter-spacing:-.15pt'> </span>eu<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>s<span style='letter-spacing:.1pt'>y</span>nc<span style='letter-spacing:-.05pt'>o</span><span style='letter-spacing:.05pt'>p</span>e<span style='letter-spacing:-.3pt'> </span>rap<span style='letter-spacing:-.05pt'>p</span>ortée<span style='letter-spacing:-.35pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>aucun<span style='letter-spacing:-.25pt'> </span>des groupes<span style='letter-spacing: -.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>t<span style='letter-spacing:-.05pt'>r</span>aitement.<span style='letter-spacing: -.4pt'> </span>Dans<span style='letter-spacing:-.25pt'> </span>le groupe<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>association<span style='letter-spacing: -.45pt'> </span>et<span style='letter-spacing:.05pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le<span style='letter-spacing:-.05pt'> </span>groupe<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span>onothérapie, l’<span style='letter-spacing:-.05pt'>h</span>ypotensi<span style='letter-spacing: -.05pt'>o</span>n<span style='letter-spacing:-.6pt'> </span>a été rapportée<span style='letter-spacing:-.4pt'> </span>c<span style='letter-spacing:.1pt'>o</span>mme<span style='letter-spacing:-.3pt'> </span>effet<span style='letter-spacing:-.2pt'> </span>indésirable<span style='letter-spacing:-.45pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>respective<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.65pt'> </span>0,6%<span style='letter-spacing:-.25pt'> </span>et 0%<span style='letter-spacing:-.15pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patients<span style='letter-spacing:-.3pt'> </span>et la sensation<span style='letter-spacing: -.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>vertige<span style='letter-spacing:-.3pt'> </span>chez<span style='letter-spacing:-.15pt'> </span>respecti<span style='letter-spacing:-.05pt'>v</span>ement<span style='letter-spacing:-.6pt'> </span>2,8%<span style='letter-spacing:-.25pt'> </span>et<span style='letter-spacing:.05pt'> </span>3<span style='letter-spacing:-.05pt'>,1</span>%<span style='letter-spacing:-.25pt'> </span>des<span style='letter-spacing:-.15pt'> </span>patients.</p>
<p class="AmmAnnexeTitre2"><a name="RcpPropPharmacocinetique">5.2. Propriétés pharmacocinétiques</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278934">L’ad<span style='letter-spacing:-.05pt'>m</span>inistration<span style='letter-spacing: -.65pt'> </span>conco<span style='letter-spacing:-.05pt'>m</span>itante<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>h<span style='letter-spacing:.1pt'>y</span>d<span style='letter-spacing:-.05pt'>r</span>ochlorothiaz<span style='letter-spacing: -.1pt'>i</span>de<span style='letter-spacing:-.9pt'> </span>et de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>irbésartan<span style='letter-spacing:-.45pt'> </span>n’a<span style='letter-spacing:-.15pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>d’effet<span style='letter-spacing:-.3pt'> </span>sur<span style='letter-spacing:-.15pt'> </span>la pharmacoci<span style='letter-spacing:.1pt'>n</span>étique<span style='letter-spacing:-.8pt'> </span>de<span style='letter-spacing:-.1pt'> </span>chacun<span style='letter-spacing:-.3pt'> </span>des<span style='letter-spacing:-.15pt'> </span>médicaments.</a></p>
<p class=AmmCorpsTexte>L<span style='letter-spacing: .05pt'>’</span>irbésartan<span style='letter-spacing:-.55pt'> </span>et l'h<span style='letter-spacing:.1pt'>y</span>droch<span style='letter-spacing:-.1pt'>l</span>orothiazide<span style='letter-spacing:-.95pt'> </span>sont<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.1pt'> m</span>édic<span style='letter-spacing:.05pt'>a</span>ments<span style='letter-spacing:-.55pt'> </span>actifs<span style='letter-spacing:-.25pt'> </span>par<span style='letter-spacing:-.05pt'> </span>voie<span style='letter-spacing:-.2pt'> </span>orale<span style='letter-spacing:-.2pt'> </span>et ne<span style='letter-spacing:-.1pt'> </span>nécessi<span style='letter-spacing: .05pt'>t</span>ent<span style='letter-spacing:-.45pt'> </span>pas de<span style='letter-spacing:-.1pt'> </span>biotransfo<span style='letter-spacing: -.05pt'>r</span>mation<span style='letter-spacing:-.8pt'> </span>pour<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.05pt'>ê</span>tre<span style='letter-spacing:-.1pt'> </span>actifs.<span style='letter-spacing:-.25pt'> </span>Après<span style='letter-spacing:-.25pt'> </span>a<span style='letter-spacing:.1pt'>d</span><span style='letter-spacing:-.1pt'>m</span>inistration<span style='letter-spacing:-.55pt'> </span>orale<span style='letter-spacing:-.2pt'> </span>d’IRBESARTAN/HYDROCHLOROTHIAZIDE SET,<span style='letter-spacing:-.5pt'> </span><span style='letter-spacing: -.05pt'>l</span>a biodisponibilité absolue<span style='letter-spacing:-.35pt'> </span>est<span style='letter-spacing:-.1pt'> </span>r<span style='letter-spacing:.05pt'>e</span>spectiv<span style='letter-spacing:.05pt'>e</span>ment<span style='letter-spacing:-.65pt'> </span>de<span style='letter-spacing:-.1pt'> </span>60-80%<span style='letter-spacing:-.35pt'> </span>et<span style='letter-spacing:-.05pt'> </span>50-80%<span style='letter-spacing:-.35pt'> </span>p<span style='letter-spacing:-.05pt'>o</span>ur<span style='letter-spacing:-.25pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>irbésartan<span style='letter-spacing:-.4pt'> </span>et l<span style='letter-spacing:-.05pt'>'</span>h<span style='letter-spacing:.1pt'>y</span>d<span style='letter-spacing:-.05pt'>r</span>ochlo<span style='letter-spacing:-.05pt'>r</span>othiazide.<span style='letter-spacing: -.85pt'> </span>Les al<span style='letter-spacing:.05pt'>i</span><span style='letter-spacing:-.1pt'>m</span>ents<span style='letter-spacing:-.25pt'> </span>ne <span style='letter-spacing:-.1pt'>m</span>odifient<span style='letter-spacing: -.4pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>la biodispon<span style='letter-spacing:-.05pt'>i</span>bilité<span style='letter-spacing:-.4pt'> </span>d’IRBESARTAN/HYDROCHLOROTHIAZIDE SET.<span style='letter-spacing:-.5pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>p<span style='letter-spacing: -.05pt'>i</span>cs<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>concentrations<span style='letter-spacing: -.65pt'> </span>plasmatiques sont<span style='letter-spacing:-.2pt'> </span>atteints<span style='letter-spacing:-.25pt'> </span>1,5<span style='letter-spacing:-.15pt'> </span>à 2<span style='letter-spacing:-.05pt'> </span>heures<span style='letter-spacing: -.35pt'> </span>après<span style='letter-spacing:-.25pt'> </span>a<span style='letter-spacing:.1pt'>d</span><span style='letter-spacing:-.1pt'>m</span>inistration<span style='letter-spacing:-.6pt'> </span>orale<span style='letter-spacing:-.2pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>irbésar<span style='letter-spacing:.05pt'>t</span>an<span style='letter-spacing:-.4pt'> </span>et 1<span style='letter-spacing:-.05pt'> </span>à 2,5<span style='letter-spacing: -.2pt'> </span>heures<span style='letter-spacing:-.3pt'> </span>pour l<span style='letter-spacing:-.05pt'>'</span>h<span style='letter-spacing:.1pt'>y</span>droch<span style='letter-spacing:-.05pt'>l</span>or<span style='letter-spacing:-.05pt'>o</span>thiazide.</p>
<p class=AmmCorpsTexte>La<span style='letter-spacing:-.1pt'> </span>liaison<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>irbésartan<span style='letter-spacing: -.45pt'> </span>aux<span style='letter-spacing:-.15pt'> </span>pr<span style='letter-spacing:-.05pt'>o</span>téines<span style='letter-spacing:-.35pt'> </span>plas<span style='letter-spacing:-.1pt'>m</span>atiques<span style='letter-spacing:-.4pt'> </span>est<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>ordre<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>96<span style='letter-spacing:-.05pt'>%</span>,<span style='letter-spacing:-.25pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>une<span style='letter-spacing:-.15pt'> </span>liaison négligeable<span style='letter-spacing:-.45pt'> </span>aux<span style='letter-spacing:-.15pt'> </span>cellules<span style='letter-spacing:-.3pt'> </span>sanguines.<span style='letter-spacing:-.45pt'> </span>Le<span style='letter-spacing:-.1pt'> </span>volu<span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>d<span style='letter-spacing:-.05pt'>i</span>s<span style='letter-spacing:.05pt'>t</span>ribution<span style='letter-spacing:-.5pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>irbésartan<span style='letter-spacing: -.45pt'> </span>est de<span style='letter-spacing:-.1pt'> </span>53<span style='letter-spacing:-.1pt'> </span>à 93<span style='letter-spacing:-.1pt'> </span>lit<span style='letter-spacing:-.05pt'>r</span>es.<span style='letter-spacing:-.1pt'> </span>La liaison<span style='letter-spacing: -.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>hydrochloro<span style='letter-spacing: -.05pt'>t</span>hiazide<span style='letter-spacing:-.85pt'> </span>aux<span style='letter-spacing:-.15pt'> </span>pro<span style='letter-spacing:-.05pt'>t</span>éines<span style='letter-spacing:-.4pt'> </span>plasm<span style='letter-spacing:-.05pt'>a</span>tiques<span style='letter-spacing:-.55pt'> </span>est<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>68<span style='letter-spacing:-.05pt'>%</span>,<span style='letter-spacing:-.25pt'> </span>et son<span style='letter-spacing:-.15pt'> </span>v<span style='letter-spacing:-.05pt'>o</span>lume<span style='letter-spacing: -.3pt'> </span>appare<span style='letter-spacing:.1pt'>n</span>t<span style='letter-spacing:-.35pt'> </span>de distribution<span style='letter-spacing: -.5pt'> </span>est<span style='letter-spacing:-.05pt'> </span>de<span style='letter-spacing:-.1pt'> </span>0,83<span style='letter-spacing:-.2pt'> </span>à<span style='letter-spacing:-.05pt'> </span>1<span style='letter-spacing:-.05pt'>,</span>14<span style='letter-spacing:-.2pt'> </span>l/<span style='letter-spacing:-.05pt'>k</span>g.</p>
<p class=AmmCorpsTexte>L<span style='letter-spacing:.05pt'>’</span>irbésartan<span style='letter-spacing:-.55pt'> </span>présente<span style='letter-spacing:-.35pt'> </span>une<span style='letter-spacing:-.15pt'> </span>pharmacoci<span style='letter-spacing:.1pt'>n</span>étique<span style='letter-spacing:-.8pt'> </span>linéaire<span style='letter-spacing:-.45pt'> </span>et proportionnelle<span style='letter-spacing: -.65pt'> </span>à la d<span style='letter-spacing:-.05pt'>o</span>se<span style='letter-spacing:-.2pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>une<span style='letter-spacing:-.15pt'> </span>fourchette<span style='letter-spacing: -.45pt'> </span>de 10<span style='letter-spacing:-.1pt'> </span>à 600<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>.<span style='letter-spacing:-.15pt'> </span>A<span style='letter-spacing:-.1pt'> </span>des<span style='letter-spacing:-.15pt'> </span>doses<span style='letter-spacing:-.25pt'> </span>supérieu<span style='letter-spacing:.05pt'>r</span>es<span style='letter-spacing:-.5pt'> </span>à 600<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>,<span style='letter-spacing:-.15pt'> </span>on<span style='letter-spacing:-.1pt'> </span>observe<span style='letter-spacing:-.35pt'> </span>une<span style='letter-spacing:-.15pt'> </span>augmentation<span style='letter-spacing:-.55pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>ins<span style='letter-spacing:-.25pt'> </span>que proport<span style='letter-spacing:-.05pt'>i</span>onne<span style='letter-spacing: -.05pt'>l</span>le<span style='letter-spacing:-.6pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>absorption<span style='letter-spacing:-.45pt'> </span>orale:<span style='letter-spacing:-.25pt'> </span>la cause<span style='letter-spacing:-.25pt'> </span>en<span style='letter-spacing:-.1pt'> </span>est<span style='letter-spacing:-.1pt'> </span>i<span style='letter-spacing:.05pt'>n</span>connue.<span style='letter-spacing:-.45pt'> </span>La<span style='letter-spacing:-.1pt'> </span>clairance<span style='letter-spacing:-.35pt'> </span>totale et la clairance<span style='letter-spacing:-.35pt'> </span>rénale sont<span style='letter-spacing: -.2pt'> </span>respective<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.6pt'> </span>de<span style='letter-spacing:-.1pt'> </span>157-176<span style='letter-spacing:-.35pt'> </span>et<span style='letter-spacing:.05pt'> </span>3<span style='letter-spacing:-.05pt'>-</span>3,5<span style='letter-spacing:-.3pt'> </span>ml<span style='letter-spacing:.05pt'>/</span><span style='letter-spacing:-.1pt'>m</span>in.<span style='letter-spacing:-.2pt'> </span>La<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'>m</span>i-vie<span style='letter-spacing:-.35pt'> </span>d<span style='letter-spacing:.05pt'>’</span>élimination<span style='letter-spacing: -.55pt'> </span>terminale<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:.05pt'>l</span><span style='letter-spacing:-.05pt'>'</span>i<span style='letter-spacing:.05pt'>r</span>bésartan est<span style='letter-spacing:-.1pt'> </span>11-15<span style='letter-spacing: -.25pt'> </span>heures.<span style='letter-spacing:-.3pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>concentrations<span style='letter-spacing: -.65pt'> </span>plas<span style='letter-spacing:-.1pt'>m</span>atiques<span style='letter-spacing:-.5pt'> </span>à <span style='letter-spacing:.05pt'>l</span>'é<span style='letter-spacing:.05pt'>t</span>at d'équilib<span style='letter-spacing: -.05pt'>r</span>e<span style='letter-spacing:-.4pt'> </span>sont<span style='letter-spacing:-.2pt'> </span>atteintes<span style='letter-spacing:-.35pt'> </span>trois<span style='letter-spacing:-.2pt'> </span>jours<span style='letter-spacing:-.2pt'> </span>après<span style='letter-spacing:-.25pt'> </span>le début<span style='letter-spacing:-.25pt'> </span>d'un<span style='letter-spacing: -.2pt'> </span>tr<span style='letter-spacing:-.05pt'>a</span>it<span style='letter-spacing:.05pt'>e</span><span style='letter-spacing:-.1pt'>m</span>ent<span style='letter-spacing:-.3pt'> </span>en<span style='letter-spacing:-.1pt'> </span>une<span style='letter-spacing:-.15pt'> </span>seule<span style='letter-spacing:-.25pt'> </span>prise<span style='letter-spacing:-.1pt'> </span>p<span style='letter-spacing: -.1pt'>a</span>r<span style='letter-spacing:-.15pt'> </span>jour.<span style='letter-spacing:-.2pt'> </span>Une<span style='letter-spacing:-.25pt'> </span>acc<span style='letter-spacing:.1pt'>u</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>u</span>lation<span style='letter-spacing:-.5pt'> </span>li<span style='letter-spacing:-.05pt'>m</span>i<span style='letter-spacing:.05pt'>t</span>ée d'irb<span style='letter-spacing:.05pt'>é</span>sartan<span style='letter-spacing: -.5pt'> </span><span style='letter-spacing:-.05pt'>(</span><span style='font-family:"Courier New"'>&lt;<span style='letter-spacing:-3.95pt'> </span></span>20<span style='letter-spacing:-.05pt'>%</span>)<span style='letter-spacing:-.25pt'> </span>est observée<span style='letter-spacing:-.4pt'> </span>dans<span style='letter-spacing: -.2pt'> </span>le plasma<span style='letter-spacing:-.3pt'> </span>après<span style='letter-spacing:-.25pt'> </span>a<span style='letter-spacing:.1pt'>d</span><span style='letter-spacing:-.1pt'>m</span>inistration<span style='letter-spacing: -.6pt'> </span>rép<span style='letter-spacing:-.05pt'>é</span>tée<span style='letter-spacing:-.2pt'> </span>d<span style='letter-spacing:-.05pt'>'</span>une<span style='letter-spacing:-.25pt'> </span>dose<span style='letter-spacing:-.2pt'> </span>unique<span style='letter-spacing:-.3pt'> </span>par<span style='letter-spacing:-.15pt'> </span>j<span style='letter-spacing:-.05pt'>ou</span>r.<span style='letter-spacing:-.2pt'> </span>Dans<span style='letter-spacing:-.25pt'> </span>une<span style='letter-spacing:-.15pt'> </span>étude,<span style='letter-spacing:-.25pt'> </span>des concentrations<span style='letter-spacing: -.6pt'> </span>pla<span style='letter-spacing:.05pt'>s</span><span style='letter-spacing:-.1pt'>m</span>atiqu<span style='letter-spacing:.05pt'>e</span>s<span style='letter-spacing:-.5pt'> </span>d<span style='letter-spacing:.05pt'>’</span>irbésartan<span style='letter-spacing:-.45pt'> </span>un<span style='letter-spacing:-.1pt'> </span>peu<span style='letter-spacing:-.25pt'> </span>plus<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.05pt'>é</span>levées<span style='letter-spacing:-.25pt'> </span>furent<span style='letter-spacing:-.25pt'> </span>observées<span style='letter-spacing:-.45pt'> </span>ch<span style='letter-spacing:.05pt'>e</span>z<span style='letter-spacing:-.15pt'> </span>des<span style='letter-spacing:-.15pt'> </span>f<span style='letter-spacing:.05pt'>e</span>mm<span style='letter-spacing:.05pt'>e</span>s h<span style='letter-spacing:.1pt'>y</span>pertendues.<span style='letter-spacing: -.6pt'> </span>Cependant,<span style='letter-spacing:-.5pt'> </span>il n’y<span style='letter-spacing:-.15pt'> </span>a pas<span style='letter-spacing:-.15pt'> </span>eu<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing: -.1pt'> </span>différence<span style='letter-spacing:-.35pt'> </span>concernant<span style='letter-spacing:-.5pt'> </span>la de<span style='letter-spacing:-.1pt'>m</span>i-vie<span style='letter-spacing:-.25pt'> </span>et l'acc<span style='letter-spacing:.1pt'>u</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>u</span>lation d<span style='letter-spacing:.05pt'>’</span>irbésartan.<span style='letter-spacing: -.55pt'> </span>Aucun<span style='letter-spacing:-.3pt'> </span>ajustement<span style='letter-spacing:-.55pt'> </span>posologique<span style='letter-spacing: -.55pt'> </span>n<span style='letter-spacing:.05pt'>’</span>est<span style='letter-spacing:-.2pt'> </span>nécessai<span style='letter-spacing:.05pt'>r</span>e<span style='letter-spacing:-.4pt'> </span>chez<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>l</span>a f<span style='letter-spacing:.05pt'>e</span>mme.<span style='letter-spacing:-.35pt'> </span>L<span style='letter-spacing:.05pt'>e</span>s<span style='letter-spacing:-.1pt'> </span>valeurs<span style='letter-spacing:-.3pt'> </span>des<span style='letter-spacing:-.15pt'> </span>AUC<span style='letter-spacing:-.25pt'> </span>et <span style='letter-spacing:.05pt'>C</span><sub><span style='font-size:7.0pt;letter-spacing:-.1pt'>m</span></sub><sub><span style='font-size:7.0pt'>ax<span style='letter-spacing:1.0pt'> </span></span></sub>de<span style='letter-spacing:-.1pt'> </span>l'irb<span style='letter-spacing:.05pt'>é</span>sartan<span style='letter-spacing:-.5pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été un<span style='letter-spacing:-.1pt'> </span>peu<span style='letter-spacing: -.2pt'> </span>p<span style='letter-spacing:-.1pt'>l</span>us<span style='letter-spacing:-.2pt'> </span>élevées<span style='letter-spacing:-.3pt'> </span>ch<span style='letter-spacing:.05pt'>e</span>z<span style='letter-spacing: -.15pt'> </span>l<span style='letter-spacing:.05pt'>e</span>s<span style='letter-spacing:-.05pt'> </span>sujets<span style='letter-spacing:-.25pt'> </span>âgés<span style='letter-spacing:-.2pt'> </span>(<u><span style='font-family:Symbol'>&gt;</span></u><span style='letter-spacing:-.05pt'> </span>65<span style='letter-spacing:-.1pt'> </span>ans)<span style='letter-spacing:-.2pt'> </span>que<span style='letter-spacing:-.2pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> suje</span><span style='letter-spacing:.05pt'>t</span>s jeunes (18-40<span style='letter-spacing:-.3pt'> </span>ans).<span style='letter-spacing:-.2pt'> </span>Cependant,<span style='letter-spacing: -.45pt'> </span>la de<span style='letter-spacing:-.1pt'>m</span>i-<span style='letter-spacing:.1pt'>v</span>ie<span style='letter-spacing:-.3pt'> </span>ter<span style='letter-spacing:-.05pt'>m</span>i<span style='letter-spacing:-.1pt'>n</span>ale<span style='letter-spacing:-.3pt'> </span><span style='letter-spacing:.1pt'>n</span><span style='letter-spacing:.05pt'>’</span>a<span style='letter-spacing:-.1pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>été significativ<span style='letter-spacing: .05pt'>e</span><span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:.1pt'>n</span>t<span style='letter-spacing:-.75pt'> </span><span style='letter-spacing:-.1pt'>m</span>odifiée.<span style='letter-spacing:-.4pt'> </span><span style='letter-spacing:.05pt'>Au</span>cun ajust<span style='letter-spacing:.05pt'>e</span>ment<span style='letter-spacing:-.5pt'> </span>posologique<span style='letter-spacing:-.6pt'> </span>n<span style='letter-spacing:.05pt'>’</span>est<span style='letter-spacing:-.2pt'> </span>néce<span style='letter-spacing:.05pt'>s</span>saire<span style='letter-spacing:-.4pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>la pers<span style='letter-spacing:.1pt'>o</span>nne<span style='letter-spacing: -.4pt'> </span>âgée.<span style='letter-spacing:-.25pt'> </span>La<span style='letter-spacing:-.1pt'> </span>d<span style='letter-spacing:.05pt'>e</span><span style='letter-spacing:-.1pt'>m</span>i-vie<span style='letter-spacing:-.35pt'> </span>pla<span style='letter-spacing:.05pt'>s</span>matique<span style='letter-spacing:-.45pt'> </span><span style='letter-spacing:-.1pt'>m</span>oyenne<span style='letter-spacing: -.4pt'> </span>de l<span style='letter-spacing:-.05pt'>'</span>h<span style='letter-spacing:.1pt'>y</span>droch<span style='letter-spacing:-.05pt'>l</span>or<span style='letter-spacing:-.05pt'>o</span>thiazide<span style='letter-spacing:-.8pt'> </span>varie<span style='letter-spacing:-.2pt'> </span>entre<span style='letter-spacing:-.2pt'> </span>5<span style='letter-spacing:-.05pt'> </span>et 15<span style='letter-spacing:-.15pt'> </span>heures.</p>
<p class=AmmCorpsTexte>Après<span style='letter-spacing:-.25pt'> </span>a<span style='letter-spacing:.1pt'>d</span><span style='letter-spacing:-.1pt'>m</span>in<span style='letter-spacing:.05pt'>i</span>stration<span style='letter-spacing:-.6pt'> </span>orale<span style='letter-spacing:-.2pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>intravein<span style='letter-spacing:-.05pt'>e</span>use<span style='letter-spacing:-.6pt'> </span>d<span style='letter-spacing:.05pt'>’</span>irbésartan<span style='letter-spacing:-.5pt'> </span>marqué<span style='letter-spacing:-.35pt'> </span>au<span style='letter-spacing:-.2pt'> </span><sup><span style='font-size:7.0pt;letter-spacing:-.05pt'>1</span></sup><sup><span style='font-size: 7.0pt;letter-spacing:.05pt'>4</span></sup>C,<span style='letter-spacing:-.1pt'> </span>80<span style='letter-spacing:-.1pt'> </span>à<span style='letter-spacing: -.05pt'> </span>8<span style='letter-spacing:-.05pt'>5</span>%<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la radioactivité pla<span style='letter-spacing:.05pt'>s</span><span style='letter-spacing:-.1pt'>m</span>atique<span style='letter-spacing:-.5pt'> </span><span style='letter-spacing:.05pt'>c</span>irculante<span style='letter-spacing:-.35pt'> </span>peut<span style='letter-spacing:-.2pt'> </span>être<span style='letter-spacing:-.15pt'> </span>attribuée<span style='letter-spacing: -.35pt'> </span>à l'irbé<span style='letter-spacing:.05pt'>s</span><span style='letter-spacing:-.05pt'>a</span>rtan<span style='letter-spacing:-.35pt'> </span>inchangé.<span style='letter-spacing:-.4pt'> </span>L'irbésartan<span style='letter-spacing: -.5pt'> </span>est métabolisé<span style='letter-spacing:-.5pt'> </span>p<span style='letter-spacing:.05pt'>a</span>r<span style='letter-spacing:-.15pt'> </span>le foie par<span style='letter-spacing:-.15pt'> </span>g<span style='letter-spacing: -.05pt'>l</span><span style='letter-spacing:.1pt'>y</span>curonoconjugaison<span style='letter-spacing:-.95pt'> </span><span style='letter-spacing:-.05pt'>e</span>t oxydation.<span style='letter-spacing:-.5pt'> </span>Le <span style='letter-spacing: -.1pt'>m</span>étabolite<span style='letter-spacing:-.25pt'> </span>circulant<span style='letter-spacing:-.35pt'> </span>principal<span style='letter-spacing: -.35pt'> </span>est<span style='letter-spacing:-.1pt'> </span>le glucuronide<span style='letter-spacing:-.55pt'> </span>d<span style='letter-spacing:.05pt'>’</span>irbésartan (approxi<span style='letter-spacing:-.05pt'>m</span>ati<span style='letter-spacing: .1pt'>v</span><span style='letter-spacing:.05pt'>e</span><span style='letter-spacing:-.1pt'>m</span>ent<span style='letter-spacing:-.8pt'> </span>6%).<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>D</span>es<span style='letter-spacing:-.15pt'> </span>études<span style='letter-spacing:-.35pt'> </span><i>in<span style='letter-spacing:-.1pt'> </span>vitro<span style='letter-spacing:-.15pt'> </span></i>ont<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>ontré<span style='letter-spacing: -.3pt'> </span>que<span style='letter-spacing:-.15pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>irbésartan<span style='letter-spacing: -.4pt'> </span>est<span style='letter-spacing:-.1pt'> </span>o<span style='letter-spacing:-.05pt'>x</span><span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.05pt'>d</span>é<span style='letter-spacing:-.2pt'> </span>principale<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.05pt'>e</span>nt<span style='letter-spacing:-.6pt'> </span>par l<span style='letter-spacing:-.05pt'>'</span>isoenz<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:-.4pt'> </span>CYP2C9<span style='letter-spacing:-.4pt'> </span>du<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>c</span><span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.05pt'>t</span>ochr<span style='letter-spacing:-.05pt'>o</span>me<span style='letter-spacing:-.45pt'> </span>P450;<span style='letter-spacing:-.25pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>isoenz<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:-.4pt'> </span>CYP3A4<span style='letter-spacing:-.4pt'> </span>a un<span style='letter-spacing:-.1pt'> </span>ef<span style='letter-spacing: -.05pt'>f</span>et<span style='letter-spacing:-.1pt'> </span>négligeable.<span style='letter-spacing:-.5pt'> </span>L<span style='letter-spacing:-.05pt'>'</span>irbésartan<span style='letter-spacing:-.5pt'> </span>et ses<span style='letter-spacing:-.05pt'> </span>métabolites<span style='letter-spacing:-.45pt'> </span>sont<span style='letter-spacing:-.25pt'> </span>él<span style='letter-spacing:.05pt'>i</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>in</span>és<span style='letter-spacing:-.25pt'> </span>par<span style='letter-spacing:-.15pt'> </span>voie<span style='letter-spacing:-.2pt'> </span>biliaire<span style='letter-spacing:-.3pt'> </span>et réna<span style='letter-spacing:.05pt'>l</span>e.<span style='letter-spacing:-.25pt'> </span>Après<span style='letter-spacing:-.3pt'> </span>a<span style='letter-spacing:.1pt'>d</span><span style='letter-spacing:-.1pt'>m</span>inistration<span style='letter-spacing:-.6pt'> </span>orale<span style='letter-spacing:-.2pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>intraveineuse d’irbésartan<span style='letter-spacing:-.4pt'> </span>m<span style='letter-spacing:.05pt'>a</span>rqué<span style='letter-spacing:-.35pt'> </span>au<span style='letter-spacing:-.15pt'> </span><sup><span style='font-size:7.0pt;letter-spacing:-.05pt'>1</span></sup><sup><span style='font-size: 7.0pt;letter-spacing:.05pt'>4</span></sup>C,<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>a</span>pproxi<span style='letter-spacing:-.1pt'>m</span>ativement<span style='letter-spacing:-.7pt'> </span>20%<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing: -.1pt'> </span>la radioactivité<span style='letter-spacing:-.5pt'> </span>sont<span style='letter-spacing:-.2pt'> </span>retrouv<span style='letter-spacing:-.05pt'>é</span>s<span style='letter-spacing:-.4pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>urines<span style='letter-spacing:-.25pt'> </span>et la radioactivité<span style='letter-spacing:-.5pt'> </span>resta<span style='letter-spacing:.1pt'>n</span>te<span style='letter-spacing:-.25pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>fèces.<span style='letter-spacing:-.25pt'> </span>Une<span style='letter-spacing:-.2pt'> </span>quantité inférieure<span style='letter-spacing:-.45pt'> </span>à 2%<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la dose<span style='letter-spacing:-.2pt'> </span>est<span style='letter-spacing: -.1pt'> </span>excré<span style='letter-spacing:.1pt'>t</span>ée<span style='letter-spacing:-.25pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>urines<span style='letter-spacing:-.2pt'> </span>sous<span style='letter-spacing:-.2pt'> </span>for<span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.1pt'>d</span><span style='letter-spacing:.05pt'>’</span>irbésartan<span style='letter-spacing: -.5pt'> </span>inchangé. L<span style='letter-spacing:-.05pt'>'</span>h<span style='letter-spacing:.1pt'>y</span>droch<span style='letter-spacing:-.05pt'>l</span>o<span style='letter-spacing:-.05pt'>r</span>othiazide<span style='letter-spacing: -.9pt'> </span><span style='letter-spacing:-.05pt'>n</span><span style='letter-spacing:.05pt'>’</span>est<span style='letter-spacing:-.2pt'> </span>pas<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span>étabolisé,<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.1pt'>m</span>ais<span style='letter-spacing:-.15pt'> </span>est<span style='letter-spacing:-.2pt'> </span>éli<span style='letter-spacing:-.05pt'>m</span>iné<span style='letter-spacing:-.15pt'> </span>rapidement<span style='letter-spacing:-.45pt'> </span>par<span style='letter-spacing:-.15pt'> </span>le rein.<span style='letter-spacing:-.2pt'> </span>Au<span style='letter-spacing: -.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>ins<span style='letter-spacing:-.25pt'> </span>61%<span style='letter-spacing:-.2pt'> </span>de la dose<span style='letter-spacing: -.2pt'> </span>orale<span style='letter-spacing:-.2pt'> </span>sont<span style='letter-spacing:-.2pt'> </span>éli<span style='letter-spacing:-.05pt'>m</span>in<span style='letter-spacing:.05pt'>é</span>s<span style='letter-spacing:-.2pt'> </span>sous<span style='letter-spacing:-.2pt'> </span>forme<span style='letter-spacing:-.25pt'> </span>inc<span style='letter-spacing:.05pt'>h</span>angée<span style='letter-spacing:-.45pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>24<span style='letter-spacing:-.1pt'> </span>heures<span style='letter-spacing:-.3pt'> </span>suivant<span style='letter-spacing:-.3pt'> </span>la prise. L'h<span style='letter-spacing: .1pt'>y</span>drochlorothiazide<span style='letter-spacing:-.9pt'> </span>traverse<span style='letter-spacing:-.35pt'> </span>la barr<span style='letter-spacing:.05pt'>i</span>è<span style='letter-spacing:.05pt'>r</span>e<span style='letter-spacing:-.3pt'> </span>placentaire<span style='letter-spacing:-.4pt'> </span>mais<span style='letter-spacing:-.2pt'> </span>pas<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.05pt'>l</span>a barrière<span style='letter-spacing:-.35pt'> </span>h<span style='letter-spacing: .05pt'>é</span>ma<span style='letter-spacing:.05pt'>to</span>-encéphalique,<span style='letter-spacing:-.95pt'> </span>et est excrété<span style='letter-spacing: -.3pt'> </span>dans<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>l</span>e lait<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:-.1pt'>m</span>at<span style='letter-spacing:.05pt'>e</span>rn<span style='letter-spacing:.05pt'>e</span>l.</p>
<p class=AmmCorpsTexte><u>Insuffisance<span style='letter-spacing:-.55pt'> </span><span style='letter-spacing:.05pt'>r</span>énale</u> <i>:<span style='letter-spacing: -.25pt'> </span></i>les<span style='letter-spacing:-.1pt'> </span>pa<span style='letter-spacing:.05pt'>ra</span><span style='letter-spacing:-.1pt'>m</span>èt<span style='letter-spacing:.05pt'>r</span>es<span style='letter-spacing:-.4pt'> </span>pha<span style='letter-spacing:.05pt'>r</span>macocinétiq<span style='letter-spacing: .1pt'>u</span>es<span style='letter-spacing:-.9pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l'i<span style='letter-spacing:-.05pt'>r</span>bésartan<span style='letter-spacing:-.5pt'> </span>ne<span style='letter-spacing:-.1pt'> </span>sont<span style='letter-spacing:-.2pt'> </span>p<span style='letter-spacing:-.05pt'>a</span>s<span style='letter-spacing:-.15pt'> </span>significativement <span style='letter-spacing: -.1pt'>m</span>odifi<span style='letter-spacing:.05pt'>é</span>s<span style='letter-spacing:-.4pt'> </span>chez<span style='letter-spacing:-.15pt'> </span>les<span style='letter-spacing:-.1pt'> </span>insuffisants<span style='letter-spacing: -.5pt'> </span>rénaux<span style='letter-spacing:-.3pt'> </span>ou<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>c</span><span style='letter-spacing:.05pt'>h</span>ez<span style='letter-spacing:-.05pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patie<span style='letter-spacing:.1pt'>n</span>ts<span style='letter-spacing:-.3pt'> </span>h<span style='letter-spacing:.05pt'>é</span><span style='letter-spacing:-.1pt'>m</span>odial<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.05pt'>s</span>és.<span style='letter-spacing:-.65pt'> </span>L'irb<span style='letter-spacing:.05pt'>é</span>sart<span style='letter-spacing:.05pt'>a</span>n<span style='letter-spacing:-.5pt'> </span>n'est<span style='letter-spacing:-.2pt'> </span>pas<span style='letter-spacing:-.15pt'> é</span><span style='letter-spacing:.1pt'>p</span>uré par h<span style='letter-spacing:.05pt'>é</span><span style='letter-spacing: -.1pt'>m</span>odial<span style='letter-spacing:.1pt'>y</span>se.<span style='letter-spacing:-.6pt'> </span>Chez<span style='letter-spacing:-.25pt'> </span>les<span style='letter-spacing:-.1pt'> </span>patients<span style='letter-spacing:-.35pt'> </span>avec<span style='letter-spacing:-.1pt'> </span>une<span style='letter-spacing:-.15pt'> </span>clairance<span style='letter-spacing: -.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la créatin<span style='letter-spacing:.1pt'>i</span><span style='letter-spacing:.05pt'>n</span>e<span style='letter-spacing:-.4pt'> </span>&lt;<span style='letter-spacing:-.05pt'> </span>20<span style='letter-spacing:-.1pt'> m</span>l<span style='letter-spacing:.05pt'>/</span>min,<span style='letter-spacing:-.3pt'> </span>une<span style='letter-spacing:-.15pt'> </span>augmentation de<span style='letter-spacing:-.05pt'> </span>la<span style='letter-spacing: .05pt'> </span>de<span style='letter-spacing:-.1pt'>m</span>i-vie<span style='letter-spacing:-.3pt'> </span>d’éli<span style='letter-spacing:-.05pt'>m</span>ination<span style='letter-spacing:-.55pt'> </span>de<span style='letter-spacing:-.05pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>hydro<span style='letter-spacing:-.05pt'>c</span>hlo<span style='letter-spacing:-.05pt'>r</span>othiazide<span style='letter-spacing: -.95pt'> </span>jusq<span style='letter-spacing:-.05pt'>u</span><span style='letter-spacing:.05pt'>’</span>à<span style='letter-spacing:-.25pt'> </span>21<span style='letter-spacing:-.15pt'> </span>heures<span style='letter-spacing:-.3pt'> </span>a été ra<span style='letter-spacing:.1pt'>p</span>portée.</p>
<p class=AmmCorpsTexte><u>Insuffisance<span style='letter-spacing:-.45pt'> </span>hépatique</u> <i>:<span style='letter-spacing:-.45pt'> </span></i>les<span style='letter-spacing: -.1pt'> </span>para<span style='letter-spacing:-.1pt'>m</span>ètres<span style='letter-spacing:-.45pt'> </span>phar<span style='letter-spacing:-.1pt'>m</span>acocinétiques<span style='letter-spacing:-.85pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>irbésartan<span style='letter-spacing: -.45pt'> </span>ne<span style='letter-spacing:-.1pt'> </span>sont<span style='letter-spacing:-.2pt'> </span>pas<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span>odifiés<span style='letter-spacing:-.4pt'> </span>de façon<span style='letter-spacing:-.25pt'> </span>significative<span style='letter-spacing:-.55pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.05pt'> </span>patients<span style='letter-spacing:-.35pt'> </span>présentant<span style='letter-spacing:-.45pt'> </span>une<span style='letter-spacing:-.15pt'> </span>cirrhose<span style='letter-spacing:-.25pt'> </span>du<span style='letter-spacing:-.1pt'> </span>foie<span style='letter-spacing: -.2pt'> </span>légère<span style='letter-spacing:-.25pt'> </span>à<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span><span style='letter-spacing:.1pt'>d</span>érée.<span style='letter-spacing:-.35pt'> </span>Aucune<span style='letter-spacing:-.25pt'> </span>étude n<span style='letter-spacing:.05pt'>’</span>a<span style='letter-spacing:-.1pt'> </span>été <span style='letter-spacing:-.1pt'>m</span>en<span style='letter-spacing:.05pt'>é</span>e<span style='letter-spacing:-.15pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>pat<span style='letter-spacing:.05pt'>i</span>ents<span style='letter-spacing:-.35pt'> </span>a<span style='letter-spacing:.1pt'>y</span>a<span style='letter-spacing:.05pt'>n</span>t<span style='letter-spacing:-.2pt'> </span>une<span style='letter-spacing:-.15pt'> </span>insuffisance<span style='letter-spacing:-.5pt'> </span>hépatique<span style='letter-spacing:-.45pt'> </span>sévère.</p>
<p class="AmmAnnexeTitre2"><a name="RcpSecuritePreclinique">5.3. Données de sécurité préclinique</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278935"><u>Irbésartan/H<span style='letter-spacing:.1pt'>y</span>drochlorothiazide</u> :<b><span style='letter-spacing:-1.4pt'> </span></b>la toxicité<span style='letter-spacing: -.3pt'> </span>potentielle<span style='letter-spacing:-.4pt'> </span>après<span style='letter-spacing:-.25pt'> </span>a<span style='letter-spacing:.1pt'>d</span><span style='letter-spacing:-.1pt'>m</span>ini<span style='letter-spacing:.05pt'>s</span>tration<span style='letter-spacing:-.55pt'> </span>orale<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l'<span style='letter-spacing:.05pt'>a</span>ssociat<span style='letter-spacing:.05pt'>i</span>on irbésartan/hydrochloro<span style='letter-spacing:-.05pt'>t</span>hiazide<span style='letter-spacing:-1.35pt'> </span>a été évaluée<span style='letter-spacing:-.35pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>les rats<span style='letter-spacing:-.15pt'> </span>et les<span style='letter-spacing:-.05pt'> </span>macaques<span style='letter-spacing:-.45pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>études<span style='letter-spacing:-.3pt'> </span>d<span style='letter-spacing:-.05pt'>'</span>u<span style='letter-spacing: .1pt'>n</span>e<span style='letter-spacing:-.2pt'> </span>durée max<span style='letter-spacing:.05pt'>i</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.1pt'>u</span>m<span style='letter-spacing:-.5pt'> </span>de 6<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>is.<span style='letter-spacing:-.25pt'> </span>Il<span style='letter-spacing:-.05pt'> </span>n<span style='letter-spacing:.05pt'>’</span>a<span style='letter-spacing:-.15pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>été obse<span style='letter-spacing:.05pt'>r</span>vé<span style='letter-spacing: -.35pt'> </span>de<span style='letter-spacing:-.15pt'> </span>données<span style='letter-spacing:-.35pt'> </span>toxicologiques<span style='letter-spacing: -.65pt'> </span>a<span style='letter-spacing:.1pt'>y</span>ant<span style='letter-spacing:-.25pt'> </span>une<span style='letter-spacing:-.15pt'> </span>i<span style='letter-spacing:-.1pt'>m</span>pli<span style='letter-spacing:.05pt'>c</span>ation<span style='letter-spacing:-.5pt'> </span>en thérapeutique<span style='letter-spacing: -.55pt'> </span>hu<span style='letter-spacing:-.1pt'>m</span>aine.</a></p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span>odifica<span style='letter-spacing:.1pt'>t</span>ions<span style='letter-spacing:-.6pt'> </span>suivant<span style='letter-spacing:-.05pt'>e</span>s,<span style='letter-spacing:-.45pt'> </span>observées<span style='letter-spacing: -.45pt'> </span><span style='letter-spacing:.05pt'>ch</span>ez<span style='letter-spacing:-.05pt'> </span>les<span style='letter-spacing:-.1pt'> </span>rats<span style='letter-spacing:-.1pt'> </span>et<span style='letter-spacing:.1pt'> </span>les<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>a</span>caques<span style='letter-spacing:-.35pt'> </span>recevant<span style='letter-spacing:-.35pt'> </span>l'as<span style='letter-spacing:.05pt'>s</span>ociation irbésartan/hydrochloro<span style='letter-spacing:-.05pt'>t</span>hiazide<span style='letter-spacing:-1.3pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le rapport<span style='letter-spacing:-.3pt'> </span>10<span style='letter-spacing:-.05pt'>/</span>10<span style='letter-spacing:-.3pt'> </span>et 90/90<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing: .05pt'>g</span>/kg/jour,<span style='letter-spacing:-.55pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>également<span style='letter-spacing: -.4pt'> </span>été observées lorsque<span style='letter-spacing:-.3pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>un<span style='letter-spacing:-.1pt'> </span>des<span style='letter-spacing:-.15pt'> </span>deux<span style='letter-spacing:-.2pt'> </span>médicaments<span style='letter-spacing:-.55pt'> </span>était<span style='letter-spacing:.1pt'> </span>a<span style='letter-spacing:.1pt'>d</span><span style='letter-spacing:-.1pt'>m</span>inistré<span style='letter-spacing:-.45pt'> </span>seul<span style='letter-spacing:-.2pt'> </span>et/ou<span style='letter-spacing:-.25pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>é<span style='letter-spacing:-.05pt'>t</span>é secondaires<span style='letter-spacing: -.5pt'> </span>à la baisse<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la pression<span style='letter-spacing: -.35pt'> </span>arté<span style='letter-spacing:.05pt'>r</span>ielle<span style='letter-spacing:-.2pt'> </span>(aucune<span style='letter-spacing:-.35pt'> </span>interaction<span style='letter-spacing:-.55pt'> </span>toxique<span style='letter-spacing:-.35pt'> </span>signifi<span style='letter-spacing:-.05pt'>c</span>ative<span style='letter-spacing:-.5pt'> </span>n<span style='letter-spacing:.05pt'>’</span>a<span style='letter-spacing:-.1pt'> </span>été observée) :</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span><span style='letter-spacing:-.1pt'>m</span>odifications<span style='letter-spacing:-.6pt'> </span>rénales,<span style='letter-spacing:-.35pt'> </span>caractérisées<span style='letter-spacing:-.5pt'> </span>par<span style='letter-spacing:-.05pt'> </span>une<span style='letter-spacing:-.15pt'> </span>légère<span style='letter-spacing:-.25pt'> </span>augmentation<span style='letter-spacing: -.55pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>urée<span style='letter-spacing:-.2pt'> </span>et de<span style='letter-spacing:-.1pt'> </span>la créatinine sériques,<span style='letter-spacing:-.4pt'> </span>et une<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.05pt'>h</span><span style='letter-spacing: .1pt'>y</span>perplasie/hypertroph<span style='letter-spacing:-.05pt'>i</span>e<span style='letter-spacing:-1.05pt'> </span>de<span style='letter-spacing:-.15pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>appareil<span style='letter-spacing:-.3pt'> </span>juxtaglo<span style='letter-spacing:-.05pt'>m</span>érulaire<span style='letter-spacing:-.7pt'> </span>qui<span style='letter-spacing:-.15pt'> </span>sont<span style='letter-spacing:-.25pt'> </span>la conséquence<span style='letter-spacing: -.55pt'> </span>directe<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l'a<span style='letter-spacing:.05pt'>c</span>tion<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l'irbésartan<span style='letter-spacing:-.5pt'> </span>sur<span style='letter-spacing:-.15pt'> </span>le syst<span style='letter-spacing:.05pt'>è</span>me<span style='letter-spacing: -.3pt'> </span>rénine<span style='letter-spacing:.05pt'>-</span>angiotensine ;</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>une<span style='letter-spacing:-.15pt'> </span>légère<span style='letter-spacing:-.2pt'> </span>diminution<span style='letter-spacing: -.45pt'> </span>des<span style='letter-spacing:-.2pt'> </span>para<span style='letter-spacing:-.1pt'>m</span>ètres<span style='letter-spacing:-.45pt'> </span>ér<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.05pt'>t</span>hro<span style='letter-spacing:-.05pt'>c</span><span style='letter-spacing:.1pt'>y</span>taires<span style='letter-spacing:-.5pt'> </span>(ér<span style='letter-spacing:.1pt'>y</span>th<span style='letter-spacing:-.05pt'>r</span><span style='letter-spacing:.05pt'>o</span><span style='letter-spacing:-.05pt'>c</span><span style='letter-spacing:.1pt'>y</span>tes,<span style='letter-spacing:-.55pt'> </span>hé<span style='letter-spacing:-.1pt'>m</span>oglobine,<span style='letter-spacing:-.6pt'> </span>hématocrite) ;</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>une<span style='letter-spacing:-.15pt'> </span>décoloration<span style='letter-spacing:-.5pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>est<span style='letter-spacing:.1pt'>o</span>mac,<span style='letter-spacing:-.4pt'> </span>des<span style='letter-spacing:-.15pt'> </span>ulcères<span style='letter-spacing:-.3pt'> </span>et <span style='letter-spacing:-.05pt'>d</span>es<span style='letter-spacing:-.15pt'> </span>nécr<span style='letter-spacing:.1pt'>o</span>ses<span style='letter-spacing:-.4pt'> </span>foca<span style='letter-spacing:.05pt'>l</span>es<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:-.1pt'>m</span>uqueuse<span style='letter-spacing:-.45pt'> </span>gastrique<span style='letter-spacing: -.4pt'> </span>ont été observés<span style='letter-spacing:-.3pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>quelques<span style='letter-spacing:-.4pt'> </span>rats<span style='letter-spacing:-.15pt'> </span>aux<span style='letter-spacing:-.15pt'> </span>doses<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>90<span style='letter-spacing: -.1pt'> m</span><span style='letter-spacing:.05pt'>g</span>/kg/jour<span style='letter-spacing:-.55pt'> </span>d<span style='letter-spacing:.05pt'>’</span>irbésartan,<span style='letter-spacing:-.55pt'> </span>de<span style='letter-spacing:-.1pt'> </span>90<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/kg/jour d’h<span style='letter-spacing: .1pt'>y</span>drochlorothiazide<span style='letter-spacing:-.95pt'> </span>et de<span style='letter-spacing:-.1pt'> </span>10<span style='letter-spacing: -.1pt'> m</span><span style='letter-spacing:-.05pt'>g</span>/10<span style='letter-spacing:-.3pt'> </span>mg/kg/jour<span style='letter-spacing: -.5pt'> </span>de<span style='letter-spacing:-.1pt'> l'association irbésartan/hydrochloro</span><span style='letter-spacing:-.05pt'>t</span>hiazide<span style='letter-spacing:.05pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>é<span style='letter-spacing:.05pt'>t</span>ude<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.1pt'> </span>toxici<span style='letter-spacing:-.05pt'>t</span>é<span style='letter-spacing:-.3pt'> </span>à 6<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>is.<span style='letter-spacing:-.25pt'> </span>Ces<span style='letter-spacing:-.15pt'> </span>lésions<span style='letter-spacing:-.3pt'> </span>n<span style='letter-spacing:.05pt'>’</span>ont<span style='letter-spacing: -.25pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>été observées<span style='letter-spacing:-.45pt'> </span>ch<span style='letter-spacing:.05pt'>e</span>z<span style='letter-spacing:-.15pt'> </span>le<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>a</span>caque ;</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>di<span style='letter-spacing:-.1pt'>m</span>inution<span style='letter-spacing:-.45pt'> </span><span style='letter-spacing:-.05pt'>d</span>e<span style='letter-spacing:-.05pt'> </span>la kalié<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.05pt'>i</span>e<span style='letter-spacing:-.3pt'> </span>due<span style='letter-spacing:-.15pt'> </span>à l<span style='letter-spacing:-.05pt'>'</span>h<span style='letter-spacing:.1pt'>y</span>d<span style='letter-spacing:-.05pt'>ro</span>chlorothiazide,<span style='letter-spacing:-.8pt'> </span>évitée<span style='letter-spacing:-.2pt'> </span>en<span style='letter-spacing:-.1pt'> </span>partie<span style='letter-spacing:-.2pt'> </span>quand l<span style='letter-spacing:-.05pt'>'</span>h<span style='letter-spacing:.1pt'>y</span>droch<span style='letter-spacing:-.05pt'>l</span>orothiazide<span style='letter-spacing: -.85pt'> </span>était<span style='letter-spacing:.05pt'> </span>donné<span style='letter-spacing:-.25pt'> </span>en<span style='letter-spacing:-.1pt'> </span>association<span style='letter-spacing:-.5pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>irbésartan.</p>
<p class=AmmCorpsTexte style='margin-top:6.0pt'>La<span style='letter-spacing: -.1pt'> </span>plupart<span style='letter-spacing:-.3pt'> </span>d<span style='letter-spacing:-.05pt'>e</span>s<span style='letter-spacing:-.15pt'> </span>effets<span style='letter-spacing:-.15pt'> </span>mentionnés<span style='letter-spacing: -.5pt'> </span>ci-dessus<span style='letter-spacing:-.4pt'> </span>se<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>b</span>lent<span style='letter-spacing:-.45pt'> </span>dus<span style='letter-spacing:-.15pt'> </span>à l<span style='letter-spacing:-.05pt'>'</span>activité<span style='letter-spacing: .05pt'> </span>pharmacologique<span style='letter-spacing:-.7pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>irbésartan<span style='letter-spacing:-.45pt'> </span>(le blocage<span style='letter-spacing: -.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>angiotensine-<span style='letter-spacing: -.05pt'>I</span>I<span style='letter-spacing:-.65pt'> </span>induit<span style='letter-spacing:-.3pt'> </span>la sti<span style='letter-spacing:-.1pt'>m</span>ulation<span style='letter-spacing:-.3pt'> </span>des<span style='letter-spacing:-.15pt'> </span>cellules<span style='letter-spacing:-.35pt'> </span>produisant<span style='letter-spacing: -.45pt'> </span>la rénine)<span style='letter-spacing:-.3pt'> </span>et se<span style='letter-spacing:-.1pt'> </span>produisent aussi<span style='letter-spacing: -.2pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>inhibiteurs<span style='letter-spacing: -.5pt'> </span><span style='letter-spacing:-.05pt'>d</span>e<span style='letter-spacing:-.05pt'> </span>l'enz<span style='letter-spacing:.1pt'>y</span><span style='letter-spacing:-.1pt'>m</span>e<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>conversion<span style='letter-spacing: -.5pt'> </span><span style='letter-spacing:-.05pt'>d</span>e<span style='letter-spacing:-.05pt'> </span>l'angiotensine.<span style='letter-spacing: -.6pt'> </span>Ces<span style='letter-spacing:-.15pt'> </span>constatations<span style='letter-spacing:-.5pt'> </span>n’ont<span style='letter-spacing:-.3pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>de rapport<span style='letter-spacing: -.3pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>utilisation<span style='letter-spacing: -.4pt'> </span>aux<span style='letter-spacing:-.15pt'> </span>doses<span style='letter-spacing:-.25pt'> </span>thérapeutiques<span style='letter-spacing: -.6pt'> </span>de<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>l'</span>association<span style='letter-spacing: -.5pt'> </span>irbésartan/h<span style='letter-spacing:.1pt'>y</span>d<span style='letter-spacing:-.05pt'>r</span>ochlorothiaz<span style='letter-spacing: -.05pt'>i</span>de<span style='letter-spacing:-1.35pt'> </span>chez l'h<span style='letter-spacing:.1pt'>o</span>mme.</p>
<p class=AmmCorpsTexte>Aucun<span style='letter-spacing:-.3pt'> </span>effet<span style='letter-spacing:-.2pt'> </span>tératogène<span style='letter-spacing:-.45pt'> </span>n<span style='letter-spacing:.05pt'>’</span>a<span style='letter-spacing:-.15pt'> </span>été observé<span style='letter-spacing: -.35pt'> </span><span style='letter-spacing:.05pt'>ch</span>ez<span style='letter-spacing:-.05pt'> </span>les<span style='letter-spacing:-.1pt'> </span>rat<span style='letter-spacing:.05pt'>e</span>s<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>r</span>ecevant<span style='letter-spacing:-.35pt'> </span>une<span style='letter-spacing:-.1pt'> </span>association d<span style='letter-spacing:.05pt'>’</span>i<span style='letter-spacing:-.05pt'>r</span>bésartan/hydrochlo<span style='letter-spacing:-.05pt'>r</span>oth<span style='letter-spacing:-.05pt'>i</span>azide<span style='letter-spacing:-1.45pt'> </span>à des<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.1pt'>d</span><span style='letter-spacing: .05pt'>o</span>ses<span style='letter-spacing:-.25pt'> </span>toxiques<span style='letter-spacing:-.35pt'> </span>pour<span style='letter-spacing:-.2pt'> </span>la <span style='letter-spacing:-.1pt'>m</span>ère.<span style='letter-spacing: -.1pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>effets<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>association d<span style='letter-spacing: .05pt'>’</span>i<span style='letter-spacing:-.05pt'>r</span>bésartan/hydrochlo<span style='letter-spacing:-.05pt'>r</span>oth<span style='letter-spacing:-.05pt'>i</span>azide<span style='letter-spacing:-1.4pt'> </span>sur<span style='letter-spacing:-.15pt'> </span>la fertilité<span style='letter-spacing:.05pt'> </span>n’ont<span style='letter-spacing:-.3pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>été évalués<span style='letter-spacing:-.35pt'> </span>dans<span style='letter-spacing: -.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>études<span style='letter-spacing:-.3pt'> </span>sur<span style='letter-spacing:-.15pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>an<span style='letter-spacing:.05pt'>im</span>al<span style='letter-spacing:-.2pt'> </span>car aucun<span style='letter-spacing:-.25pt'> </span>effet<span style='letter-spacing:-.2pt'> </span>indésirable<span style='letter-spacing:-.5pt'> </span>sur<span style='letter-spacing:-.15pt'> </span>la fertilité<span style='letter-spacing:.05pt'> </span>n’a<span style='letter-spacing: -.15pt'> </span>été<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:-.05pt'>i</span>s<span style='letter-spacing:-.15pt'> </span>en<span style='letter-spacing:-.1pt'> </span>é<span style='letter-spacing:.1pt'>v</span>idence<span style='letter-spacing:-.4pt'> </span>chez<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>l</span>'an<span style='letter-spacing:.05pt'>i</span><span style='letter-spacing:-.1pt'>m</span>al<span style='letter-spacing:-.25pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>chez<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>l</span><span style='letter-spacing:-.05pt'>'</span>homme,<span style='letter-spacing:-.3pt'> </span>que<span style='letter-spacing:-.15pt'> </span>ce soit<span style='letter-spacing:-.15pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>ir<span style='letter-spacing:.1pt'>b</span>ésartan<span style='letter-spacing:-.45pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span><span style='letter-spacing:.1pt'>h</span>ydrochlo<span style='letter-spacing:-.05pt'>r</span>oth<span style='letter-spacing:-.05pt'>i</span>azide,<span style='letter-spacing:-.9pt'> </span>a<span style='letter-spacing:.1pt'>d</span><span style='letter-spacing:-.1pt'>mi</span>n<span style='letter-spacing:.05pt'>i</span>strés<span style='letter-spacing:-.5pt'> </span>seuls.<span style='letter-spacing:-.25pt'> </span>Cependant,<span style='letter-spacing:-.5pt'> </span>un<span style='letter-spacing:-.15pt'> </span>autre<span style='letter-spacing:-.2pt'> </span>antagoniste<span style='letter-spacing:-.45pt'> </span>de l<span style='letter-spacing:-.05pt'>'</span>angiotensine-II<span style='letter-spacing:-.65pt'> </span>a affec<span style='letter-spacing:.1pt'>t</span>é<span style='letter-spacing:-.25pt'> </span>les<span style='letter-spacing:-.1pt'> </span>paramètres<span style='letter-spacing:-.5pt'> </span>de<span style='letter-spacing:-.1pt'> </span>fe<span style='letter-spacing:.05pt'>r</span>tilité<span style='letter-spacing:-.1pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>des<span style='letter-spacing:-.15pt'> </span>études<span style='letter-spacing:-.3pt'> </span>chez<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>l</span><span style='letter-spacing:-.05pt'>'</span>an<span style='letter-spacing:.05pt'>i</span><span style='letter-spacing:-.1pt'>m</span>al,<span style='letter-spacing:-.25pt'> </span>lorsqu<span style='letter-spacing:.05pt'>’</span>il<span style='letter-spacing:-.3pt'> </span>était a<span style='letter-spacing:.1pt'>d</span><span style='letter-spacing:-.1pt'>m</span>inistré<span style='letter-spacing:-.45pt'> </span>seul.<span style='letter-spacing:-.2pt'> </span>Ces<span style='letter-spacing:-.15pt'> </span>résultats<span style='letter-spacing: -.35pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>également<span style='letter-spacing:-.45pt'> </span>été observés<span style='letter-spacing: -.4pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:.05pt'>f</span>aibles<span style='letter-spacing:-.25pt'> </span>doses<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>cet antagoniste<span style='letter-spacing:-.5pt'> </span>de l'angiotensine-II<span style='letter-spacing:-.7pt'> </span>lorsqu<span style='letter-spacing:.05pt'>’</span>il<span style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>é</span>tait a<span style='letter-spacing:.1pt'>d</span><span style='letter-spacing:-.1pt'>m</span>inistré<span style='letter-spacing:-.45pt'> </span>en<span style='letter-spacing:-.1pt'> </span>associat<span style='letter-spacing:.1pt'>i</span>on<span style='letter-spacing:-.5pt'> </span>avec<span style='letter-spacing:-.2pt'> </span>l'h<span style='letter-spacing:.1pt'>y</span>drochlorothia<span style='letter-spacing:-.05pt'>z</span>ide.</p>
<p class=AmmCorpsTexte>Il<span style='letter-spacing:-.05pt'> </span>n<span style='letter-spacing:.05pt'>’</span>a<span style='letter-spacing:-.15pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>été mis<span style='letter-spacing:-.15pt'> </span>en<span style='letter-spacing:-.1pt'> </span>évidence<span style='letter-spacing:-.4pt'> </span>de <span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>u</span>tag<span style='letter-spacing:.05pt'>é</span>nicité<span style='letter-spacing:-.3pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>c</span>lastogénicité<span style='letter-spacing:-.45pt'> </span>avec<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>l</span><span style='letter-spacing:-.05pt'>'</span>a<span style='letter-spacing:.05pt'>s</span>soci<span style='letter-spacing:.05pt'>a</span>tion i<span style='letter-spacing:-.05pt'>r</span>bésartan/hydrochlo<span style='letter-spacing:-.05pt'>r</span>oth<span style='letter-spacing:-.05pt'>i</span>azide.<span style='letter-spacing:-1.45pt'> </span>Le<span style='letter-spacing:-.1pt'> </span>potentiel<span style='letter-spacing:-.35pt'> </span>carc<span style='letter-spacing:-.05pt'>i</span>nogène<span style='letter-spacing:-.55pt'> </span>n<span style='letter-spacing:.05pt'>’</span>a<span style='letter-spacing:-.15pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>été étudié<span style='letter-spacing:-.25pt'> </span>chez<span style='letter-spacing: -.2pt'> </span>l'an<span style='letter-spacing:.05pt'>i</span><span style='letter-spacing:-.1pt'>m</span>al<span style='letter-spacing:-.25pt'> </span>avec l'<span style='letter-spacing:.05pt'>a</span>ssociation<span style='letter-spacing: -.45pt'> </span>irbésartan/h<span style='letter-spacing:.1pt'>y</span>drochlorothia<span style='letter-spacing:-.05pt'>z</span>ide.</p>
<p class=AmmCorpsTexte><u>Irbésarta<span style='letter-spacing:.05pt'>n</span></u><span style='letter-spacing:.05pt'> </span>:<span style='letter-spacing:-.5pt'> </span>a<span style='letter-spacing:.1pt'>u</span>cune<span style='letter-spacing:-.3pt'> </span>toxicité<span style='letter-spacing:-.3pt'> </span>anormale<span style='letter-spacing:-.35pt'> </span>s<span style='letter-spacing:.1pt'>y</span>sté<span style='letter-spacing: -.1pt'>m</span>ique<span style='letter-spacing:-.5pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>cib<span style='letter-spacing:-.1pt'>l</span>ée<span style='letter-spacing:-.15pt'> </span>sur<span style='letter-spacing:-.15pt'> </span>un<span style='letter-spacing:-.1pt'> </span>organe<span style='letter-spacing:-.3pt'> </span>n<span style='letter-spacing:.05pt'>’</span>a<span style='letter-spacing:-.1pt'> </span>été<span style='letter-spacing:-.05pt'> </span>mise<span style='letter-spacing:-.2pt'> </span>en<span style='letter-spacing:-.1pt'> </span>évid<span style='letter-spacing:.05pt'>en</span>ce<span style='letter-spacing:-.3pt'> </span>aux posologies<span style='letter-spacing: -.45pt'> </span>cl<span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.05pt'>n</span>ique<span style='letter-spacing:-.05pt'>m</span>ent<span style='letter-spacing:-.4pt'> </span>a<span style='letter-spacing:.1pt'>p</span>propriées.<span style='letter-spacing:-.55pt'> </span>Dans<span style='letter-spacing:-.25pt'> </span>les<span style='letter-spacing:-.1pt'> </span>é<span style='letter-spacing:.05pt'>t</span>udes<span style='letter-spacing:-.2pt'> </span>non<span style='letter-spacing:-.15pt'> </span>clin<span style='letter-spacing:-.05pt'>i</span>ques<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.1pt'> </span>sécurité,<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>fortes<span style='letter-spacing:-.25pt'> </span>doses d<span style='letter-spacing:.05pt'>’</span>irbésartan<span style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.05pt'>(</span>&#8805;<span style='letter-spacing:-.05pt'> </span>250<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/kg/jour<span style='letter-spacing:-.5pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>le rat<span style='letter-spacing:-.1pt'> </span>et &#8805; 100<span style='letter-spacing:-.15pt'> </span>mg<span style='letter-spacing:-.15pt'> </span>/kg/<span style='letter-spacing:-.05pt'>j</span>our<span style='letter-spacing:-.35pt'> </span>ch<span style='letter-spacing:-.05pt'>e</span>z<span style='letter-spacing:-.15pt'> </span>le<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>a</span>caque)<span style='letter-spacing:-.35pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>causé<span style='letter-spacing:-.2pt'> </span>des réductions<span style='letter-spacing: -.45pt'> </span>sur<span style='letter-spacing:-.15pt'> </span>la lignée<span style='letter-spacing:-.25pt'> </span>rouge<span style='letter-spacing:-.25pt'> </span>sanguine<span style='letter-spacing:-.4pt'> </span><span style='letter-spacing:-.05pt'>(</span>ér<span style='letter-spacing:.1pt'>y</span>th<span style='letter-spacing:-.05pt'>r</span><span style='letter-spacing:.05pt'>o</span><span style='letter-spacing:-.05pt'>c</span><span style='letter-spacing:.1pt'>y</span>tes,<span style='letter-spacing:-.5pt'> </span>hé<span style='letter-spacing:-.1pt'>m</span>oglobine,<span style='letter-spacing:-.6pt'> </span>hématocrite).<span style='letter-spacing: -.5pt'> </span>A<span style='letter-spacing:-.1pt'> </span>très<span style='letter-spacing:-.15pt'> </span>fortes<span style='letter-spacing:-.2pt'> </span>doses (&#8805; 500<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/kg/jour),<span style='letter-spacing:-.5pt'> </span>des<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>odifications<span style='letter-spacing: -.55pt'> </span>dégénératives<span style='letter-spacing:-.6pt'> </span>du<span style='letter-spacing:-.1pt'> </span>rein<span style='letter-spacing:-.15pt'> </span>(telles<span style='letter-spacing:-.25pt'> </span>que<span style='letter-spacing:-.15pt'> </span>néphrite<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.05pt'>n</span>terstitielle, distension<span style='letter-spacing:-.45pt'> </span>tubulaire,<span style='letter-spacing: -.4pt'> </span>présence<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>basophiles<span style='letter-spacing: -.45pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>les<span style='letter-spacing:-.1pt'> </span>tubules,<span style='letter-spacing:-.35pt'> </span>augmentation<span style='letter-spacing:-.55pt'> </span>des<span style='letter-spacing:-.15pt'> </span>concentrations pla<span style='letter-spacing: .05pt'>s</span><span style='letter-spacing:-.1pt'>m</span>atiques<span style='letter-spacing:-.4pt'> </span>d’urée<span style='letter-spacing:-.3pt'> </span>et de<span style='letter-spacing:-.1pt'> </span>créatinine)<span style='letter-spacing: -.45pt'> </span>furent<span style='letter-spacing:-.25pt'> </span>induites<span style='letter-spacing:-.35pt'> </span>par<span style='letter-spacing:-.15pt'> </span>l'irb<span style='letter-spacing:.05pt'>é</span>sartan<span style='letter-spacing:-.4pt'> </span>chez<span style='letter-spacing:-.2pt'> </span>le rat<span style='letter-spacing:-.1pt'> </span>et<span style='letter-spacing:.1pt'> </span>le<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:-.1pt'>m</span>a<span style='letter-spacing:.05pt'>c</span>aque.<span style='letter-spacing:-.25pt'> </span>Ces effets<span style='letter-spacing: -.25pt'> </span>furent<span style='letter-spacing:-.25pt'> </span>considérés<span style='letter-spacing:-.45pt'> </span>comme<span style='letter-spacing:-.2pt'> </span>secondaires<span style='letter-spacing:-.5pt'> </span>à une<span style='letter-spacing:-.15pt'> </span>d<span style='letter-spacing:-.05pt'>i</span>minution<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing: -.05pt'>l</span>a perfusion<span style='letter-spacing:-.4pt'> </span>rénale<span style='letter-spacing:-.25pt'> </span>due<span style='letter-spacing:-.15pt'> </span>aux<span style='letter-spacing:-.2pt'> </span>effets h<span style='letter-spacing:.1pt'>y</span>potenseurs<span style='letter-spacing:-.65pt'> </span>du<span style='letter-spacing:-.1pt'> m</span>édicament.<span style='letter-spacing:-.45pt'> </span>De<span style='letter-spacing:-.15pt'> </span>plus,<span style='letter-spacing:-.2pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>irbésartan<span style='letter-spacing:-.4pt'> </span>a <span style='letter-spacing:.05pt'>i</span>nduit<span style='letter-spacing:-.3pt'> </span>une<span style='letter-spacing:-.15pt'> </span>hyperplasie/h<span style='letter-spacing:.1pt'>y</span>p<span style='letter-spacing:-.05pt'>e</span>rtrophie<span style='letter-spacing:-1.1pt'> </span>des<span style='letter-spacing:-.15pt'> </span>cellules juxtaglo<span style='letter-spacing:-.05pt'>m</span>ér<span style='letter-spacing: .1pt'>u</span>laires<span style='letter-spacing:-.75pt'> </span>(ch<span style='letter-spacing:.05pt'>e</span>z<span style='letter-spacing:-.2pt'> </span>le<span style='letter-spacing:.05pt'> </span>rat<span style='letter-spacing:-.1pt'> </span>à des<span style='letter-spacing:-.15pt'> </span>doses<span style='letter-spacing: -.25pt'> </span>&#8805; 90 <span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/kg/jour<span style='letter-spacing:-.5pt'> </span>et chez<span style='letter-spacing:-.2pt'> </span>le<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:-.1pt'>m</span>a<span style='letter-spacing:.05pt'>c</span>aque<span style='letter-spacing:-.25pt'> </span>à<span style='letter-spacing:.05pt'> </span>des<span style='letter-spacing:-.15pt'> </span>doses &#8805; 10<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing: .05pt'>g</span>/kg/jour).<span style='letter-spacing:-.5pt'> </span>L<span style='letter-spacing:-.05pt'>'</span>action<span style='letter-spacing:-.3pt'> </span>pharmacologique<span style='letter-spacing:-.7pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>irb<span style='letter-spacing:-.1pt'>é</span><span style='letter-spacing:.05pt'>s</span>artan<span style='letter-spacing:-.4pt'> </span>a été c<span style='letter-spacing:.1pt'>o</span>nsidérée<span style='letter-spacing:-.45pt'> </span>c<span style='letter-spacing:.1pt'>o</span>mme<span style='letter-spacing:-.3pt'> </span>étant<span style='letter-spacing:-.2pt'> </span>la <span style='letter-spacing:.05pt'>cau</span>se<span style='letter-spacing: -.15pt'> </span>de toutes<span style='letter-spacing:-.25pt'> </span>ces<span style='letter-spacing:-.1pt'> m</span><span style='letter-spacing:.1pt'>o</span>difications.<span style='letter-spacing:-.65pt'> </span>Chez<span style='letter-spacing:-.25pt'> </span>l'h<span style='letter-spacing:.1pt'>o</span>mme,<span style='letter-spacing:-.3pt'> </span>aux<span style='letter-spacing:-.2pt'> </span>doses<span style='letter-spacing:-.25pt'> </span>thérapeutiques<span style='letter-spacing:-.65pt'> </span>d<span style='letter-spacing:.05pt'>’</span>irbésartan,<span style='letter-spacing:-.55pt'> </span>une <span style='letter-spacing:-.05pt'>h</span><span style='letter-spacing:.1pt'>y</span>perplasie/hypertrophie<span style='letter-spacing:-1.05pt'> </span><span style='letter-spacing:-.05pt'>d</span>es<span style='letter-spacing:-.15pt'> </span>cellules<span style='letter-spacing:-.35pt'> </span>j<span style='letter-spacing:.1pt'>u</span>xtaglo<span style='letter-spacing: -.05pt'>m</span>érulaires<span style='letter-spacing:-.75pt'> </span>n’apparaît<span style='letter-spacing:-.4pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>avoir<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.05pt'>d</span><span style='letter-spacing:.05pt'>’</span><span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:-.1pt'>m</span>plication. L<span style='letter-spacing: .05pt'>’</span>irbésartan<span style='letter-spacing:-.55pt'> </span>n<span style='letter-spacing:.05pt'>’</span>a<span style='letter-spacing:-.1pt'> m</span>ontré<span style='letter-spacing:-.3pt'> </span>aucun<span style='letter-spacing:-.25pt'> </span>signe<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>m</span>u<span style='letter-spacing:.05pt'>t</span>agénicité,<span style='letter-spacing:-.4pt'> </span>clastogénicité<span style='letter-spacing: -.55pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>carcinogenicité.</p>
<p class=AmmCorpsTexte>Dans<span style='letter-spacing:-.25pt'> </span>les<span style='letter-spacing:-.1pt'> </span>étu<span style='letter-spacing:.1pt'>d</span>es<span style='letter-spacing:-.3pt'> </span>cliniques<span style='letter-spacing:-.4pt'> </span>mené<span style='letter-spacing:.05pt'>e</span>s<span style='letter-spacing: -.35pt'> </span>chez<span style='letter-spacing:-.1pt'> </span>le rat <span style='letter-spacing:-.1pt'>m</span>a<span style='letter-spacing:.05pt'>l</span>e<span style='letter-spacing:-.2pt'> </span>et<span style='letter-spacing:.1pt'> </span>f<span style='letter-spacing:.05pt'>e</span><span style='letter-spacing:-.1pt'>m</span>el<span style='letter-spacing:.05pt'>l</span>e,<span style='letter-spacing:-.25pt'> </span>la f<span style='letter-spacing:.05pt'>é</span>condité<span style='letter-spacing: -.4pt'> </span>et la performance<span style='letter-spacing:-.45pt'> </span>de reproduction<span style='letter-spacing:-.6pt'> </span>n<span style='letter-spacing: -.05pt'>'</span>ont<span style='letter-spacing:-.2pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>été affec<span style='letter-spacing: .1pt'>t</span>ées<span style='letter-spacing:-.3pt'> </span>même<span style='letter-spacing:-.25pt'> </span>à des<span style='letter-spacing:-.15pt'> </span>doses<span style='letter-spacing:-.25pt'> </span>orales<span style='letter-spacing:-.25pt'> </span>d<span style='letter-spacing:-.05pt'>'</span>irbesartan<span style='letter-spacing:-.5pt'> </span>entrai<span style='letter-spacing:.1pt'>n</span>ant<span style='letter-spacing:-.4pt'> </span>une<span style='letter-spacing:-.15pt'> </span>certaine<span style='letter-spacing:-.35pt'> toxicité</span><span style='letter-spacing:.05pt'> </span>parentale<span style='letter-spacing:-.35pt'> </span>(de<span style='letter-spacing:-.15pt'> </span>50<span style='letter-spacing:-.1pt'> </span>à 650<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing: -.1pt'>m</span><span style='letter-spacing:.05pt'>g</span>/kg/jour)<span style='letter-spacing:-.55pt'> </span>y<span style='letter-spacing:.05pt'> </span>co<span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>ris<span style='letter-spacing:-.35pt'> </span>la <span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span>rtalité<span style='letter-spacing:-.1pt'> </span>à la dose<span style='letter-spacing:-.2pt'> </span>la plus<span style='letter-spacing:-.2pt'> </span>élevée.<span style='letter-spacing:-.25pt'> </span>Aucun<span style='letter-spacing:-.3pt'> </span>effet significatif<span style='letter-spacing:-.45pt'> </span>n'a<span style='letter-spacing:-.1pt'> </span>été observé<span style='letter-spacing:-.25pt'> </span>sur<span style='letter-spacing: -.15pt'> </span>le no<span style='letter-spacing:-.1pt'>m</span>bre<span style='letter-spacing:-.3pt'> </span>de<span style='letter-spacing:-.1pt'> </span>corpora<span style='letter-spacing:-.35pt'> </span>l<span style='letter-spacing:-.05pt'>u</span>tea,<span style='letter-spacing:-.25pt'> </span>d'<span style='letter-spacing:.05pt'>i</span><span style='letter-spacing:-.1pt'>m</span>p<span style='letter-spacing:.05pt'>l</span>ants<span style='letter-spacing:-.45pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:-.1pt'> </span>fœt<span style='letter-spacing:-.05pt'>u</span>s<span style='letter-spacing:-.3pt'> </span>vivants.<span style='letter-spacing:-.35pt'> </span>L'irbesartan n<span style='letter-spacing:-.05pt'>'</span>a<span style='letter-spacing:-.05pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>affec<span style='letter-spacing:.1pt'>t</span>é<span style='letter-spacing:-.25pt'> </span>la survie,<span style='letter-spacing:-.3pt'> </span>le développe<span style='letter-spacing:-.05pt'>m</span><span style='letter-spacing:.05pt'>e</span>nt<span style='letter-spacing:-.6pt'> </span>et<span style='letter-spacing:-.05pt'> </span>la reproduction<span style='letter-spacing:-.55pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la descendance.<span style='letter-spacing: -.6pt'> </span>Les<span style='letter-spacing:-.15pt'> </span>études<span style='letter-spacing:-.3pt'> </span>c<span style='letter-spacing:.1pt'>h</span>ez l'an<span style='letter-spacing:.05pt'>i</span>mal<span style='letter-spacing: -.25pt'> </span>d<span style='letter-spacing:.05pt'>é</span>montrent<span style='letter-spacing:-.5pt'> </span>que<span style='letter-spacing:-.15pt'> </span>l'<span style='letter-spacing:.05pt'>i</span>rbesartan<span style='letter-spacing:-.4pt'> </span>r<span style='letter-spacing:-.1pt'>a</span>d<span style='letter-spacing: .05pt'>i</span>omarqué<span style='letter-spacing:-.55pt'> </span>est détecté<span style='letter-spacing:-.3pt'> </span>dans<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>l</span>es<span style='letter-spacing:-.1pt'> </span>fœtus<span style='letter-spacing:-.25pt'> </span>ch<span style='letter-spacing:.05pt'>e</span>z<span style='letter-spacing:-.15pt'> </span>le rat<span style='letter-spacing:-.1pt'> </span>et ch<span style='letter-spacing:.05pt'>e</span>z<span style='letter-spacing: -.15pt'> </span>le lapin. Chez<span style='letter-spacing:-.25pt'> </span>la rate<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing: .05pt'>a</span>llaitante, l'ir<span style='letter-spacing:.1pt'>b</span>esartan<span style='letter-spacing:-.5pt'> </span><span style='letter-spacing:.05pt'>e</span>st<span style='letter-spacing:-.05pt'> </span>excrété<span style='letter-spacing:-.3pt'> </span>dans<span style='letter-spacing:-.2pt'> </span>le <span style='letter-spacing:.05pt'>l</span>ait.</p>
<p class=AmmCorpsTexte>Les<span style='letter-spacing:-.15pt'> </span>études<span style='letter-spacing:-.2pt'> </span>menées<span style='letter-spacing:-.35pt'> </span>ch<span style='letter-spacing:.05pt'>e</span>z<span style='letter-spacing: -.15pt'> </span><span style='letter-spacing:.05pt'>l</span><span style='letter-spacing:-.05pt'>'</span><span style='letter-spacing:.05pt'>an</span>imal<span style='letter-spacing:-.05pt'> </span>avec<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>l</span><span style='letter-spacing:-.05pt'>'</span><span style='letter-spacing:.05pt'>i</span>rbésartan<span style='letter-spacing:-.4pt'> </span>ont<span style='letter-spacing:-.2pt'> </span>mis<span style='letter-spacing: -.15pt'> </span>en<span style='letter-spacing:-.1pt'> </span>évidence<span style='letter-spacing:-.4pt'> </span>des<span style='letter-spacing:-.15pt'> </span>ef<span style='letter-spacing:.05pt'>f</span>ets<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>t</span>oxiques<span style='letter-spacing:-.35pt'> </span>transitoires (augmentation<span style='letter-spacing:-.6pt'> </span>de<span style='letter-spacing:-.1pt'> </span>la for<span style='letter-spacing:-.1pt'>m</span>a<span style='letter-spacing:.05pt'>t</span>ion<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>cavernes<span style='letter-spacing:-.4pt'> </span>au<span style='letter-spacing:-.1pt'> </span>niveau<span style='letter-spacing:-.3pt'> </span>rénal<span style='letter-spacing:-.2pt'> </span>et pelvien,<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing: -.05pt'>h</span>ydro-ure<span style='letter-spacing:-.05pt'>t</span>ère<span style='letter-spacing:-.6pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>oedème<span style='letter-spacing:-.35pt'> </span>sous cutané)<span style='letter-spacing: -.3pt'> </span>chez<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>l</span>es<span style='letter-spacing:-.1pt'> </span>foetus<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:-.1pt'> </span>rats.<span style='letter-spacing:-.2pt'> </span>Ces<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.05pt'>e</span>ffets<span style='letter-spacing:-.15pt'> </span>n<span style='letter-spacing:.05pt'>’</span>étaient<span style='letter-spacing:-.15pt'> </span>plus<span style='letter-spacing:-.2pt'> </span>retrouvés<span style='letter-spacing:-.4pt'> </span>après<span style='letter-spacing:-.25pt'> </span>la nais<span style='letter-spacing:.05pt'>s</span>ance.<span style='letter-spacing: -.4pt'> </span>Chez<span style='letter-spacing:-.25pt'> </span>le l<span style='letter-spacing:.05pt'>a</span>pin,<span style='letter-spacing:-.15pt'> </span>des avort<span style='letter-spacing:.05pt'>e</span><span style='letter-spacing: -.1pt'>m</span>ents<span style='letter-spacing:-.4pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>des<span style='letter-spacing:-.15pt'> </span>résorptions<span style='letter-spacing:-.5pt'> </span>précoces<span style='letter-spacing:-.4pt'> </span>ont<span style='letter-spacing:-.15pt'> </span>été obse<span style='letter-spacing:.05pt'>r</span>vés<span style='letter-spacing:-.4pt'> </span>à des<span style='letter-spacing:-.15pt'> </span>doses<span style='letter-spacing: -.25pt'> </span>entraînant<span style='letter-spacing:-.45pt'> </span>des<span style='letter-spacing:-.15pt'> </span>effets<span style='letter-spacing:-.25pt'> </span>toxiques i<span style='letter-spacing:-.1pt'>m</span>portants<span style='letter-spacing:-.45pt'> </span>y<span style='letter-spacing:-.1pt'> </span>c<span style='letter-spacing:.1pt'>o</span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>p</span>ris<span style='letter-spacing:-.35pt'> </span>léta<span style='letter-spacing:.1pt'>u</span>x<span style='letter-spacing:-.2pt'> </span>p<span style='letter-spacing:-.05pt'>o</span>ur<span style='letter-spacing:-.2pt'> </span>la <span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>è</span>re.<span style='letter-spacing:-.2pt'> </span>Aucun<span style='letter-spacing:-.3pt'> </span>eff<span style='letter-spacing:-.1pt'>e</span>t<span style='letter-spacing:-.15pt'> </span>tératogène<span style='letter-spacing:-.45pt'> </span>n’a<span style='letter-spacing:-.15pt'> </span>été constaté<span style='letter-spacing:-.35pt'> </span>chez<span style='letter-spacing: -.2pt'> </span>le rat<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:.1pt'>o</span>u<span style='letter-spacing:-.05pt'> </span>le lapin.</p>
<p class=AmmCorpsTexte><u>H<span style='letter-spacing:.1pt'>y</span>d<span style='letter-spacing:-.05pt'>r</span>ochloro<span style='letter-spacing:-.05pt'>t</span>hiazid<span style='letter-spacing:-.05pt'>e</span></u><span style='letter-spacing:-.05pt'> </span>:<span style='letter-spacing:-.9pt'> </span><span style='letter-spacing:-.1pt'>m</span>al<span style='letter-spacing:.1pt'>g</span>ré<span style='letter-spacing:-.25pt'> </span>l'existence<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.1pt'> </span>données<span style='letter-spacing:-.35pt'> </span>a<span style='letter-spacing:-.1pt'>m</span>biguës<span style='letter-spacing:-.4pt'> </span>sur<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.05pt'>l</span>'effet<span style='letter-spacing:-.2pt'> </span>génotox<span style='letter-spacing:-.05pt'>i</span>que<span style='letter-spacing:-.55pt'> </span>ou<span style='letter-spacing:-.1pt'> </span>cancérigène dans<span style='letter-spacing: -.2pt'> </span>certains<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.1pt'>m</span>odèles<span style='letter-spacing:-.35pt'> </span>expéri<span style='letter-spacing:-.05pt'>m</span>entaux,<span style='letter-spacing:-.65pt'> </span>la longue<span style='letter-spacing: -.3pt'> </span>expérience<span style='letter-spacing:-.45pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>utilisation<span style='letter-spacing:-.4pt'> </span>de<span style='letter-spacing:-.1pt'> </span>l<span style='letter-spacing:-.05pt'>'</span>hydrochloro<span style='letter-spacing: -.05pt'>t</span>hiazide chez<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>l</span><span style='letter-spacing:-.05pt'>'</span>homme<span style='letter-spacing:-.35pt'> </span>ne<span style='letter-spacing:-.1pt'> </span>permet<span style='letter-spacing:-.3pt'> </span>pas<span style='letter-spacing:-.15pt'> </span>de <span style='letter-spacing:-.1pt'>m</span>ontrer<span style='letter-spacing: -.35pt'> </span>une<span style='letter-spacing:-.15pt'> </span>associat<span style='letter-spacing:.05pt'>i</span>on<span style='letter-spacing:-.45pt'> </span>entre<span style='letter-spacing:-.15pt'> </span>son<span style='letter-spacing:-.2pt'> </span>utilisation<span style='letter-spacing:-.4pt'> </span>et<span style='letter-spacing:-.05pt'> </span>une<span style='letter-spacing:-.15pt'> </span>aug<span style='letter-spacing:-.1pt'>m</span>entation<span style='letter-spacing:-.55pt'> </span>des néoplas<span style='letter-spacing: -.05pt'>m</span>es.</p>
<p class="AmmAnnexeTitre1"><a name="RcpDonneesPharmaceutiques">6. DONNEES PHARMACEUTIQUES</a></p>
<p class="AmmAnnexeTitre2"><a name="RcpListeExcipients">6.1. Liste des excipients</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278937"><u>Noyau</u> :</a></p>
<p class=AmmCorpsTexte>Lactose<span style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.05pt'>o</span><span style='letter-spacing:.1pt'>n</span><span style='letter-spacing:.05pt'>o</span>h<span style='letter-spacing:.1pt'>y</span>draté, cellulose microcristalline, hypromellose, croscarmellose sodique, dioxyde de silice colloïdale, stéarate de magnésium.</p>
<p class=AmmCorpsTexte> </p>
<p class=AmmCorpsTexte><u>Pelliculage</u> :</p>
<p class=AmmCorpsTexte>OPADRY II orange : alcool polyvinylique partiellement hydrolysé, dioxyde de titane (E171), macrogol 3350, talc, oxyde de fer jaune (E172), oxyde de fer rouge (E172).</p>
<p class="AmmAnnexeTitre2"><a name="RcpIncompatibilites">6.2. Incompatibilités</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278938">Sans objet. </a></p>
<p class="AmmAnnexeTitre2"><a name="RcpDureeConservation">6.3. Durée de conservation</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278939">2 ans.</a></p>
<p class="AmmAnnexeTitre2"><a name="RcpPrecConservation">6.4. Précautions particulières de conservation</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278940">A conserver à une température ne dépassant pas </a>30°C.</p>
<p class="AmmAnnexeTitre2"><a name="RcpEmballage">6.5. Nature et contenu de l'emballage extérieur</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278941">14, 28, 30, 56, 60, 84 et 90 comprimés pelliculés sous plaquettes thermoformées (PVC/PVDC/Aluminium).</a></p>
<p class=AmmCorpsTexte>Toutes les présentations peuvent ne pas être commercialisées.</p>
<p class="AmmAnnexeTitre2"><a name="RcpPrecEmpl">6.6. Précautions particulières d’élimination et de manipulation</a></p>
<p class=AmmCorpsTexte>Pas d’exigences particulières. </p>
<p class="AmmAnnexeTitre1"><a name="RcpTitulaireAmm">7. TITULAIRE DE L’AUTORISATION DE MISE SUR LE MARCHE</a></p>
<p class=AmmTitulaireNom>biogaran</p>
<p class=AmmTitulaireAdresse>15 boulevard charles de gaulle</p>
<p class=AmmTitulaireAdresse>92700 colombes</p>
<p class="AmmAnnexeTitre1"><a name="RcpPresentation">8. NUMERO(S) D’AUTORISATION DE MISE SUR LE MARCHE</a></p>
<p class=AmmListePuces><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>268 414-9 ou 34009 268 414 9 2 : 14 comprimés sous plaquettes (PVC/PVDC/Aluminium) </p>
<p class=AmmListePuces><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>268 415-5 ou 34009 268 415 5 3 : 28 comprimés sous plaquettes (PVC/PVDC/Aluminium) </p>
<p class=AmmListePuces><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>268 416-1 ou 34009 268 416 1 4 : 30 comprimés sous plaquettes (PVC/PVDC/Aluminium) </p>
<p class=AmmListePuces><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>268 417-8 ou 34009 268 417 8 2 : 56 comprimés sous plaquettes (PVC/PVDC/Aluminium) </p>
<p class=AmmListePuces><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>268 418-4 ou 34009 268 418 4 3 : 60 comprimés sous plaquettes (PVC/PVDC/Aluminium) </p>
<p class=AmmListePuces><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>268 419-0 ou 34009 268 419 0 4 : 84 comprimés sous plaquettes (PVC/PVDC/Aluminium) </p>
<p class=AmmListePuces><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>268 420-9 ou 34009 268 420 9 3 : 90 comprimés sous plaquettes (PVC/PVDC/Aluminium)</p>
<p class="AmmAnnexeTitre1"><a name="RcpPremiereAutorisation">9. DATE DE PREMIERE AUTORISATION/DE RENOUVELLEMENT DE L’AUTORISATION</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278945">[à compléter par le titulaire]</a></p>
<p class="AmmAnnexeTitre1"><a name="RcpDateRevision">10. DATE DE MISE A JOUR DU TEXTE</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278946">[à compléter par le titulaire]</a></p>
<p class="AmmAnnexeTitre1"><a name="RcpDosimetrie">11. DOSIMETRIE</a></p>
<p class=AmmCorpsTexte>Sans objet.</p>
<p class="AmmAnnexeTitre1"><a name="RcpInstPrepRadioph">12. INSTRUCTIONS POUR LA PREPARATION DES RADIOPHARMACEUTIQUES</a></p>
<p class=AmmCorpsTexte>Sans objet.</p>
<div style='border:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0cm 0cm 0cm'>
<p class="AmmAnnexeTitre"><a name="RcpCondPrescription">CONDITIONS DE PRESCRIPTION ET DE DELIVRANCE</a></p>
</div>
<p class=AmmCorpsTexte style='margin-top:6.0pt'>Liste I. </p>
<b><span style='font-size:12.0pt;font-family:Arial;color:#0B3D92;text-transform:
uppercase'><br clear=all>
</span></b>
</BODY>
</HTML>
